Anti-GLP1R antibody-drug conjugates comprising GLP1 peptidomimetics and uses thereof

By developing antibody-tethered drug conjugates specifically binding to GLP1R, the problems of short duration and insufficient safety of existing GLP1R agonists are solved, and long half-life and high safety GLP1R targeted therapy is achieved in plasma , significantly improved the therapeutic effect of diabetes and obesity.

CN119072335APending Publication Date: 2024-12-03REGENERON PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380027101.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-11
Filing Date
2023-03-11
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing GLP1R agonists have short duration and insufficient safety in the treatment of diabetes and obesity, and cannot effectively control hyperglycemia and cardiovascular risk factors.

Method used

An antibody-tethered drug conjugate (ATDC) was developed that contains antibodies or antigen-binding fragments thereof that specifically bind GLP1R and forms an amination product by reacting with glutamine residues, binding to an uncleavable linker. and payload, forming a drug conjugate with a long half-life, ensuring stable presence in plasma.

Benefits of technology

The half-life of ATDC in plasma is achieved for longer than 7 days, avoiding binding to non-GLP1R receptors, significantly improving the duration and safety of the drug, and enhancing the targeting of GLP1R.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005039190910000031
    Figure BDA0005039190910000031
  • Figure BDA0005039190910000034
    Figure BDA0005039190910000034
  • Figure BDA0005039190910000043
    Figure BDA0005039190910000043
Patent Text Reader

Abstract

The present invention provides drug conjugates (ATDCs) and compositions thereof that are useful, for example, in antibody tethering that targets the glucagon-like peptide 1 receptor (GLP1R) and treats various conditions (e.g., diabetes). Methods for making such ATDCs and methods of using ATDCs are also provided.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to U.S. Provisional Application No. 63 / 319,175, filed on March 11, 2022, which is hereby incorporated by reference in its entirety.

[0003] FIELD OF THE DISCLOSURE

[0004] The present disclosure relates to antibody-tethered drug conjugates, pharmaceutical compositions, and methods of using the same to treat GLP1R-associated conditions.

[0005] Background of the Disclosure

[0006] Diabetes is a chronic disease characterized by abnormal glucose metabolism. An estimated 425 million people worldwide live with diabetes. Global diabetes medications include insulin, DPP-4 inhibitors, and glucagon-like peptide 1 receptor (GLP1R) agonists, but most patients fail to achieve the combined treatment goal of controlling hyperglycemia and cardiovascular risk factors.

[0007] The glucagon-like peptide 1 receptor (GLP1R) is a receptor for glucagon-like peptide 1 (GLP1) and is expressed in pancreatic beta cells. GLP1R is also expressed in the brain, where it plays a role in controlling appetite, memory, and learning. GLP1R is a member of the secretin family (class B) of G protein-coupled receptors (GPCRs). Upon binding to its ligand, GLP1R, via the Gas G protein (which increases intracellular cyclic AMP (cAMP) levels), initiates a downstream signaling cascade, leading to transcriptional regulation of genes (Donnelly 2011). Activation of GLP1R leads to increased insulin synthesis and release.

[0008] GLP1R and GLP1 are highly effective targets for obesity and type 2 diabetes. Marketed GLP1R agonists increase insulin secretion, thereby lowering blood sugar levels, but they require weekly or more frequent administration.

[0009] Therefore, there is a need in the art for GLP1R agonists with longer duration and improved safety. In certain embodiments, the present disclosure satisfies this need and provides other advantages.

[0010] The foregoing discussion is presented solely to provide a better understanding of the nature of the problems faced in the art and should not in any way be construed as an admission that prior art is available, nor should the citation of any reference herein be construed as an admission that such reference constitutes "prior art" to the present application.

[0011] Overview of the Disclosure

[0012] Various non-limiting aspects and embodiments of the present disclosure are described below.

[0013] The present invention provides an antibody-tethered drug conjugate (ATDC) having the structure of Formula (A):

[0014] BA-(LP)m(A),

[0015] in:

[0016] BA is an antibody or antigen-binding fragment thereof that specifically binds to GLP1R, and for example, the antibody or antigen-binding fragment thereof that specifically binds to GLP1R

[0017] (i) comprises a heavy chain immunoglobulin or a variable region thereof, said heavy chain immunoglobulin or its variable region comprising a CDR-H1, CDR-H2 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411; or a variant thereof; and / or

[0018] a light chain immunoglobulin or a variable region thereof, comprising a CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373;393 or 413; or a variant thereof;

[0019] (ii) is an antibody or antigen-binding fragment thereof that competes with the antibody or fragment of (i) for binding to GLP1R; and / or

[0020] (iii) an antibody or antigen-binding fragment thereof that binds to the same epitope of GLP1R as the antibody or fragment of (i);

[0021] L is a non-cleavable linker;

[0022] Optionally, wherein the heavy chain immunoglobulin of the BA does not comprise a C-terminal lysine or a lysine and a glycine;

[0023] P is a payload having a structure selected from the group consisting of:

[0024]

[0025] in is the attachment point where the payload is attached to L;

[0026] X1 is selected from H;

[0027] X2 is selected from

[0028] X3 is selected from a bond, -(CH2) 2-6 -NH-, -(CH2) 2-6 -Tr- and -(CH2) 2-6 -Tr-(CH2) 1-6 -NH, wherein Tr is a triazole moiety;

[0029] n is 0 or 1;

[0030] X4 is selected from -NH2, -OH and -N(H)(phenyl);

[0031] X5 is selected from -OH, -NH2, -NH-OH and

[0032] X6, at each occurrence, is independently selected from H, -OH, -CH3, and -CH2OH;

[0033] X7 is selected from H,

[0034] X8 is selected from H, -OH, -NH2 and

[0035] Ar is selected from

[0036] X9 is selected from -NH2, and

[0037] m is an integer from 1 to 4

[0038] or a pharmaceutically acceptable salt thereof.

[0039] The present invention also provides ATDC having the structure of formula (I):

[0040] BA-LP(I),

[0041] in:

[0042] BA is an antibody or antigen-binding fragment thereof that specifically binds to GLP1R, and for example, the antibody or antigen-binding fragment thereof that specifically binds to GLP1R

[0043] (i) comprises a heavy chain immunoglobulin or a variable region thereof, said heavy chain immunoglobulin or its variable region comprising a CDR-H1, CDR-H2 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411; or a variant thereof; and / or

[0044] a light chain immunoglobulin or a variable region thereof, comprising a CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373;393 or 413; or a variant thereof;

[0045] (ii) is an antibody or antigen-binding fragment thereof that competes with the antibody or fragment of (i) for binding to GLP1R; and / or

[0046] (iii) an antibody or antigen-binding fragment thereof that binds to the same epitope of GLP1R as the antibody or fragment of (i);

[0047] L is a non-cleavable linker;

[0048] Optionally, wherein the heavy chain immunoglobulin of the BA does not comprise a C-terminal lysine or a lysine and a glycine;

[0049] P is a payload having a structure selected from the group consisting of:

[0050]

[0051] in is the attachment point where the payload P is attached to L;

[0052] X1 is selected from H;

[0053] X2 is selected from

[0054] X3 is selected from -(CH2) 2-6 -NH- and -(CH2) 2-6 -Tr-, wherein Tr is a triazole moiety;

[0055] n is 0 or 1;

[0056] X4 is selected from H and phenyl;

[0057] X5 is selected from -OH, -NH2, -NH-OH and

[0058] X6, at each occurrence, is independently selected from H, -OH, -CH3, and -CH2OH;

[0059] X7 is selected from H,

[0060] X8 is selected from H, -OH, -NH2 and

[0061] or a pharmaceutically acceptable salt thereof.

[0062] In some embodiments of the present invention, the BA of ATDC is an antibody or an antigen-binding fragment thereof that specifically binds to GLP1R, and the antibody that specifically binds to GLP1R is antibody 5A10, 9A10, AB9433-I, h38C2, PA5-111834, NLS1205, MAB2814, EPR21819, or glutazumab.

[0063] In some embodiments, Linker L is attached to one or both heavy chains of BA. In some embodiments, Linker L is attached to one or both heavy chain variable domains of BA. In some embodiments, Linker L is attached to one or both light chains of BA. In some embodiments, Linker L is attached to one or both light chain variable domains of BA.

[0064] In some embodiments of the present invention, linker L is attached to BA via a glutamine residue on BA. In some embodiments, a glutamine residue is introduced into the N-terminus of one or both heavy chains of BA. In some embodiments of the present invention, a glutamine residue is introduced into the N-terminus of one or both light chains of BA. In some embodiments of the present invention, a glutamine residue is naturally present in the CH2 domain or the CH3 domain of BA. In some embodiments of the present invention, a glutamine residue is introduced into BA by modifying one or more amino acids. In some embodiments of the present invention, the glutamine residue is Q295 or N297Q.

[0065] In some embodiments of the invention, linker L is attached to BA via a lysine residue.

[0066] In some embodiments, the heavy chain immunoglobulin of BA does not contain a C-terminal lysine or a lysine and a glycine. In some embodiments, the heavy chain immunoglobulin of BA does not contain a C-terminal lysine. In some embodiments, the heavy chain immunoglobulin does not contain a C-terminal lysine and a glycine. A heavy chain immunoglobulin that does not contain a C-terminal lysine and a glycine also means a heavy chain immunoglobulin that does not contain a lysine and a glycine at the C-terminus.

[0067] In some embodiments of the invention, the antibody or antigen-binding fragment thereof is non-glycosylated. In some embodiments of the invention, the antibody or antigen-binding fragment thereof is deglycosylated. In some embodiments of the invention, the antigen-binding fragment is a Fab fragment.

[0068] In one embodiment of the present invention, m is 1. In one embodiment, m is an integer from 2 to 4. In one embodiment of the present invention, m is 2.

[0069] In some embodiments of the invention, more than one LP is attached to a BA. In some embodiments, two LPs are attached to a BA.

[0070] In one embodiment, the linker L has the structure of formula (L'):

[0071] -La-Y-Lp-(L'),

[0072] wherein La is a first linker covalently attached to said BA;

[0073] Y is a triazole-containing group, and

[0074] Lp is absent or is a second linker covalently attached to said P, wherein when Lp is absent, Y is also absent.

[0075] In some embodiments, Y has a structure selected from the group consisting of:

[0076] Wherein Q is C or N.

[0077] In some embodiments of the invention, Lp comprises a polyethylene glycol (PEG) segment having 1 to 36 -CH2C2O-(EG) units. In some embodiments of the invention, the PEG segment comprises between 2 and 30 EG units. In some embodiments of the invention, the PEG segment comprises between 4 and 24 EG units. In some embodiments of the invention, the PEG segment comprises 4 EG units, or 8 EG units, or 12 EG units, or 24 EG units. In some embodiments of the invention, the PEG segment comprises 4 EG units. In some embodiments, the PEG segment comprises 8 EG units.

[0078] In some embodiments, Y-Lp has a structure selected from the group consisting of:

[0079] or a triazole positional isomer thereof,

[0080] Wherein p is an integer from 1 to 36.

[0081] In some embodiments of the present invention, Lp comprises one or more amino acids selected from glycine, serine, glutamic acid, alanine, valine, and proline, and combinations thereof. In some embodiments, Lp comprises 1 to 10 glycines. In some embodiments, Lp comprises 1 to 6 serines. In some embodiments of the present invention, Lp comprises 1 to 10 glycines and 1 to 6 serines. In some embodiments of the present invention, Lp comprises 4 glycines and 1 serine. In some embodiments of the present invention, Lp is selected from the group consisting of Gly-Gly-Gly-Gly-Ser (G4S) (SEQ ID NO: 1), Ser-Gly-Gly-Gly-Gly (SG4) (SEQ ID NO: 2), and Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser (G4S-G4S) (SEQ ID NO: 3).

[0082] In some embodiments of the invention, Lp comprises a PEG segment having 1 to 36 EG units and a combination of one or more amino acids selected from glycine, serine, glutamic acid, alanine, valine, and proline, and combinations thereof. In some embodiments of the invention, the serine residue comprises a carbohydrate group. In some embodiments of the invention, the serine residue comprises a glucose group.

[0083] In some embodiments of the invention, Lp has a structure selected from the group consisting of:

[0084]

[0085] wherein Y is a triazole-containing group, and P is a payload, and wherein Rc is selected from H and glucose, g is an integer from 1 to 10, and s is an integer from 0 to 4.

[0086] In some embodiments, Y-Lp has a structure selected from the group consisting of:

[0087] or a triazole positional isomer thereof.

[0088] In some embodiments of the present invention, La comprises a polyethylene glycol (PEG) segment having 1 to 36 -CH2CH2O-(EG) units. In some embodiments of the present invention, the PEG segment comprises 4 EG units, or 8 EG units, or 12 EG units, or 24 EG units. In some embodiments, the PEG segment comprises 8 EG units. In some embodiments of the present invention, La has a structure selected from the group consisting of:

[0089] In some embodiments of the present invention, La includes one or more amino acids selected from glycine, threonine, serine, glutamine, glutamic acid, alanine, valine, leucine and proline and combinations thereof. In some embodiments of the present invention, La includes 1 to 10 glycines and 1 to 6 serines. In some embodiments of the present invention, La includes 4 glycines and 1 serine. In some embodiments of the present invention, La is selected from the group consisting of Gly-Gly-Gly-Gly-Ser (G4S), Ser-Gly-Gly-Gly-Gly (SG4), Gly-Gly-Ser-Gly-Gly-Ser-Gly-Gly (G2S-G2S-G2) and Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly (G4S-G4).

[0090] In some embodiments of the invention, La comprises a PEG segment having 1 to 36 EG units and a combination of one or more amino acids selected from glycine, threonine, serine, glutamine, glutamic acid, alanine, valine, leucine and proline, and combinations thereof. In some embodiments of the invention, La is selected from the group consisting of:

[0091]

[0092] In some embodiments of the present invention, La comprises -(CH2) 2-24 -chain. In some embodiments, La comprises a PEG segment having 1 to 36 EG units and a combination of one or more amino acids selected from glycine, threonine, serine, glutamine, glutamic acid, alanine, valine, leucine and proline, and combinations thereof. La is selected from the group consisting of:

[0093] In various embodiments of the present invention, P has the structure

[0094]

[0095] In some embodiments of the present invention, X1 is H; X2 is X3 is selected from -(CH2) 2-6 -NH- and -(CH2) 2-6 -Tr-, wherein Tr is a triazole moiety; n is 1, and X4 is H.

[0096] In some embodiments of the present invention, X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1; X4 is H, and X5 is selected from -OH, -NH2, -NH-OH and

[0097] In some embodiments of the present invention, X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1, and X4 is H.

[0098] In some embodiments of the present invention, X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1; X4 is H; X6 at each occurrence is independently selected from H and -CH2OH, and X7 is H.

[0099] In some embodiments of the present invention, X1 is X2 is X3 is -(CH2) 2-6 -Tr-, wherein Tr is a triazole moiety; n is 1; X4 is H, and X5 is

[0100] In some embodiments of the present invention, X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1; X4 is H; X6 is independently selected at each occurrence from H and -CH3; X7 is And X8 is -NH2.

[0101] In some embodiments of the present invention, X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1; X4 is H, and X8 is H.

[0102] In some embodiments of the present invention, X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1; X4 is H; X6 is H at every occurrence; X7 is And X8 is H.

[0103] In some embodiments of the present invention, X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1; X4 is H; X6 is independently selected at each occurrence from H and -CH3; X7 is And X8 is

[0104] In some embodiments of the present invention, X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1, and X4 is H.

[0105] In some embodiments of the present invention, X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1, and X4 is H.

[0106] In some embodiments of the present invention, X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1; X4 is H; X6 is independently selected at each occurrence from H and -CH3, and X7 is

[0107] In some embodiments of the present invention, X1 is H; X2 is X3 is -(CH2) 2-6-NH-; n is 1, and X4 is H.

[0108] In some embodiments of the present invention, X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1; X4 is H, and X5 is

[0109] In some embodiments of the present invention, X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 0; X4 is phenyl, and X5 is

[0110] In some embodiments of the present invention, X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1; X4 is phenyl, and X5 is

[0111] In various embodiments of the present invention, P has the structure

[0112]

[0113] In some embodiments of the present invention, X1 is X2 is X3 is -(CH2) 2-6 -NH-; X4 is H, and X5 is

[0114] In various embodiments of the present invention, P has a structure selected from the group consisting of:

[0115]

[0116]

[0117]

[0118]

[0119]

[0120]

[0121]

[0122] In various embodiments of the present invention, the ATDC of the present invention has a half-life in plasma greater than 7 days.

[0123] In various embodiments of the present invention, the ATDCs of the present invention do not bind to G protein-coupled receptors (GPCRs) other than GLP1R.

[0124] In another aspect of the invention, provided herein are pharmaceutical compositions comprising antibodies or antigen-binding fragments thereof, or ATDCs, wherein at least about 80% of the antibodies or antigen-binding fragments thereof, or ATDCs do not comprise a C-terminal lysine or lysine and glycine in any heavy chain.

[0125] In some embodiments, the antibody or antigen-binding fragment thereof or ATDC does not comprise a C-terminal lysine. In some embodiments, the antibody or antigen-binding fragment thereof or ATDC does not comprise a C-terminal lysine and a glycine.

[0126] In an embodiment of the invention, in a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof or ATDC, at least about 90% of the antibody or antigen-binding fragment thereof or ATDC does not comprise a C-terminal lysine or lysine and glycine in any heavy chain.

[0127] In one embodiment of the invention, in a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof or ATDC, about 90% of the antibody or antigen-binding fragment thereof or ATDC does not comprise a C-terminal lysine or lysine and glycine in any heavy chain.

[0128] In an embodiment of the invention, in a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof or ATDC, at least about 95% of the antibody or antigen-binding fragment thereof or ATDC does not comprise a C-terminal lysine or lysine and glycine in any heavy chain.

[0129] In an embodiment of the invention, in a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof, or ATDC, at least about 99% of the antibody or antigen-binding fragment thereof, or ATDC does not comprise a C-terminal lysine or lysine and glycine in any heavy chain.

[0130] In an embodiment of the invention, the above-described heavy chain immunoglobulin that does not comprise a C-terminal lysine comprises the amino acid sequence set forth in SEQ ID NO: 414 or 416, or a variant thereof.

[0131] In an embodiment of the invention, in a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof or ATDC, less than about 20% of the antibodies or antigen-binding fragments or ATDC comprise a C-terminal lysine or lysine and glycine in at least one heavy chain.

[0132] In an embodiment of the invention, in a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof or ATDC, less than about 10% of the antibodies or antigen-binding fragments or ATDC comprise a C-terminal lysine or lysine and glycine in at least one heavy chain.

[0133] In an embodiment of the invention, in a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof or ATDC, about 10% of the antibodies or antigen-binding fragments or ATDC comprise a C-terminal lysine or lysine and glycine in at least one heavy chain.

[0134] In an embodiment of the invention, in a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof or ATDC, less than about 5% of the antibodies or antigen-binding fragments or ATDC comprise a C-terminal lysine or lysine and glycine in at least one heavy chain.

[0135] In an embodiment of the invention, in a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof or ATDC, less than about 1% of the antibody or antigen-binding fragment or ATDC comprises a C-terminal lysine or lysine and glycine in at least one heavy chain.

[0136] In an embodiment of the invention, in a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof or ATDC, about 10% of the antibodies or antigen-binding fragments or ATDC comprise a C-terminal lysine or lysine and glycine in at least one heavy chain.

[0137] In an embodiment of the invention, at least one heavy chain comprising the C-terminal lysine or lysine and glycine described above comprises the amino acid sequence set forth in SEQ ID NO: 42; 62; 82; 102; 122; 142; 162; 182; 203; 223; 243; 263; 267; 271; 291; 311; 331; 351; 371; 391 or 411; or a variant thereof.

[0138] In an embodiment of the invention, at least one heavy chain comprising the above-described C-terminal lysine comprises the amino acid sequence set forth in SEQ ID NO:82.

[0139] In another aspect of the present invention, provided herein is a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof or ATDC and a pharmaceutically acceptable carrier.

[0140] In another aspect of the present invention, provided herein is a pharmaceutical dosage form comprising an antibody or antigen-binding fragment thereof or ATDC described herein.

[0141] In embodiments of the invention, an antibody or antigen-binding fragment thereof that specifically binds to GLP1R (e.g., a BA of an ATDC as described herein) comprises: (a) a heavy chain immunoglobulin or its variable region comprising an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO: 26; 46; 66; 86; 106; 126; 146; 166; 187; 207; 227; 247; 275; 295; 315; 335; 355; 375; 395; 42; 62; 82; 414; 416; 102; 122; 142; 162; 182; 203; 223; 243; 263; 267; 271; 291; 311; 331; 351; 371; 391; or 411; and / or (b) a light chain immunoglobulin or its variable region comprising an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO: or 413. In some embodiments, the heavy chain immunoglobulin does not comprise a C-terminal lysine or a lysine and a glycine.

[0142] In an embodiment of the present invention, an antibody or antigen-binding fragment thereof that specifically binds to GLP1R (e.g., a BA of an ATDC as described herein) comprises: (a) a heavy chain immunoglobulin or a variable region thereof comprising CDR-H1, CDR-H2, and CDR-H3 of a heavy chain immunoglobulin or a variable region thereof comprising: SEQ ID NO: NO:26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;the amino acid sequence set forth in SEQ ID NO:26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411; and the amino acid sequence set forth in SEQ ID NO: NO:26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411; and / or (b) a light chain immunoglobulin or a variable region thereof comprising a CDR-L1, CDR-L2 and CDR-L3 comprising the following light chain immunoglobulin or variable region thereof: SEQ ID NO:26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271 NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373;393 or 413; and the amino acid sequence set forth in SEQ ID or 413. In some embodiments, the heavy chain immunoglobulin does not comprise a C-terminal lysine or a lysine and a glycine.

[0143] In an embodiment of the present invention, an antibody or antigen-binding fragment thereof that specifically binds to GLP1R (e.g., a BA of an ATDC as described herein) comprises: a heavy chain immunoglobulin or variable region thereof comprising: (i) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 28 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 30 or a variant thereof; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 32 or a variant thereof; (ii) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 48 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 50 or a variant thereof; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 52 or a variant thereof; (iii) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 68 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 70 or a variant thereof; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 72 or a variant thereof; (iv) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 80 or a variant thereof; (i) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 148 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 150 or a variant thereof; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 152 or a variant thereof; (ii) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 148 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 150 or a variant thereof; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 152 or a variant thereof; (iii) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 154 or a variant thereof; (viii) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 168 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 170 or a variant thereof; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 172 or a variant thereof; (ix) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 189 or a variant thereof;a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 191 or a variant thereof; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 193 or a variant thereof; (x) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 209 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 211 or a variant thereof; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 213 or a variant thereof; (xi) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 229 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 231 or a variant thereof; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 233 or a variant thereof; (xii) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 249 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 251 or a variant thereof; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 254 or a variant thereof (xiii) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 277 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 279 or a variant thereof; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 281 or a variant thereof; (xiv) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 297 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 299 or a variant thereof; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 301 or a variant thereof;

[0144] (xv) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 317 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 319 or a variant thereof; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 321 or a variant thereof; (xvi) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 337 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 339 or a variant thereof; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 341 or a variant thereof; (xvii) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 357 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 359 or a variant thereof; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 361 or a variant thereof; and / or (xviii) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 377 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 379 or a variant thereof NO: 379 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 379 or a variant thereof; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 381 or a variant thereof; (xix) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 397 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 399 or a variant thereof; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 401 or a variant thereof; and / or a light chain immunoglobulin or variable region thereof comprises: (a) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 36 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 38 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 40 or a variant thereof; (b) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 56 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 58 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: (c) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 76 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 78 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 80 or a variant thereof; (d) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 96 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 98 or a variant thereof;a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 100 or a variant thereof; (e) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 116 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 118 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 120 or a variant thereof; (f) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 136 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 138 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 140 or a variant thereof; (g) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 156 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 158 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 160 or a variant thereof; (h) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 161 or a variant thereof NO: 176 or a variant thereof; CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 178 or a variant thereof; CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 178 or a variant thereof; CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 180 or a variant thereof; (i) CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 197 or a variant thereof; CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 199 or a variant thereof; CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 201 or a variant thereof;

[0145] (j) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 217 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 219 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 221 or a variant thereof; (k) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 237 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 239 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 241 or a variant thereof; (l) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 257 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 259 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 261 or a variant thereof; (m) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 285 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 289 or a variant thereof; NO: 287 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 289 or a variant thereof; (n) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 305 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 307 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 309 or a variant thereof; (o) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 325 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 327 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 329 or a variant thereof; (p) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 345 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 347 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 349 or a variant thereof NO: 349 or a variant thereof; (q) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 365 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 367 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 369 or a variant thereof; (r) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 385 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 387 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 389 or a variant thereof;and / or (s) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 405 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 407 or a variant thereof; and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 409 or a variant thereof. ;

[0146] In an embodiment of the present invention, an antibody or antigen-binding fragment thereof that specifically binds to GLP1R (e.g., a BA of an ATDC as described herein) comprises: (1) a heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 28 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 30 or a variant thereof; and a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 32; and a light chain immunoglobulin or its variable region comprises a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 36 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 38 or a variant thereof; and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 40 or a variant thereof; (2) a heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 48 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 50 or a variant thereof; and a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 52 and a light chain immunoglobulin or its variable region comprises a CDR-L1 comprising an amino acid sequence set forth in SEQ ID NO: 56 or a variant thereof; a CDR-L2 comprising an amino acid sequence set forth in SEQ ID NO: 58 or a variant thereof; and a CDR-L3 comprising an amino acid sequence set forth in SEQ ID NO: 60 or a variant thereof; (3) a heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising an amino acid sequence set forth in SEQ ID NO: 68 or a variant thereof; a CDR-H2 comprising an amino acid sequence set forth in SEQ ID NO: 70 or a variant thereof; and a CDR-H3 comprising an amino acid sequence set forth in SEQ ID NO: 72; and a light chain immunoglobulin or its variable region comprises a CDR-L1 comprising an amino acid sequence set forth in SEQ ID NO: 76 or a variant thereof; a CDR-L2 comprising an amino acid sequence set forth in SEQ ID NO: 78 or a variant thereof; and a CDR-L3 comprising an amino acid sequence set forth in SEQ ID NO: NO:80 or a variant thereof; (4) the heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO:88 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO:90 or a variant thereof; and a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO:92; and the light chain immunoglobulin or its variable region comprises a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO:96 or a variant thereof; and a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO:98 or a variant thereof;and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 100 or a variant thereof; (5) the heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 108 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 110 or a variant thereof; and a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 112; and the light chain immunoglobulin or its variable region comprises a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 116 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 118 or a variant thereof; and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 120 or a variant thereof; (6) the heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 128 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 130 or a variant thereof; and a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: NO: 132; and the light chain immunoglobulin or its variable region comprises a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 136 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 138 or a variant thereof; and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 140 or a variant thereof; (7) the heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 148 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 150 or a variant thereof; and a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 152; and the light chain immunoglobulin or its variable region comprises a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 156 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 158 or a variant thereof; and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 141 NO: 160 or a variant thereof; (8) a heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising an amino acid sequence set forth in SEQ ID NO: 168 or a variant thereof; a CDR-H2 comprising an amino acid sequence set forth in SEQ ID NO: 170 or a variant thereof; and a CDR-H3 comprising an amino acid sequence set forth in SEQ ID NO: 172; and a light chain immunoglobulin or its variable region comprises a CDR-L1 comprising an amino acid sequence set forth in SEQ ID NO: 176 or a variant thereof; and a CDR-L2 comprising an amino acid sequence set forth in SEQ ID NO: 178 or a variant thereof;and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 180 or a variant thereof; (9) the heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 189 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 191 or a variant thereof; and a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 193 or a variant thereof; and the light chain immunoglobulin or its variable region comprises a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 197 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 199 or a variant thereof; and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 201 or a variant thereof; (10) the heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 209 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 211 or a variant thereof; and a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 214 or a variant thereof. NO: 213 or a variant thereof; and the light chain immunoglobulin or its variable region comprises a CDR-L1 comprising an amino acid sequence set forth in SEQ ID NO: 217 or a variant thereof; a CDR-L2 comprising an amino acid sequence set forth in SEQ ID NO: 219 or a variant thereof; and a CDR-L3 comprising an amino acid sequence set forth in SEQ ID NO: 221 or a variant thereof; (11) the heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising an amino acid sequence set forth in SEQ ID NO: 229 or a variant thereof; a CDR-H2 comprising an amino acid sequence set forth in SEQ ID NO: 231 or a variant thereof; and a CDR-H3 comprising an amino acid sequence set forth in SEQ ID NO: 233 or a variant thereof; and the light chain immunoglobulin or its variable region comprises a CDR-L1 comprising an amino acid sequence set forth in SEQ ID NO: 237 or a variant thereof; a CDR-L2 comprising an amino acid sequence set forth in SEQ ID NO: 239 or a variant thereof; and a CDR-L3 comprising an amino acid sequence set forth in SEQ ID NO: 240 or a variant thereof. (12) the heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 249 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 251 or a variant thereof; and a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 253 or a variant thereof; and the light chain immunoglobulin or its variable region comprises a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 257 or a variant thereof; and a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 259 or a variant thereof;comprising a CDR-L3 having the amino acid sequence set forth in SEQ ID NO: 261 or a variant thereof; (13) a heavy chain immunoglobulin or its variable region comprises a CDR-H1 having the amino acid sequence set forth in SEQ ID NO: 277 or a variant thereof; a CDR-H2 having the amino acid sequence set forth in SEQ ID NO: 279 or a variant thereof; and a CDR-H3 having the amino acid sequence set forth in SEQ ID NO: 281 or a variant thereof; and a light chain immunoglobulin or its variable region comprises a CDR-L1 having the amino acid sequence set forth in SEQ ID NO: 285 or a variant thereof; a CDR-L2 having the amino acid sequence set forth in SEQ ID NO: 287 or a variant thereof; and a CDR-L3 having the amino acid sequence set forth in SEQ ID NO: 289 or a variant thereof; (14) a heavy chain immunoglobulin or its variable region comprises a CDR-H1 having the amino acid sequence set forth in SEQ ID NO: 297 or a variant thereof; a CDR-H2 having the amino acid sequence set forth in SEQ ID NO: 299 or a variant thereof; and a CDR-H3 having the amino acid sequence set forth in SEQ ID NO: 281 NO: 301 or a variant thereof; and the light chain immunoglobulin or its variable region comprises a CDR-L1 comprising an amino acid sequence set forth in SEQ ID NO: 305 or a variant thereof; a CDR-L2 comprising an amino acid sequence set forth in SEQ ID NO: 307 or a variant thereof; and a CDR-L3 comprising an amino acid sequence set forth in SEQ ID NO: 309 or a variant thereof; (15) the heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising an amino acid sequence set forth in SEQ ID NO: 317 or a variant thereof; a CDR-H2 comprising an amino acid sequence set forth in SEQ ID NO: 319 or a variant thereof; and a CDR-H3 comprising an amino acid sequence set forth in SEQ ID NO: 321 or a variant thereof; and the light chain immunoglobulin or its variable region comprises a CDR-L1 comprising an amino acid sequence set forth in SEQ ID NO: 325 or a variant thereof; a CDR-L2 comprising an amino acid sequence set forth in SEQ ID NO: 327 or a variant thereof; and a CDR-L3 comprising an amino acid sequence set forth in SEQ ID NO: 329 or a variant thereof. NO: 329 or a variant thereof; (16) a heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising an amino acid sequence set forth in SEQ ID NO: 337 or a variant thereof; a CDR-H2 comprising an amino acid sequence set forth in SEQ ID NO: 339 or a variant thereof; and a CDR-H3 comprising an amino acid sequence set forth in SEQ ID NO: 341 or a variant thereof; and a light chain immunoglobulin or its variable region comprises a CDR-L1 comprising an amino acid sequence set forth in SEQ ID NO: 345 or a variant thereof; and a CDR-L2 comprising an amino acid sequence set forth in SEQ ID NO: 347 or a variant thereof;comprising a CDR-L3 having the amino acid sequence set forth in SEQ ID NO: 349 or a variant thereof; (17) a heavy chain immunoglobulin or its variable region comprises a CDR-H1 having the amino acid sequence set forth in SEQ ID NO: 357 or a variant thereof; a CDR-H2 having the amino acid sequence set forth in SEQ ID NO: 359 or a variant thereof; and a CDR-H3 having the amino acid sequence set forth in SEQ ID NO: 361 or a variant thereof; and a light chain immunoglobulin or its variable region comprises a CDR-L1 having the amino acid sequence set forth in SEQ ID NO: 365 or a variant thereof; a CDR-L2 having the amino acid sequence set forth in SEQ ID NO: 367 or a variant thereof; and a CDR-L3 having the amino acid sequence set forth in SEQ ID NO: 369 or a variant thereof; (18) a heavy chain immunoglobulin or its variable region comprises a CDR-H1 having the amino acid sequence set forth in SEQ ID NO: 377 or a variant thereof; a CDR-H2 having the amino acid sequence set forth in SEQ ID NO: 379 or a variant thereof; and a CDR-H3 having the amino acid sequence set forth in SEQ ID NO: 361 or a variant thereof. NO: 381 or a variant thereof; and the light chain immunoglobulin or its variable region comprises a CDR-L1 comprising an amino acid sequence set forth in SEQ ID NO: 385 or a variant thereof; a CDR-L2 comprising an amino acid sequence set forth in SEQ ID NO: 387 or a variant thereof; and a CDR-L3 comprising an amino acid sequence set forth in SEQ ID NO: 389 or a variant thereof; or (19) the heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising an amino acid sequence set forth in SEQ ID NO: 397 or a variant thereof; a CDR-H2 comprising an amino acid sequence set forth in SEQ ID NO: 399 or a variant thereof; and a CDR-H3 comprising an amino acid sequence set forth in SEQ ID NO: 401 or a variant thereof; and the light chain immunoglobulin or its variable region comprises a CDR-L1 comprising an amino acid sequence set forth in SEQ ID NO: 405 or a variant thereof; a CDR-L2 comprising an amino acid sequence set forth in SEQ ID NO: 407 or a variant thereof; and a CDR-L3 comprising an amino acid sequence set forth in SEQ ID NO: 410 or a variant thereof. NO:409 or a CDR-L3 of a variant thereof. In an embodiment of the present invention, an antibody or antigen-binding fragment thereof that specifically binds to GLP1R (e.g., a BA of an ATDC as described herein) comprises: (a) a heavy chain immunoglobulin or a variable region thereof comprising SEQ ID NO:26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;or a variant thereof. In some embodiments, the heavy chain immunoglobulin does not comprise a C-terminal lysine or a lysine and a glycine.

[0147] In an embodiment of the present invention, an antibody or antigen-binding fragment thereof that specifically binds to GLP1R (e.g., a BA of an ATDC as described herein) comprises: (a) a heavy chain immunoglobulin variable region comprising the amino acid sequence set forth in SEQ ID NO: 26, and a light chain immunoglobulin variable region comprising the amino acid sequence set forth in SEQ ID NO: 34; (b) a heavy chain immunoglobulin variable region comprising the amino acid sequence set forth in SEQ ID NO: 46, and a light chain immunoglobulin variable region comprising the amino acid sequence set forth in SEQ ID NO: 54; (c) a heavy chain immunoglobulin variable region comprising the amino acid sequence set forth in SEQ ID NO: 66, and a light chain immunoglobulin variable region comprising the amino acid sequence set forth in SEQ ID NO: 74; (d) a heavy chain immunoglobulin variable region comprising the amino acid sequence set forth in SEQ ID NO: 86, and a light chain immunoglobulin variable region comprising the amino acid sequence set forth in SEQ ID NO: 94; (e) a heavy chain immunoglobulin variable region comprising the amino acid sequence set forth in SEQ ID NO: 106, and a light chain immunoglobulin variable region comprising the amino acid sequence set forth in SEQ ID NO: NO: 114; (f) the heavy chain immunoglobulin variable region comprises the amino acid sequence set forth in SEQ ID NO: 126, and the light chain immunoglobulin variable region comprises the amino acid sequence set forth in SEQ ID NO: 134; (g) the heavy chain immunoglobulin variable region comprises the amino acid sequence set forth in SEQ ID NO: 146, and the light chain immunoglobulin variable region comprises the amino acid sequence set forth in SEQ ID NO: 154; (h) the heavy chain immunoglobulin variable region comprises the amino acid sequence set forth in SEQ ID NO: 166, and the light chain immunoglobulin variable region comprises the amino acid sequence set forth in SEQ ID NO: 174; (i) the heavy chain immunoglobulin variable region comprises the amino acid sequence set forth in SEQ ID NO: 187, and the light chain immunoglobulin variable region comprises the amino acid sequence set forth in SEQ ID NO: 195; (j) the heavy chain immunoglobulin variable region comprises the amino acid sequence set forth in SEQ ID NO: 207, and the light chain immunoglobulin variable region comprises the amino acid sequence set forth in SEQ ID NO: (k) the heavy chain immunoglobulin variable region comprises the amino acid sequence set forth in SEQ ID NO: 227, and the light chain immunoglobulin variable region comprises the amino acid sequence set forth in SEQ ID NO: 235; (l) the heavy chain immunoglobulin variable region comprises the amino acid sequence set forth in SEQ ID NO: 247, and the light chain immunoglobulin variable region comprises the amino acid sequence set forth in SEQ ID NO: 255;(m) the heavy chain immunoglobulin variable region comprises the amino acid sequence set forth in SEQ ID NO: 275, and the light chain immunoglobulin variable region comprises the amino acid sequence set forth in SEQ ID NO: 283; (n) the heavy chain immunoglobulin variable region comprises the amino acid sequence set forth in SEQ ID NO: 295, and the light chain immunoglobulin variable region comprises the amino acid sequence set forth in SEQ ID NO: 303;

[0148] (o) the heavy chain immunoglobulin variable region comprises the amino acid sequence set forth in SEQ ID NO: 315, and the light chain immunoglobulin variable region comprises the amino acid sequence set forth in SEQ ID NO: 323; (p) the heavy chain immunoglobulin variable region comprises the amino acid sequence set forth in SEQ ID NO: 335, and the light chain immunoglobulin variable region comprises the amino acid sequence set forth in SEQ ID NO: 343; (q) the heavy chain immunoglobulin variable region comprises the amino acid sequence set forth in SEQ ID NO: 355, and the light chain immunoglobulin variable region comprises the amino acid sequence set forth in SEQ ID NO: 363; (r) the heavy chain immunoglobulin variable region comprises the amino acid sequence set forth in SEQ ID NO: 375, and the light chain immunoglobulin variable region comprises the amino acid sequence set forth in SEQ ID NO: 383; and / or (s) the heavy chain immunoglobulin variable region comprises the amino acid sequence set forth in SEQ ID NO: 395, and the light chain immunoglobulin variable region comprises the amino acid sequence set forth in SEQ ID NO: 403. In embodiments of the present invention, an antibody or antigen-binding fragment thereof that specifically binds to GLP1R (e.g., a BA of an ATDC as described herein) comprises: (a) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 42, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 44; (b) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 62, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 64; (c) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 82, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 84; (d) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 102, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 104; (e) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 122, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 124; (f) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: (g) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 162, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 164; (h) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 182, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 184;(i) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 203, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 205; (j) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 223, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 225; (k) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 243, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 245; (l) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 263, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 265; (m) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 267, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 269; (n) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 271, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: (o) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 291, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 293; (p) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 311, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 313; (q) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 331, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 333; (r) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 351, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 353; (s) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 371, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 373; (t) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 372. NO:391, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO:393; or (u) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO:411, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO:413.;

[0149] The present invention provides an antibody-tethered drug conjugate, the antibody-tethered drug conjugate comprising an antibody or an antigen-binding fragment thereof targeting a glucagon-like peptide-1 receptor (GLP1R), wherein the antibody or the antigen-binding fragment thereof targeting a glucagon-like peptide-1 receptor (GLP1R) comprises: (a) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 42, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 44; (b) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 62, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 64; (c) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 82, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 84; (d) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 102, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 104; (e) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: (i) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 203, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 205; (j) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 223, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 224. (k) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 243, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 245; (l) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 263, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 265; (m) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 267, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 269;(n) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 271, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 273; (o) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 291, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 293; (p) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 311, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 313; (q) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 331, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 333; (r) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 351, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 353; (s) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 371, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: NO: 373; (t) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 391, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 393; (u) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 411, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 413; (v) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 414, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 84; or (w) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 416, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 84; wherein the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 417, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 84; The structure of amino acid 3 (Gln) conjugated linker-payload of NO: 44, 64, 84, 104, 124, 144, 164, 184, 205, 225, 245, 265, 269, 273, 293, 313, 333, 353, 373, 393 or 413 is represented by:

[0150]

[0151] in The point of attachment is amino acids 1-6 (LLQGSG (contained in the above structures)) of SEQ ID NO: 44, 64, 84, 104, 124, 144, 164, 184, 205, 225, 245, 265, 269, 273, 293, 313, 333, 353, 373, 393, or 413 attached to amino acid 7. In some embodiments, the heavy chain immunoglobulin does not comprise a C-terminal lysine or a lysine and a glycine.

[0152] The present invention provides an antibody-tethered drug conjugate, wherein the antibody-tethered drug conjugate comprises an antibody or an antigen-binding fragment thereof targeting the glucagon-like peptide-1 receptor (GLP1R), wherein the antibody or the antigen-binding fragment thereof targeting the glucagon-like peptide-1 receptor (GLP1R) comprises:

[0153] (a) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO:42, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO:44; (b) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO:62, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO:64; (c) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO:82, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO:84; (d) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO:102, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO:104; (e) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO:122, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO:124; (f) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO:142, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: (g) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 162, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 164; (h) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 182, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 184; (i) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 203, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 205; (j) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 223, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 225; (k) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 243, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 245; (l) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: (m) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 267, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 269; (n) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 271, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 273;(o) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 291, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 293; (p) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 311, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 313; (q) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 331, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 333; (r) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 351, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 353; (s) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 371, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 373; (t) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 391, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: NO: 393; (u) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 411, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 413; (v) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 414, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 84; or (w) the heavy chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 416, and the light chain immunoglobulin comprises the amino acid sequence set forth in SEQ ID NO: 84; wherein the structure of the linker-payload conjugated to amino acid 3 (Gln) of SEQ ID NO: 44, 64, 84, 104, 124, 144, 164, 184, 205, 225, 245, 265, 269, 273, 293, 313, 333, 353, 373, 393 or 413 is represented by the following: (Structure);

[0154]

[0155] in The point of attachment is amino acids 1-6 (LLQGSG (contained in the above structures)) of SEQ ID NOS: 44, 64, 84, 104, 124, 144, 164, 184, 205, 225, 245, 265, 269, 273, 293, 313, 333, 353, 373, 393, or 413 attached to amino acid 7. In some embodiments, the heavy chain immunoglobulin does not comprise a C-terminal lysine or a lysine and a glycine.

[0156] The present invention also provides an antibody-tethered drug conjugate (ATDC), comprising an antibody or antigen-binding fragment thereof that specifically binds to GLP1R and a payload conjugated to a linker, wherein the linker is conjugated to two immunoglobulin heavy chains or one or both of their variable regions and / or two immunoglobulin light chains or one or both of their variable regions of the antibody or fragment, wherein the antibody or fragment is characterized by the following structure:

[0157]

[0158] in

[0159] Immunoglobulins are immunoglobulin chains of antibodies or fragments (e.g., light chain immunoglobulins);

[0160] The linker is a linker as discussed herein;

[0161] CapAib is 3-((2-(1H-imidazol-5-yl)ethyl)amino)-2,2-dimethyl-3-oxopropanoic acid;

[0162] E* is (S)-2-amino-3-(2H-tetrazol-5-yl)propanoic acid;

[0163] G is glycine;

[0164] T is threonine;

[0165] F* is (S)-2-amino-3-(2-fluorophenyl)-2-methylpropanoic acid;

[0166] S is serine;

[0167] D is aspartic acid;

[0168] AA2 is (S)-2-amino-3-(4'-(4-(4-(25-amino-2,5,8,11,14,17,20,23-octaoxapentacosyl)-1H-1,2,3-triazol-1-yl)butoxy)-2'-ethyl-[1,1'-biphenyl]-4-yl)propanoic acid [AA2 includes the linker]; and

[0169] AA1 = (S)-2-amino-5-(3,5-dimethylphenyl)pentanamide. Structure:

[0170] CapAib-E*-GTF*-TSD-AA2-AA1

[0171] Includes, for example, GT or CapAib-E*, which indicates that these residues are connected by a bond, such as a peptide bond. In an embodiment of the present invention, the antibody or fragment comprises a Q tag in both immunoglobulin light chains, the Q tag comprising the amino acid sequence LLQGSG (SEQ ID NO: 18). A linker having the structure R-NH2 in the linker-payload (e.g., including the general structure H2N-linker-payload) can be conjugated to the side group of the Q tag glutamine (Gln) at the side chain -C(=O)-NH2 via a transglutaminase reaction (e.g., according to the following reaction scheme):

[0172]

[0173] *H2N-LP is a linker-payload with an -NH2 group.

[0174] This reaction can be referred to as amination. Amination refers to the process in which a primary amine, for example, a primary amine of a linker-payload, is covalently coupled to a glutamine residue bound to a peptide by transglutaminase. When transglutaminase is near a peptide Gln residue and there is an available primary amine substrate (for example, a linker-payload with a primary amine, such as M3190), the enzyme catalyzes the incorporation of the primary amino group into glutamine, resulting in the formation of a γ-glutamine bond. The result of such a reaction can be referred to as an "aminated product" in this article. An aminated product can be, but is not necessarily, the product of two molecules catalyzed by transglutaminase. For example, an aminated product can be the result of chemical synthesis without the use of transglutaminase. See Lai et al., Tissue transglutaminase (TG2) and mitochondrial function and dysfunction, Frontiers in Bioscience-Landmark. 2017. 22 (7); 1114-1137.

[0175] The present invention also provides methods (e.g., in vivo or in vitro in a subject) of selectively targeting GLP1R on the surface of a cell to deliver a payload (e.g., L11, L30, or L32) using any of the embodiments of the ATDC described herein (e.g., REGN7990; REGN9268; REGN15869; REGN18121; REGN18123; REGN8070; REGN8072; REGN9267; REGN7988; REGN5619; REGN7989; REGN8069; REGN8071; REGN9426; REGN5203; REGN5204; REGN5617; REGN5619; REGN7987; REGN9270; REGN9278; REGN9279 or REGN9280, for example, wherein the linker-payload is LP11, LP30 or LP32), the method comprising the step of contacting the cell with ATDC. In embodiments of the present invention, the method comprises the step of administering ATDC or a pharmaceutical composition thereof to a subject in which the cell is present in vivo. In some embodiments, the cell is a mammalian cell. In some embodiments, the cell is a human cell. In some embodiments, the cell is a pancreatic cell, a brain cell, a heart cell, a vascular tissue cell, a kidney cell, a fat tissue cell, a liver cell, or a muscle cell.

[0176] The present invention provides a method of enhancing GLP1R activity in a subject in need thereof, comprising administering to the subject an effective amount of any embodiment of the ATDC described herein (e.g., REGN7990; REGN9268; REGN15869; REGN18121; REGN18123; REGN8070; REGN8072; REGN9267; REGN7988; REGN5619; REGN7989; REGN8069; REGN8071; REGN9426; REGN5203; REGN5204; REGN5617; REGN5619; REGN7987; REGN9270; REGN9278; REGN9279 or REGN9280, e.g., wherein the linker-payload is LP11, LP30 or LP32), a composition described herein, or a dosage form described herein. In embodiments of the invention, the subject suffers from a GLP1R-associated condition (eg, obesity and / or diabetes (type 1 or type 2)).

[0177] In another aspect, provided herein is a method of lowering blood glucose levels in a subject in need thereof, comprising administering to the subject an effective amount of any embodiment of the ATDC described herein (e.g., REGN7990; REGN9268; REGN15869; REGN18121; REGN18123; REGN8070; REGN8072; REGN9267; REGN7988; REGN5619; REGN7989; REGN8069; REGN8071; REGN9426; REGN5203; REGN5204; REGN5617; REGN5619; REGN7987; REGN9270; REGN9278; REGN9279, or REGN9280, e.g., wherein the linker-payload is LP11, LP30, or LP32), a composition described herein, or a dosage form described herein. In embodiments of the invention, the subject suffers from a GLP1R-associated condition (eg, obesity and / or diabetes (type 1 or type 2)).

[0178] In another aspect, provided herein is a method of reducing body weight in an individual in need thereof, comprising administering to the individual an effective amount of any embodiment of the ATDC described herein (e.g., REGN7990; REGN9268; REGN15869; REGN18121; REGN18123; REGN8070; REGN8072; REGN9267; REGN7988; REGN5619; REGN7989; REGN8069; REGN8071; REGN9426; REGN5203; REGN5204; REGN5617; REGN5619; REGN7987; REGN9270; REGN9278; REGN9279 or REGN9280, e.g., wherein the linker-payload is LP11, LP30 or LP32), a composition described herein, or a dosage form described herein. In embodiments of the invention, the subject suffers from a GLP1R-associated condition (eg, obesity and / or diabetes (type 1 or type 2)).

[0179] In another aspect, provided herein is a method of treating a GLP1R-associated condition in a subject in need thereof, comprising administering to the subject an effective amount of any embodiment of the ATDC described herein (e.g., REGN7990; REGN9268; REGN15869; REGN18121; REGN18123; REGN8070; REGN8072; REGN9267; REGN7988; REGN5619; REGN7989; REGN8069; REGN8071; REGN9426; REGN5203; REGN5204; REGN5617; REGN5619; REGN7987; REGN9270; REGN9278; REGN9279, or REGN9280, e.g., wherein the linker-payload is LP11, LP30, or LP32), a composition described herein, or a dosage form described herein. In some embodiments, the GLP1R-associated condition is type II diabetes, obesity, liver disease, coronary artery disease, or kidney disease. In some embodiments, the GLP1R-associated condition is type II diabetes and / or obesity.

[0180] In various embodiments of any of the methods described herein, an ATDC, composition, or dosage form of the present disclosure (e.g., REGN7990; REGN9268; REGN15869; REGN18121; REGN18123; REGN8070; REGN8072; REGN9267; REGN7988; REGN5619; REGN7989; REGN8069; REGN8071; REGN9426; REGN5203; REGN5204; REGN5617; REGN5619; REGN7987; REGN9270; REGN9278; REGN9279, or REGN9280, e.g., wherein the linker-payload is LP11, LP30, or LP32) is administered subcutaneously, intravenously, intradermally, intraperitoneally, or intramuscularly.

[0181] In another aspect, provided herein is a method of producing the ATDC described herein having the structure of Formula (A):

[0182] BA-(LP)m(A),

[0183] The method comprises the following steps:

[0184] a) contacting BA comprising at least m glutamine residues Gln with at least m equivalents of a compound LP in the presence of a transglutaminase, and

[0185] b) isolating the produced ATDC of formula (A);

[0186] wherein BA is an antibody or antigen-binding fragment thereof that specifically binds to GLP1R, and for example, the antibody or antigen-binding fragment thereof that specifically binds to GLP1R

[0187] (i) comprises a heavy chain immunoglobulin or a variable region thereof, said heavy chain immunoglobulin or its variable region comprising a CDR-H1, CDR-H2 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411; or a variant thereof; and / or

[0188] a light chain immunoglobulin or a variable region thereof, comprising a CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373;393 or 413; or a variant thereof;

[0189] (ii) is an antibody or antigen-binding fragment thereof that competes with the antibody or fragment of (i) for binding to GLP1R; and / or

[0190] (iii) an antibody or antigen-binding fragment thereof that binds to the same epitope of GLP1R as the antibody or fragment of (i);

[0191] Optionally, wherein the heavy chain immunoglobulin does not comprise a C-terminal lysine or a lysine and a glycine.

[0192] In another aspect, provided herein is a method of producing an ATDC described herein having the structure of Formula (I):

[0193] BA-LP(I),

[0194] The method comprises the following steps:

[0195] a) contacting a BA comprising at least one glutamine residue Gln with a compound LP in the presence of a transglutaminase, and

[0196] b) isolating the produced ATDC of formula (I);

[0197] Wherein, BA is an antibody or antigen-binding fragment thereof that specifically binds to GLP1R, and for example, the antibody or antigen-binding fragment thereof that specifically binds to GLP1R

[0198] (i) comprises a heavy chain immunoglobulin or a variable region thereof, said heavy chain immunoglobulin or its variable region comprising a CDR-H1, CDR-H2 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411; or a variant thereof; and / or

[0199] a light chain immunoglobulin or a variable region thereof, comprising a CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373;393 or 413; or a variant thereof;

[0200] (ii) is an antibody or antigen-binding fragment thereof that competes with the antibody or fragment of (i) for binding to GLP1R; and / or

[0201] (iii) an antibody or antigen-binding fragment thereof that binds to the same epitope of GLP1R as the antibody or fragment of (i);

[0202] Optionally, wherein the heavy chain immunoglobulin does not comprise a C-terminal lysine or a lysine and a glycine.

[0203] In another aspect, provided herein is a method for preparing ATDC having the structure of formula (A):

[0204] BA-(LP)m(A),

[0205] Wherein the linker L has a structure of formula (L'):

[0206] -La-Y-Lp-(L'),

[0207] wherein La is a first linker covalently attached to said BA;

[0208] Y is a triazole-containing group, and

[0209] Lp is a second linker covalently attached to said P,

[0210] The method comprises the following steps:

[0211] a) contacting BA comprising at least m glutamine residues Gln with a first linker La comprising an azide or alkyne moiety in the presence of a transglutaminase;

[0212] b) contacting the product of step a) with at least m equivalents of a compound Lp-P, wherein the second linker Lp comprises an azide or alkyne moiety, wherein La and Lp are capable of reacting to produce a triazole, and

[0213] c) isolating the produced ATDC of formula (A);

[0214] wherein BA is an antibody or antigen-binding fragment thereof that specifically binds to GLP1R, and wherein the antibody or antigen-binding fragment thereof that specifically binds to GLP1R is

[0215] (i) comprises a heavy chain immunoglobulin or a variable region thereof, said heavy chain immunoglobulin or its variable region comprising a CDR-H1, CDR-H2 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411; or a variant thereof; and / or

[0216] a light chain immunoglobulin or a variable region thereof, comprising a CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373;393 or 413; or a variant thereof;

[0217] (ii) is an antibody or antigen-binding fragment thereof that competes with the antibody or fragment of (i) for binding to GLP1R; and / or

[0218] (iii) an antibody or antigen-binding fragment thereof that binds to the same epitope of GLP1R as the antibody or fragment of (i);

[0219] Optionally, wherein the heavy chain immunoglobulin does not comprise a C-terminal lysine or a lysine and a glycine.

[0220] In another aspect, provided herein is a method of producing an ATDC described herein having the structure of Formula (I):

[0221] BA-LP(I),

[0222] Wherein the linker L has a structure of formula (L'):

[0223] -La-Y-Lp-(L'),

[0224] wherein La is a first linker covalently attached to said BA;

[0225] Y is a triazole-containing group, and

[0226] Lp is a second linker covalently attached to said P,

[0227] The method comprises the following steps:

[0228] a) contacting BA comprising at least one glutamine residue Gln with a first linker La comprising an azide or alkyne moiety in the presence of a transglutaminase;

[0229] b) contacting the product of step a) with a compound Lp-P, wherein the second linker Lp comprises an azide or alkyne moiety, wherein La and Lp are capable of reacting to produce a triazole, and

[0230] c) isolating the produced ATDC of formula (I);

[0231] wherein BA is an antibody or antigen-binding fragment thereof that specifically binds to GLP1R, and for example, the antibody or antigen-binding fragment thereof that specifically binds to GLP1R

[0232] (i) comprises a heavy chain immunoglobulin or a variable region thereof, said heavy chain immunoglobulin or its variable region comprising a CDR-H1, CDR-H2 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411; or a variant thereof; and / or

[0233] a light chain immunoglobulin or a variable region thereof, comprising a CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373;393 or 413; or a variant thereof;

[0234] (ii) is an antibody or antigen-binding fragment thereof that competes with the antibody or fragment of (i) for binding to GLP1R; and / or

[0235] (iii) an antibody or antigen-binding fragment thereof that binds to the same epitope of GLP1R as the antibody or fragment of (i);

[0236] Optionally, wherein the heavy chain immunoglobulin does not comprise a C-terminal lysine or a lysine and a glycine.

[0237] In another aspect, an ATDC is provided herein, comprising an antibody or antigen-binding fragment thereof that specifically binds to GLP1R, and for example, the antibody or antigen-binding fragment thereof that specifically binds to GLP1R

[0238] (i) comprises a heavy chain immunoglobulin or a variable region thereof, said heavy chain immunoglobulin or its variable region comprising a CDR-H1, CDR-H2 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411; or a variant thereof; and / or

[0239] a light chain immunoglobulin or a variable region thereof, comprising a CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373;393 or 413; or a variant thereof;

[0240] (ii) is an antibody or antigen-binding fragment thereof that competes with the antibody or fragment of (i) for binding to GLP1R; and / or

[0241] (iii) is an antibody or antigen-binding fragment thereof that binds to the same epitope of GLP1R as the antibody or fragment of (i); the antibody or antigen-binding fragment thereof is conjugated to a compound having a structure selected from the group consisting of Formula (P-IB), Formula (P-IIB) and Formula (P-IIIB), for example, via a linker:

[0242]

[0243] in:

[0244] X1 is selected from H;

[0245] X2 is selected from

[0246] X3 is selected from -CH3, -(CH2) 2-6 -NH2, -(CH2) 2-6 -N3 and -(CH2)2-6 -Tr-(CH2) 1-6 -NH2, wherein Tr is a triazole moiety;

[0247] n is 0 or 1;

[0248] X4 is selected from -NH2, -OH and -N(H)(phenyl);

[0249] X5 is selected from -OH, -NH2, -NH-OH and

[0250] X6, at each occurrence, is independently selected from H, -OH, -CH3, and -CH2OH;

[0251] X7 is selected from H,

[0252]

[0253] X8 is selected from H, -OH, -NH2 and

[0254] Ar is selected from

[0255] X9 is selected from -NH2, and

[0256] m is an integer from 1 to 4

[0257] or a pharmaceutically acceptable salt thereof;

[0258] Optionally, wherein the heavy chain immunoglobulin does not comprise a C-terminal lysine or a lysine and a glycine.

[0259] In another aspect of the present invention, an ATDC is provided herein, comprising an antibody or antigen-binding fragment thereof that specifically binds to GLP1R, and for example, the antibody or antigen-binding fragment thereof that specifically binds to GLP1R

[0260] (i) comprises a heavy chain immunoglobulin or a variable region thereof, said heavy chain immunoglobulin or its variable region comprising a CDR-H1, CDR-H2 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411; or a variant thereof; and / or

[0261] a light chain immunoglobulin or a variable region thereof, comprising a CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373;393 or 413; or a variant thereof;

[0262] (ii) is an antibody or antigen-binding fragment thereof that competes with the antibody or fragment of (i) for binding to GLP1R; and / or

[0263] (iii) an antibody or antigen-binding fragment thereof that binds to the same epitope of GLP1R as the antibody or fragment of (i);

[0264] The antibody or antigen-binding fragment thereof that specifically binds to GLP1R is conjugated to a compound having the structure of formula (II), for example, via a linker:

[0265]

[0266] in:

[0267] X1 is selected from H;

[0268] X2 is selected from

[0269] X3 is selected from -(CH2) 2-6 -NH2, -(CH2) 2-6 -N3 and -CH3, provided that when X3 is -CH3, n is 1, and Ra is selected from -(CH2) in at least one occurrence 2-6 -NH2 and -(CH2) 2-6 -N3;

[0270] n is 0 or 1;

[0271] m is an integer from 0 to 3;

[0272] Ra is independently selected at each occurrence from -CH3, -(CH2) 2-6 -NH2 and -(CH2) 2-6 -N3;

[0273] X4 is selected from H and phenyl;

[0274] X5 is selected from -OH, -NH2, -NH-OH and

[0275] X6, at each occurrence, is independently selected from H, -OH, -CH3, and -CH2OH;

[0276] X7 is selected from H,

[0277] X8 is selected from H, -OH, -NH2 and

[0278] and pharmaceutically acceptable salts thereof;

[0279] Optionally, wherein the heavy chain immunoglobulin does not comprise a C-terminal lysine or a lysine and a glycine.

[0280] In some embodiments, in the ATDC described herein, P (payload) has a structure selected from the group consisting of:

[0281]

[0282]

[0283]

[0284]

[0285]

[0286]

[0287]

[0288] For example, wherein such P (payload) is conjugated to an antibody or antigen-binding fragment thereof that specifically binds to GLP1R, and for example, said antibody or antigen-binding fragment thereof that specifically binds to GLP1R

[0289] (i) comprises a heavy chain immunoglobulin or a variable region thereof, said heavy chain immunoglobulin or its variable region comprising a CDR-H1, CDR-H2 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411; or a variant thereof; and / or

[0290] a light chain immunoglobulin or a variable region thereof, comprising a CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373;393 or 413; or a variant thereof;

[0291] (ii) is an antibody or antigen-binding fragment thereof that competes with the antibody or fragment of (i) for binding to GLP1R; and / or

[0292] (iii) an antibody or antigen-binding fragment thereof that binds to the same epitope of GLP1R as the antibody or fragment of (i);

[0293] Optionally, wherein the heavy chain immunoglobulin does not comprise a C-terminal lysine or a lysine and a glycine.

[0294] In another aspect of the present invention, an ATDC is provided herein, comprising an antibody or antigen-binding fragment thereof that specifically binds to GLP1R, and for example, the antibody or antigen-binding fragment thereof that specifically binds to GLP1R

[0295] (i) comprises a heavy chain immunoglobulin or a variable region thereof, said heavy chain immunoglobulin or its variable region comprising a CDR-H1, CDR-H2 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411; or a variant thereof; and / or

[0296] a light chain immunoglobulin or a variable region thereof, comprising a CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373;393 or 413; or a variant thereof;

[0297] (ii) is an antibody or antigen-binding fragment thereof that competes with the antibody or fragment of (i) for binding to GLP1R; and / or

[0298] (iii) an antibody or antigen-binding fragment thereof that binds to the same epitope of GLP1R as the antibody or fragment of (i);

[0299] The antibody or antigen-binding fragment thereof that specifically binds to GLP1R is conjugated to a compound having the structure of formula (C):

[0300]

[0301] in:

[0302] L p The linker is absent or includes one or more of the following: Carbamate group; cyclodextrin; polyethylene glycol (PEG) segment having 1 to 36 -CH2CH2O-(EG) units; -(CH2) 2-24 -chain; triazole; one or more amino acids selected from glycine, serine, glutamic acid, alanine, valine and proline and combinations thereof;

[0303] Q is selected from -NH2, -N3, wherein A is C or N;

[0304] X1 is selected from H;

[0305] X2 is selected from

[0306] X3 is selected from -CH3, -(CH2) 2-6 -NH2, -(CH2) 2-6 -N3 and -(CH2) 2-6 -Tr-(CH2) 1-6 -NH2, wherein Tr is a triazole moiety;

[0307] n is 0 or 1;

[0308] X4 is selected from -NH2, -OH and -N(H)(phenyl);

[0309] X5 is selected from -OH, -NH2, -NH-OH and

[0310] X6, at each occurrence, is independently selected from H, -OH, -CH3, and -CH2OH;

[0311] X7 is selected from H,

[0312] X8 is selected from H, -OH, -NH2 and

[0313] Ar is selected from

[0314] X9 is selected from -NH2, and

[0315] m is an integer from 1 to 4;

[0316] or a pharmaceutically acceptable salt thereof;

[0317] Optionally, wherein the heavy chain immunoglobulin does not comprise a C-terminal lysine or a lysine and a glycine.

[0318] In another aspect, an ATDC is provided herein, comprising an antibody or antigen-binding fragment thereof that specifically binds to GLP1R, and for example, the antibody or antigen-binding fragment thereof that specifically binds to GLP1R

[0319] (i) comprises a heavy chain immunoglobulin or a variable region thereof, said heavy chain immunoglobulin or its variable region comprising a CDR-H1, CDR-H2 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411; or a variant thereof; and / or

[0320] a light chain immunoglobulin or a variable region thereof, comprising a CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373;393 or 413; or a variant thereof;

[0321] (ii) is an antibody or antigen-binding fragment thereof that competes with the antibody or fragment of (i) for binding to GLP1R; and / or

[0322] (iii) is an antibody or antigen-binding fragment thereof that binds to the same epitope of GLP1R as the antibody or fragment of (i); the antibody or antigen-binding fragment thereof that specifically binds to GLP1R is conjugated to a compound having the structure of formula (III):

[0323]

[0324] in:

[0325] L p The linker is absent or includes one or more of the following: a carbamate group; a cyclodextrin; a polyethylene glycol (PEG) segment having 1 to 36 -CH2CH2O-(EG) units; one or more amino acids selected from glycine, serine, glutamic acid, alanine, valine, and proline, and combinations thereof;

[0326] Q is selected from -N3, wherein A is C or N;

[0327] X1 is selected from H;

[0328] X2 is selected from

[0329] X3 is selected from -(CH2) 2-6 -NH2, -(CH2) 2-6 -N3 and -CH3, provided that when X3 is -CH3, n is 1, and Ra is selected from -(CH2) in at least one occurrence 2-6 -NH2 and -(CH2) 2-6 -N3;

[0330] n is 0 or 1;

[0331] Ra is independently selected at each occurrence from H, -CH3, -(CH2) 2-6 -NH2 and -(CH2) 2-6 -N3;

[0332] X4 is selected from H and phenyl;

[0333] X5 is selected from -OH, -NH2, -NH-OH and

[0334] X6, at each occurrence, is independently selected from H, -OH, -CH3, and -CH2OH;

[0335] X7 is selected from H,

[0336] X8 is selected from H, -OH, -NH2 and

[0337] and pharmaceutically acceptable salts thereof;

[0338] Optionally, wherein the heavy chain immunoglobulin does not comprise a C-terminal lysine or a lysine and a glycine.

[0339] The present invention provides an ATDC, wherein the ATDC comprises an antibody or an antigen-binding fragment thereof that specifically binds to GLP1R, and for example, the antibody or antigen-binding fragment thereof that specifically binds to GLP1R

[0340] (i) comprises a heavy chain immunoglobulin or a variable region thereof, said heavy chain immunoglobulin or its variable region comprising a CDR-H1, CDR-H2 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411; or a variant thereof; and / or

[0341] a light chain immunoglobulin or a variable region thereof, comprising a CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373;393 or 413; or a variant thereof;

[0342] (ii) is an antibody or antigen-binding fragment thereof that competes with the antibody or fragment of (i) for binding to GLP1R; and / or

[0343] (iii) an antibody or antigen-binding fragment thereof that binds to the same epitope of GLP1R as the antibody or fragment of (i);

[0344] The antibody or antigen-binding fragment thereof that specifically binds to GLP1R is conjugated to a compound having a structure selected from the group consisting of:

[0345]

[0346]

[0347]

[0348]

[0349]

[0350]

[0351]

[0352]

[0353]

[0354]

[0355] or a pharmaceutically acceptable salt thereof;

[0356] Optionally, wherein the heavy chain immunoglobulin does not comprise a C-terminal lysine or a lysine and a glycine.

[0357] The present invention includes an ATDC comprising an antibody or antigen-binding fragment thereof that specifically binds to GLP1R, and for example, the antibody or antigen-binding fragment thereof that specifically binds to GLP1R

[0358] (i) comprises a heavy chain immunoglobulin or a variable region thereof, said heavy chain immunoglobulin or its variable region comprising a CDR-H1, CDR-H2 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411; or a variant thereof; and / or

[0359] a light chain immunoglobulin or a variable region thereof, comprising a CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373;393 or 413; or a variant thereof;

[0360] (ii) is an antibody or antigen-binding fragment thereof that competes with the antibody or fragment of (i) for binding to GLP1R; and / or

[0361] (iii) an antibody or antigen-binding fragment thereof that binds to the same epitope of GLP1R as the antibody or fragment of (i);

[0362] Optionally, the antibody or antigen-binding fragment thereof that specifically binds to GLP1R is conjugated to a payload having a structure selected from the group consisting of:

[0363]

[0364]

[0365]

[0366]

[0367]

[0368]

[0369]

[0370]

[0371] or a pharmaceutically acceptable salt thereof;

[0372] Optionally, wherein the heavy chain immunoglobulin does not comprise a C-terminal lysine or a lysine and a glycine.

[0373] In yet another aspect, an ATDC is provided herein, comprising an antibody or antigen-binding fragment thereof that specifically binds to GLP1R, and for example, the antibody or antigen-binding fragment thereof that specifically binds to GLP1R

[0374] (i) comprises a heavy chain immunoglobulin or a variable region thereof, said heavy chain immunoglobulin or its variable region comprising a CDR-H1, CDR-H2 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411; or a variant thereof; and / or

[0375] a light chain immunoglobulin or a variable region thereof, comprising a CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373;393 or 413; or a variant thereof;

[0376] (ii) is an antibody or antigen-binding fragment thereof that competes with the antibody or fragment of (i) for binding to GLP1R; and / or

[0377] (iii) an antibody or antigen-binding fragment thereof that binds to the same epitope of GLP1R as the antibody or fragment of (i);

[0378] The antibody or antigen-binding fragment thereof that specifically binds to GLP1R is conjugated to a payload having the following structure:

[0379]

[0380] in is the attachment point where the payload is attached to the antibody or antigen-binding fragment thereof directly or through a linker;

[0381] Optionally, wherein the heavy chain immunoglobulin does not comprise a C-terminal lysine or a lysine and a glycine.

[0382] In one embodiment, the payload on the ATDC comprises an antibody or antigen-binding fragment thereof that specifically binds to GLP1R, and for example, the antibody or antigen-binding fragment thereof that specifically binds to GLP1R

[0383] (i) comprises a heavy chain immunoglobulin or a variable region thereof, said heavy chain immunoglobulin or its variable region comprising a CDR-H1, CDR-H2 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411; or a variant thereof; and / or

[0384] a light chain immunoglobulin or a variable region thereof, comprising a CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373;393 or 413; or a variant thereof;

[0385] (ii) is an antibody or antigen-binding fragment thereof that competes with the antibody or fragment of (i) for binding to GLP1R; and / or

[0386] (iii) is an antibody or antigen-binding fragment thereof that binds to the same epitope of GLP1R as the antibody or fragment of (i); having the following structure:

[0387]

[0388] Optionally, wherein the heavy chain immunoglobulin does not comprise a C-terminal lysine or a lysine and a glycine.

[0389] In yet another aspect, provided herein is an ATDC comprising an antibody or antigen-binding fragment thereof targeting glucagon-like peptide-1 receptor (GLP1R).

[0390] The antibody or antigen-binding fragment thereof targeting the glucagon-like peptide-1 receptor (GLP1R) specifically binds to GLP1R, and for example, the antibody or antigen-binding fragment thereof targeting the glucagon-like peptide-1 receptor (GLP1R)

[0391] (i) comprises a heavy chain immunoglobulin or a variable region thereof, said heavy chain immunoglobulin or its variable region comprising a CDR-H1, CDR-H2 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411; or a variant thereof; and / or

[0392] a light chain immunoglobulin or a variable region thereof, comprising a CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373;393 or 413; or a variant thereof;

[0393] (ii) is an antibody or antigen-binding fragment thereof that competes with the antibody or fragment of (i) for binding to GLP1R; and / or

[0394] (iii) is an antibody or antigen-binding fragment thereof that binds to the same epitope of GLP1R as the antibody or fragment of (i); and the linker-payload has the following structure:

[0395]

[0396] in is the point of attachment of the linker-payload to the antibody or antigen-binding fragment thereof;

[0397] Optionally, wherein the heavy chain immunoglobulin does not comprise a C-terminal lysine or a lysine and a glycine.

[0398] In an embodiment of the present invention, a linker-payload of an ATDC comprising an antibody or antigen-binding fragment thereof that specifically binds to GLP1R, and for example, the antibody or antigen-binding fragment thereof that specifically binds to GLP1R

[0399] (i) comprises a heavy chain immunoglobulin or a variable region thereof, said heavy chain immunoglobulin or its variable region comprising a CDR-H1, CDR-H2 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411; or a variant thereof; and / or

[0400] a light chain immunoglobulin or a variable region thereof, comprising a CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373;393 or 413; or a variant thereof;

[0401] (ii) is an antibody or antigen-binding fragment thereof that competes with the antibody or fragment of (i) for binding to GLP1R; and / or

[0402] (iii) is an antibody or antigen-binding fragment thereof that binds to the same epitope of GLP1R as the antibody or fragment of (i); having the following structure:

[0403]

[0404] Optionally, wherein the heavy chain immunoglobulin does not comprise a C-terminal lysine or a lysine and a glycine.

[0405] These and other aspects of the present disclosure will become apparent to those skilled in the art after reading the following detailed description of the disclosure, including the appended claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0407] Figure 1A Schematic diagram showing exemplary antibody-tethered drug conjugate (ATDC) designs and their mechanism of action.

[0408] Figure 1BSchematic diagram showing conventional antibody-drug conjugate (ADC) design and its mechanism of action.

[0409] Figure 2 Shown is a model of an antibody-tethered drug conjugate with the antibody bound to the extracellular domain (ECD) and the payload bound to the transmembrane domain (TMD).

[0410] Figure 3A A schematic diagram of GLP1 (7-36) amide (SEQ ID NO: 4) is shown. The numbers above the sequence correspond to the amino acid positions in the proglucagon propeptide. The arrow between position 8 and position 9 indicates a dipeptidyl peptidase-4 (DPP-IV) cleavage site. The arrows between position 9 and position 10, between position 11 and position 12, between position 15 and position 16, between position 17 and position 18, between position 18 and position 19, between position 27 and position 28, between position 28 and position 29, and between position 31 and position 32 indicate neutral endopeptidase (NEP) cleavage sites. The dotted arrows between position 30 and position 31 and between position 32 and position 33 indicate cleavage sites by one or more unknown endoproteases. The residues at positions 7, 10, 13, 15, 28, and 29 are amino acids that, when substituted, reduce GLP1R binding and cAMP production. The residues at positions 9, 12, 32, and 36 are amino acids that, when substituted, reduce GLP1R binding.

[0411] Figure 3B The structure of GLP1R bound to GLP1 is shown (Protein Database ID: 3IOL). References to this structure can be found in Zhang et al. Nature 2017, Chepurny et al. JBC 2019, De Graaf et al. Pharmacological reviews 2016, and Manandhar and Ahn Journal of Medical Chemistry 2014, each of which is incorporated herein by reference in its entirety.

[0412] Figure 4A The sequence and structure of the GLP1 peptidomimetic peptide 5 (SEQ ID NO: 5) are shown. The numbers above the sequence correspond to the amino acid positions in the proglucagon propeptide.

[0413] Figure 4BShown are superimposed structures of GLP1R bound to peptide 5 (Protein Database ID: 5NX2) and GLP1 bound to GLP1 (Protein Database ID: 3IOL) using GLP1R in 5NX2 as a template. References to the 5NX2 structure can be found in Jazayeri A, et al., Nature, Vol. 546, pp. 254-258 (2017), which is incorporated herein by reference in its entirety.

[0414] Figure 5 A synthetic scheme for preparing GLP1 peptide mimetic payloads of the present disclosure is shown. Solid-phase peptide synthesis on resin was established, which efficiently produced the payloads of the present disclosure in good yields. Additional GLP1R peptide mimetic payloads were generated via systematic R1 / R2 / R3 modifications.

[0415] Figures 6A-6D It was shown that the GLP1R peptidomimetic payloads of the present disclosure showed no activation in relevant GPCR bioassays.

[0416] Figure 7A-7B It is shown that the shorter linker GLP1R ATDC displayed greater potency than the control ATDC.

[0417] Figure 8 It was shown that the leader linker-payload displayed the best in vitro ADME profile without in vitro cardiotoxicity and mutagenic potential, and its ATDC was highly stable in plasma.

[0418] Figure 9A Two methods for conjugating linker-payload to the antibodies of the disclosure are shown.

[0419] Figure 9B Representative hydrophobic interaction chromatography (HIC) images of the drug loading profiles of anti-GLP1R ATDCs are shown. HIC was used in the conjugability screen to triage ATDCs that showed low conjugation yield, low DAR, high aggregates, and poor Biacore binding.

[0420] Figure 10 CRE-dependent luciferase reporter gene activity of anti-GLP1R ATDC is shown. Anti-GLP1R ATDC showed better in vitro potency than isotype control ATDC. Unconjugated mAb did not activate hGLP1R cells (not shown). ATDC did not activate glucagon-like peptide-2 receptor (GLP2R), glucagon receptor (GCGR) or gastric inhibitory polypeptide receptor (GIPR) (not shown).

[0421] Figure 11AThe cyclic AMP response element (CRE)-dependent luciferase reporter gene activity of anti-GLP1R ATDC in the presence of unconjugated anti-GLP1R antibody is shown. It shows that unconjugated anti-GLP1R mAb concentrations <10 nM have no effect on anti-GLP1R ATDC activity. 100 nM unconjugated anti-GLP1R mAb reduced anti-GLP1R ATDC potency by 3.8-fold. The assay was performed by first adding unconjugated anti-GLP1R mAb, then immediately adding anti-GLP1R ATDC, and incubating for 4 hours.

[0422] Figure 11B Shown with Figure 11A The data corresponding to the graph in .

[0423] Figure 12 Shown is a schematic diagram of an exemplary GLP1R Q-tag mAb-GLP1R agonist conjugate of the present disclosure.

[0424] Figure 13 A general synthetic scheme for preparing GLP1 peptidomimetics according to the present disclosure is shown.

[0425] Figure 14 Shown is the sequence of solid supported synthesis of GLP1 peptidomimetic payloads P1 and P8 according to the present disclosure.

[0426] Figure 15 Shown is the sequence of solid supported synthesis of GLP1 peptidomimetic payloads P2 and P9 according to the present disclosure.

[0427] Figure 16 Shown is the order of solid supported synthesis of GLP1 peptidomimetic payloads P3, P4, P5, P6, P7, P11, P13, P14, P15, P16, and P17 according to the present disclosure.

[0428] Figure 17A and Figure 17B Shown is the order of solid supported synthesis of GLP1 peptidomimetic payloads P10, P12, P18, P19, P25, P26, P27, P28, P29, P30, P31, P36, P37, and P38 according to the present disclosure.

[0429] Figure 18 Shown is the sequence of solid supported synthesis of GLP1 peptidomimetic payloads P20 and P21 according to the present disclosure.

[0430] Figure 19 Shown is the sequence of solid supported synthesis of GLP1 peptidomimetic payloads P22 and P23 according to the present disclosure.

[0431] Figure 20 Shown is the sequence of the solid supported synthesis of the GLP1 peptidomimetic payload P24 according to the present disclosure.

[0432] Figure 21 Shown is the sequence of solid supported synthesis of GLP1 peptidomimetic payloads P32, P33, P34, and P35 according to the present disclosure.

[0433] Figure 22 Shown is the sequence of the solid supported synthesis of the GLP1 peptidomimetic payload P39 according to the present disclosure.

[0434] Figure 23 Shown is the sequence of the solid supported synthesis of the GLP1 peptidomimetic payload P40 according to the present disclosure.

[0435] Figure 24 Shown is the sequence of the solid supported synthesis of the GLP1 peptidomimetic payload P41 according to the present disclosure.

[0436] Figure 25 Shown is the sequence of the solid supported synthesis of the GLP1 peptidomimetic payload P42 according to the present disclosure.

[0437] Figure 26 Shown are synthetic routes for preparing linker-payloads LP1, LP2, LP3, LP4, and LP5 according to the present disclosure.

[0438] Figure 27 Shown are synthetic routes for preparing linker-payloads LP6 and LP7 according to the present disclosure.

[0439] Figure 28 Shown are synthetic routes for preparing linker-payloads LP8, LP9, LP10, and LP11 according to the present disclosure.

[0440] Figure 29 Shown is a synthetic route for preparing linker-payload LP12 according to the present disclosure.

[0441] Figure 30 Shown are synthetic routes for preparing linker-payloads LP13 and LP14 according to the present disclosure.

[0442] Figure 31 Shown are synthetic routes for preparing linker-payloads LP15 and LP18 according to the present disclosure.

[0443] Figure 32 Shown is a synthetic route for preparing linker-payload LP17 according to the present disclosure.

[0444] Figure 33 Shown are synthetic routes for preparing linker-payloads LP18 and LP20 according to the present disclosure.

[0445] Figure 34 Shown is a synthetic route for preparing linker-payload LP19 according to the present disclosure.

[0446] Figure 35 Shown is a synthetic route for preparing linker-payload LP21 according to the present disclosure.

[0447] Figure 36 Shown is a synthetic route for preparing linker-payload LP22 according to the present disclosure.

[0448] Figure 37 Shown is a synthetic route for preparing linker-payload LP23 according to the present disclosure.

[0449] Figure 38 Shown is a synthetic route for preparing linker-payload LP24 according to the present disclosure.

[0450] Figure 39 Shown is a synthetic route for preparing linker-payload LP25 according to the present disclosure.

[0451] Figure 40 Shown is a synthetic route for preparing linker-payload LP26 according to the present disclosure.

[0452] Figure 41 Shown are synthetic routes for preparing linker-payloads LP27 and LP28 according to the present disclosure.

[0453] Figure 42 Shown is a synthetic route for preparing linker-payload LP29 according to the present disclosure.

[0454] Figure 43 Shown is a synthetic route for preparing linker-payload LP30 according to the present disclosure.

[0455] Figure 44 Shown is a synthetic route for preparing linker-payload LP31 according to the present disclosure.

[0456] Figure 45 Shown is a synthetic route for preparing linker-payload LP32 according to the present disclosure.

[0457] Figure 46 Shown is a synthetic route for preparing linker-payload LP33 according to the present disclosure.

[0458] Figure 47A synthetic route for preparing linker-payload LP34 according to the present disclosure is shown.

[0459] Figure 48 Shown is a synthetic route for preparing linker-payload LP35 according to the present disclosure.

[0460] Figure 49 Shown are synthetic routes for preparing linker-payloads LP36, LP37, LP38, LP39, LP40, and LP41 according to the present disclosure.

[0461] Figure 50 Shown is a synthetic route for preparing linker-payload LP42 according to the present disclosure.

[0462] Figure 51 Shown is a synthetic route for preparing linker-payload LP43 according to the present disclosure.

[0463] Figure 52 A synthetic route for preparing linker-payload LP44 according to the present disclosure is shown.

[0464] Figure 53 Shown is a synthetic route for preparing linker-payload LP45 according to the present disclosure.

[0465] Figure 54 Schematic diagram showing the general two-step conjugation procedure for preparing site-specific antibody-drug conjugates.

[0466] Figure 55 Schematic diagram showing the general one-step conjugation procedure for preparing site-specific antibody-drug conjugates.

[0467] Figure 56 The command voltage scheme of electrophysiological research is shown. Starting from the holding potential of-80mV, voltage is first stepped to-50mV, continues 80ms, for leak subtraction (leak subtraction), and then stepped to+20mV, continues 4800ms, to open hERG channel. After this, voltage stepping is returned to-50mV, continues 5000ms, causes " rebound " or tail current, measures and collects this electric current for data analysis. Finally, voltage stepping is returned to holding potential (-80mV, 1000ms). Voltage command scheme is repeated once every 20 seconds, and is carried out continuously during test (vehicle control and test compound).

[0468] Figure 57 The in vitro stability of anti-GLP1R mAB2-LP11 in mouse, monkey, and human plasma following 7 days of incubation at 37°C is shown.

[0469] Figure 58Shown are the effects of GLP1R ATDC on the percent body weight change in obese GLP1R humanized mice.

[0470] Figure 59 Shown are the effects of GLP1R ATDC on blood glucose levels in obese GLP1R humanized mice.

[0471] Figure 60 is a schematic diagram of a GLP1R ATDC according to an exemplary embodiment of the present disclosure. Such ATDCs, including those wherein the antibody is REGN15869, REGN18121 or REGN18123, form part of the present invention.

[0472] Figure 61 Figure 1 is a diagram of an anti-GLP1R antibody with a linker payload (LP) attached to each LCVR via a glutamine residue (Q) in the Q tag (LLQGSG (SEQ ID NO: 18)), the linker payload (LP) being M3190. The bond between the glutamine side chain and the linker is shown; and the bond between the N-terminal LCVR residue and the C-terminal Q tag glycine is shown. [Image of the antibody Q tag Gln attached to the linker of M3190] = point of attachment of the antibody Q tag Gln to M3190. Such ATDCs, including those in which the antibody is REGN15869, REGN18121, or REGN18123, form part of the present invention.

[0473] Figure 62 is a comparison between GLP1 (upper panel) and ATDC comprising an anti-GLP1R antibody with a LLQGSG (SEQ ID NO: 18) Q-tag conjugated to a linker-payload, which is M3190 (lower panel). E* is (S)-2-amino-3-(2H-tetrazol-5-yl)propanoic acid; F* is (S)-2-amino-3-(2-fluorophenyl)-2-methylpropanoic acid; Cap-Aib is 3-((2-(1H-imidazol-5-yl)ethyl)amino)-2,2-dimethyl-3-oxopropanoic acid; AA2 is (S)-2-amino-3-(4'-(4-(25-amino-2,5,8,11,14,17,20,23-octaoxapentacosyl)-1H-1,2,3-triazol-1-yl)butoxy)-2'-ethyl-[1,1'-biphenyl]-4-yl)propanoic acid [AA2 includes the linker]; and AA1 = (S)-2-amino-5-(3,5-dimethylphenyl)pentanamide. Such ATDCs, including those wherein the antibody is REGN15869, REGN18121 or REGN18123, form part of the present invention.

[0474] Figure 63CryoEM reconstructions and epitopes of the GLP-1R / REGN9268 / M3190 complex are shown. (A) shows a CryoEM reconstruction of REGN9268-M3190 Fab bound to GLP-1R / Gs ("tethered" complex). (B) shows a CryoEM reconstruction of REGN9268 Fab bound to GLP1R / Gs / M3190 ("untethered" complex). There is no density for G protein in (B) because the map was calculated from a local refinement after subtracting the G protein signal. The positions of the GLP-1R domains and complex components are labeled in (A), (B), and (C). An expanded view of the REGN9268 / GLP-1R interface is shown. GLP-1R contact residues (in the REGN9268 inside) are shown as bars and are labeled.

[0475] Figure 64 CryoEM reconstructions and epitopes of the GLP-1R / REGN15869 / M3190 complex are shown. (A) CryoEM reconstruction of REGN15869-M3190 Fab bound to GLP-1R / Gs ("tethered" complex) is shown. (B) CryoEM reconstruction of REGN15869 Fab bound to GLP1R / Gs / M3190 ("untethered" complex) is shown. The positions of the GLP-1R domains and complex components are labeled in (A), (B), and (C), with (C) showing an expanded view of the REGN15869 / GLP-1R interface. GLP-1R contact residues (in the REGN15869) inside) are shown as bars and are labeled.

[0476] The drawings of the present application are related to the drawings of WO 2022056494 (PCT / US2021 / 050337), which is hereby incorporated by reference. DETAILED DESCRIPTION

[0477] In some aspects, the present disclosure provides antibody-drug conjugates that specifically bind to glucagon-like peptide 1 receptor (GLP1R) protein. As described in the background section above, GLP1R and its ligand GLP1 are highly effective targets for obesity and type 2 diabetes. However, direct agonist antibodies for the treatment of type 2 diabetes have not yet been identified. Single peptides with agonist activity against GLP1R are effective therapeutic agents for glucose control and weight loss, but in-line peptide-antibody fusions are susceptible to proteolysis. In certain embodiments of the present disclosure, antibody-drug conjugates are produced that combine an antibody or antigen-binding fragment thereof that specifically targets the extracellular domain of GLP1R with a GLP1 peptide mimetic that functionally activates GLP1R. In certain embodiments, the antibody-drug conjugates of the present disclosure have longer drug duration, comparable or better weight and glucose lowering efficacy, and minimized off-target side effects.

[0478] Detailed embodiments of the present disclosure are disclosed herein; however, it should be understood that the disclosed embodiments are merely illustrative of the present disclosure that can be embodied in various forms. Furthermore, each example provided in conjunction with the various embodiments of the present disclosure is intended to be illustrative rather than limiting. Therefore, the specific structural and functional details disclosed herein should not be interpreted as limiting, but merely as a representative basis for teaching one skilled in the art to variously utilize the present disclosure.

[0479] definition

[0480] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

[0481] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a method" includes one or more methods, and / or steps of the type described herein and / or which will become apparent to those skilled in the art upon reading this disclosure.

[0482] As used herein, "subject" or "patient" or "individual" or "animal" refers to humans, veterinary animals (e.g., cats, dogs, cows, horses, sheep, pigs, etc.), and experimental animal models of disease (e.g., mice, rats). In preferred embodiments, the subject is a human.

[0483] The phrase "pharmaceutically acceptable salt" as used in conjunction with the compositions of the present disclosure refers to any salt suitable for administration to a patient. Suitable salts include, but are not limited to, those disclosed in Berge et al., "Pharmaceutical Salts", J. Pharm. Sci., 1977, 66:1, which is incorporated herein by reference. Examples of salts include, but are not limited to, salts of acid origin, salts of base origin, organic salts, inorganic salts, amine salts, and alkali metal or alkaline earth metal salts, including, but not limited to, calcium salts, magnesium salts, potassium salts, sodium salts, salts of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. In some instances, the payload described herein comprises a tertiary amine, wherein the nitrogen atom in the tertiary amine is the atom through which the payload is bonded to the linker or linker-spacer. In such cases, bonding to the tertiary amine of the payload creates a quaternary amine in the linker-payload molecule. The positive charge on the quaternary amine can be balanced by a counter ion (e.g., chloride, bromide, iodide, or any other suitably charged moiety, such as those described herein).

[0484] Ranges may be expressed herein as from "about" or "approximately" one particular value, and / or to "about" or "approximately" another particular value. When such a range is expressed, another embodiment includes from the one particular value and / or to the other particular value.

[0485] “Comprising” or “containing” or “including” means that at least the specified compound, element, particle or method step is present in the composition or article or method, but does not exclude the presence of other compounds, materials, particles or method steps, even if such other compounds, materials, particles or method steps have the same function as the specified compound, material, particle or method step.

[0486] The compounds of the present disclosure, such as payloads and linker-payloads, include those generally described herein and are further illustrated by the classes, subclasses, and species disclosed herein. As used herein, unless otherwise indicated, the following definitions shall apply. For the purposes of the present disclosure, chemical elements are identified according to the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th edition. Additionally, the general principles of organic chemistry are described in: "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999, and "March's Advanced Organic Chemistry", 5th edition, eds.: Smith, MB and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference.

[0487] As used herein, the term "alkyl" is given its ordinary meaning in the art and can include saturated aliphatic groups, including straight chain alkyl groups, branched chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl-substituted cycloalkyl groups, and cycloalkyl-substituted alkyl groups. In certain embodiments, a straight chain alkyl group or a branched chain alkyl group has about 1 to 20 carbon atoms in its backbone (e.g., a straight chain is C1-C1 20 , the branch chain is C2-C 20 ), and optionally, about 1-10 carbon atoms or about 1 to 6 carbon atoms. In some embodiments, the cycloalkyl ring has about 3-10 carbon atoms in its ring structure, wherein such ring is monocyclic or bicyclic, and optionally has about 5, 6 or 7 carbons in the ring structure. In some embodiments, the alkyl group can be a lower alkyl group, wherein the lower alkyl group includes 1-4 carbon atoms (e.g., C1-C4 for straight chain lower alkyl).

[0488] As used herein, the term "alkenyl" refers to an alkyl group, as defined herein, having one or more double bonds.

[0489] As used herein, the term "alkynyl" refers to an alkyl group, as defined herein, having one or more triple bonds.

[0490] The term "heteroatom" means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen; or a substitutable nitrogen of a heterocycle).

[0491] The term "halogen" means F, Cl, Br or I; the term "halide" refers to a halogen group or substituent, ie, -F, -Cl, -Br or -I.

[0492] The term "adduct" of the present disclosure, such as "Diels-Alder adduct", encompasses any moiety comprising the product of an addition reaction (such as a Diels-Alder reaction), regardless of the synthetic steps taken to produce that moiety.

[0493] The term "covalent attachment" means the formation of a covalent bond, i.e., a chemical bond involving a common pair of one or more electrons between two atoms. Covalent bonding can include different interactions, including but not limited to σ bonding, π-bonding, metal-to-metal bonding, agostic interactions, bent bonds, and three-center two-electron bonds. When a first group is referred to as "capable of covalent attachment" to a second group, this means that the first group is capable of forming a covalent bond directly or indirectly with the second group, for example, by using a catalyst or under specific reaction conditions. Non-limiting examples of groups capable of covalent attachment to each other can include, for example, amines and carboxylic acids (forming amide bonds), dienes and dienophiles (via Diels-Alder reactions), maleimides and thiols (forming thiol-maleimides), and azides and alkynes (forming triazoles via 1,3-cycloaddition reactions).

[0494] As described herein, compounds of the present disclosure (e.g., payloads and linker-payloads) can contain "optionally substituted" moieties. In general, the term "substituted," whether or not preceded by the term "optionally," means that one or more hydrogens of the designated moiety are replaced by a suitable substituent. Unless otherwise indicated, an "optionally substituted" group can have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure can be substituted by more than one substituent selected from a designated group, the substituent can be the same or different at each position. Combinations of substituents contemplated by the present disclosure are preferably those that result in the formation of stable or chemically feasible compounds.

[0495] As used herein, the term "stable" with reference to a compound refers to a compound that is not substantially altered when subjected to conditions that allow for its production, detection, and, in certain embodiments, its recovery, purification, and use for one or more of the purposes disclosed herein.

[0496] Unless otherwise indicated, structures depicted herein are also intended to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of this disclosure.

[0497] Unless otherwise indicated, cycloadducts described herein, such as products of cycloaddition reactions, such as products of azide-acetylene cycloaddition reactions or Diels-Alder reactions, include all positional isomers, i.e., structural isomers that differ only in the position of functional groups or substituents. By way of example, the following structures represent triazole positional isomers that differ only in the position of substituents on the triazole ring:

[0498] Triazole positional isomers can also be represented by the following structures:

[0499] Unless otherwise stated, all tautomeric forms of the compounds of the present disclosure are within the scope of the present disclosure.

[0500] Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, in addition to replacing hydrogen with deuterium or tritium, or with 11 C- or 13 C- or 14 Compounds having the present structures other than C-enriched carbon in place of carbon are within the scope of this disclosure.

[0501] It should also be understood that reference to one or more method steps does not exclude the presence of additional method steps or intermediate method steps between those steps that are explicitly identified. Similarly, it should also be understood that reference to one or more components in an apparatus or system does not exclude the presence of additional components or intermediate components between those components that are explicitly identified.

[0502] Unless otherwise indicated, all crystalline forms of the compounds of the present disclosure and their salts are also within the scope of the present disclosure. The compounds of the present disclosure can be isolated in a variety of amorphous and crystalline forms, including but not limited to anhydrous, hydrated, non-solvated or solvated forms. Exemplary hydrates include hemihydrates, monohydrates, dihydrates, etc. In some embodiments, the compounds of the present disclosure are anhydrous and non-solvated. "Anhydrous" means that the crystalline form of the compound is substantially free of bound water in the crystal lattice structure, i.e., the compound does not form a crystalline hydrate.

[0503] As used herein, "crystalline form" means a certain lattice configuration of a crystalline material. Different crystalline forms of the same material typically have different crystal lattices (e.g., unit cells), which result in different physical properties characteristic of each crystalline form. In some cases, different lattice configurations have different water or solvent contents. Different crystal lattices can be identified by solid-state characterization methods such as X-ray powder diffraction (PXRD). Other characterization methods, such as differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), dynamic vapor sorption (DVS), solid-state NMR, etc., further help identify the crystalline form and help determine stability and solvent / water content.

[0504] Crystalline forms of substances include both solvated (e.g., hydrated) and non-solvated (e.g., anhydrous) forms. A hydrated form is a crystalline form that includes water in the crystal lattice. A hydrated form can be a stoichiometric hydrate, wherein water is present in the crystal lattice at a certain water / molecule ratio, such as a hemihydrate, a monohydrate, a dihydrate, etc. A hydrated form can also be a non-stoichiometric form, wherein the water content is variable and depends on external conditions such as humidity.

[0505] In some embodiments, the compounds of the present disclosure are substantially isolated. "Substantially isolated" means that a particular compound is at least partially separated from impurities. For example, in some embodiments, the compounds of the present disclosure include less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 2.5%, less than about 1%, or less than about 0.5% impurities. Impurities generally include anything that is not a substantially isolated compound, including, for example, other crystalline forms and other substances.

[0506] Certain groups, moieties, substituents, and atoms are depicted with wavy lines. The wavy lines may intersect or cap one or more bonds. The wavy lines indicate the atoms to which the groups, moieties, substituents, or atoms are bonded. For example, a phenyl group substituted with a propyl group as depicted below:

[0507] Has the following structure:

[0508] The term "GLP1R" refers to the glucagon-like peptide 1 receptor and includes recombinant GLP1R proteins or fragments thereof. GLP1R has a sequence of 463 residues. Donnelly, Br J Pharmacol, 166(1):27-41(2011). Glucagon-like peptide 1 (GLP1) is a 31-amino acid peptide hormone released from intestinal L cells after nutrient consumption. Binding of GLP1 to GLP1R enhances glucose-induced insulin secretion from pancreatic β cells, increases insulin expression, inhibits β cell apoptosis, promotes β cell regeneration, reduces glucagon secretion, delays gastric emptying, promotes satiety, and increases peripheral glucose disposal.

[0509] Antibody-tethered drug conjugates (ATDCs) or antibody-drug conjugates (ADCs) refer to antibodies or antigen-binding fragments thereof tethered to a payload (e.g., a GLP1 peptide mimetic) with or without a linker. Antibody-payload conjugates refer to such antibodies or fragments connected to a payload, while antibody-linker-payload conjugates refer to antibodies or fragments conjugated to a payload via a linker. The antibodies or antigen-binding fragments mentioned herein include embodiments in which the antibody or fragment is conjugated to a payload or linker-payload.

[0510] Anti-GLP1R antigen binding proteins and conjugates

[0511] The present invention provides antigen binding proteins, such as antibodies and antigen binding fragments thereof, that specifically bind to GLP1R that can be conjugated to a payload, e.g., via a linker (linker-payload) (e.g., REGN7990; REGN9268; REGN15869; REGN18121; REGN18123; REGN8070; REGN8072; REGN9267; REGN7988; REGN5619; REGN7989; REGN8069; REGN8071; REGN9426; REGN5203; REGN5204; REGN5617; REGN5619; REGN7987; REGN9270; REGN9278; REGN9279 or REGN9280, e.g., wherein the linker-payload is LP11, LP30 or LP32). In an embodiment of the invention, the anti-GLP1R antibody or antigen-binding fragment tethered to the payload has the following structure:

[0512] BA-(LP)m(A),

[0513] BA-LP(I)

[0514] in:

[0515] BA is an anti-GLP1R antibody or an antigen-binding fragment thereof:

[0516] (i) comprises a heavy chain immunoglobulin or a variable region thereof, said heavy chain immunoglobulin or its variable region comprising a CDR-H1, CDR-H2 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411; or a variant thereof; and / or

[0517] a light chain immunoglobulin or a variable region thereof, comprising a CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373;393 or 413; or a variant thereof;

[0518] (ii) the anti-GLP1R antibody or antigen-binding fragment thereof is an antibody or antigen-binding fragment thereof that competes with the antibody or fragment of (i) for binding to GLP1R; and / or

[0519] (iii) the anti-GLP1R antibody or antigen-binding fragment thereof is an antibody or antigen-binding fragment thereof that binds to the same epitope of GLP1R as the antibody or fragment of (i);

[0520] L is a non-cleavable linker;

[0521] P is a payload (e.g., a drug payload such as a GLP1 peptide mimetic); and

[0522] m is 1, 2, 3, or 4.

[0523] For example, see Figure 61 ATDC in.

[0524] Antibodies or antigen-binding fragments thereof or conjugates thereof that specifically bind to GLP1R may be referred to as "anti-GLP1R". Anti-GLP1R antibodies and antigen-binding fragments thereof refer to antibodies that bind to GLP1R with a K affinity of about 1-2 nM or greater. D Antibodies and fragments that bind to GLP1R.

[0525] As used herein, an "agonist" antibody or antigen-binding fragment thereof (e.g., ATDC) is an antibody or fragment that increases or enhances at least one biological activity of GLP1R. Such an increase or enhancement can be mediated by the antibody itself or by the payload or linker-payload of the ATDC. For example, if the cell is a mammalian pancreatic beta cell, the agonist antibody or fragment can trigger stimulation of the adenylate cyclase pathway, resulting in increased synthesis of cyclic AMP and release of insulin. Other biological activities of GLP1R can be cAMP-dependent activation of protein kinase A (PKA) and / or cAMP-regulated guanine nucleotide exchange factor 2 (Epac2). The agonist antibody or fragment can also reduce glucose levels or reduce body weight after administration to a subject in need thereof.

[0526] A "neutral" antibody or "neutral" binder with respect to an anti-GLP1R antibody or antigen-binding fragment thereof refers to an antibody or fragment that binds to GLP1R but does not significantly activate a biological activity of GLP1R (eg, stimulation of the adenylate cyclase pathway).

[0527] All amino acid abbreviations used in this disclosure are those accepted by the United States Patent and Trademark Office as set forth in 37 CFR §1.822(B)(J).

[0528] The term "protein" or "polypeptide" means any amino acid polymer having amino acids covalently linked via peptide bonds."Protein" includes recombinant proteins used in biotherapeutic proteins, research or therapy, trap proteins and other Fc fusion proteins, chimeric proteins, antibodies, monoclonal antibodies, human antibodies, bispecific antibodies, antibody fragments, nanobodies, recombinant antibody chimeras, scFv fusion proteins, cytokines, chemokines, peptide hormones, etc. Proteins can be produced using a recombinant cell-based production system, such as an insect baculovirus system, a yeast system (e.g., Pichia species (Pichiasp) such as Pichia pastoris (Pichia pastoris)), a mammalian system (e.g., CHO cells and CHO derivatives such as CHO-K1 cells).

[0529] Polynucleotides include DNA and RNA.

[0530] Unless specified as being from a non-human species, eg, "mouse GLP1R," "monkey GLP1R," etc., "GLP1R" means human GLP1R.

[0531] The amino acid sequence of an antibody or antigen-binding fragment thereof can be numbered using any known numbering scheme, including those described by Kabat et al., (the "Kabat" numbering scheme); Al-Lazikani et al., 1997, J. Mol. Biol., 273:927-948 (the "Chothia" numbering scheme); MacCallum et al., 1996, J. Mol. Biol. 262:732-745 (the "Contact" numbering scheme); Lefranc et al., Dev. Comp. Immunol., 2003, 27:55-77 (the "IMGT" numbering scheme); and Honegge and Pluckthun, J. Mol. Biol., 2001, 309:657-70 (the "AHo" numbering scheme). In embodiments of the invention, the CDRs of the heavy or light chain immunoglobulin of an anti-GLP1R antibody or antigen-binding fragment (e.g., REGN7990; REGN9268; REGN15869; REGN18121; REGN18123; REGN8070; REGN8072; REGN9267; REGN7988; REGN5619; REGN7989; REGN8069; REGN8071; REGN9426; REGN5203; REGN5204; REGN5617; REGN5619; REGN7987; REGN9270; REGN9278; REGN9279 or REGN9280, e.g., wherein the linker-payload is LP11, LP30 or LP32) are as defined by Kabat, Chohia, Contact, IMGT or AHo.

[0532] The anti-GLP1R antibodies and antigen-binding fragments of the present invention may be glutamine-modified. The term "glutamine-modified" antibodies, for example, refers to antibodies of the present disclosure having a glutamine side chain (from LLQGSG (SEQ ID In certain embodiments of the invention, the primary amine compound is linked via an amide linkage on the glutamine side chain. In certain embodiments of the present invention, glutamine is endogenous glutamine. In other embodiments of the present invention, glutamine is endogenous glutamine that is made reactive by polypeptide engineering (e.g., via amino acid deletion, insertion, substitution, or mutation on the polypeptide). In another embodiment of the present invention, glutamine is a polypeptide engineered with a tag containing an acyl donor glutamine (e.g., a glutamine-containing peptide tag, Q-tag, or TG enzyme recognition tag).

[0533] Transglutaminase (TG enzyme) is an enzyme that catalyzes the transamidation reaction of glutamine (Q) residues in a recognition sequence ("Q-tag" or "Q tag" or "TG enzyme recognition tag") relative to other glutamines in the heavy chain of, for example, IgG to promote site-specific modification. In an embodiment of the present invention, the antibody or its antigen-binding fragment has been modified to include a TG enzyme recognition tag. Suitable TG enzyme recognition tags include those described herein. In an embodiment of the present invention, the TG enzyme is a microbial transglutaminase, such as a Streptomyces transglutaminase. Sarafeddinov, A Novel Transglutaminase Substrate from Streptomyces mobaraensis Inhibiting Papain-Like Cysteine ​​Proteases”, J. Microbiol. Biotechnol. 2011, 21: 617-26. In an embodiment of the present invention, a transglutaminase enzyme links an amine to glutamine (Gln, Q) (e.g., in a Q tag having the amino acid sequence LLQGSG (SEQ ID NO: 18)) according to the following reaction scheme: Gln(C=O)NH2+RNH2→Gln(C=O)NHR+NH3; for example, wherein RNH2 comprises H2N-((CH2)2-O)n-.

[0534] The term "TG enzyme recognition tag" refers to an amino acid sequence comprising an acceptor glutamine residue, and the acceptor glutamine residue, when incorporated into (e.g., attached to) a polypeptide sequence, is recognized by a TG enzyme (transglutaminase) under suitable conditions, and the reaction between the amino acid side chains in the amino acid sequence and the reaction partner causes the cross-linking of the TG enzyme. The recognition tag can be a peptide sequence that is not naturally present in the polypeptide comprising the TG enzyme recognition tag. In some embodiments of the invention, the TG enzyme recognition tag includes at least one Gln. In some embodiments of the invention, the TG enzyme recognition tag includes an amino acid sequence XXQX, wherein X is any amino acid (e.g., conventional amino acids Leu, Ala, Gly, Ser, Val, Phe, Tyr, His, Arg, Asn, Glu, Asp, Cys, Met, Pro, Thr, Lys, or Trp or unconventional amino acids). In some embodiments of the invention, the acyl donor glutamine-containing tag comprises an amino acid sequence selected from the group consisting of LLQGG (SEQ ID NO: 6), LLQG (SEQ ID NO: 7), LSLSQG (SEQ ID NO: 8), GGGLLQGG (SEQ ID NO: 9), GLLQG (SEQ ID NO: 10), LLQ, GSPLAQSHGG (SEQ ID NO: 11), GLLQGGG (SEQ ID NO: 12), GLLQGG (SEQ ID NO: 13), GLLQ (SEQ ID NO: 14), LLQLLQGA (SEQ ID NO: 15), LLQGA (SEQ ID NO: 16), LLQYQGA (SEQ ID NO: 17), LLQGSG (SEQ ID NO: 18), LLQYQG (SEQ ID NO: 19), LLQLLQG (SEQ ID NO: 20), SLLQG (SEQ ID NO: 21), LLQLQ (SEQ ID NO: 22), LLQLLQ (SEQ ID NO: 23). NO: 23), LLQGSGSG (SEQ ID NO: 185) and LLQGR (SEQ ID NO: 24). See, for example, International Patent Application Publication No. WO 2012 / 059882 or U.S. Patent No. 10,842,881, the entire contents of which are incorporated herein by reference.

[0535] In certain embodiments, the antibody or antigen-binding fragment thereof has been modified to include a Q-tag at the N-terminus of one or both antibody or fragment light chains. In certain embodiments, the antibody or fragment has been modified to include a Q-tag at the N-terminus of both antibody light chains.

[0536] In certain embodiments, the antibody or antigen-binding fragment thereof has been modified to include a Q-tag at the N-terminus of one or both antibody or antigen-binding fragment heavy chains. In certain embodiments, the antibody or antigen-binding fragment thereof has been modified to include a Q-tag at the N-terminus of both antibody heavy chains.

[0537] In certain embodiments, the antibody or antigen-binding fragment thereof has been modified to include a Q-tag at the C-terminus of one or both antibody or antigen-binding fragment light chains. In certain embodiments, the antibody or antigen-binding fragment thereof has been modified to include a Q-tag at the C-terminus of both antibody light chains.

[0538] In certain embodiments, the antibody or antigen-binding fragment thereof has been modified to include a Q-tag at the C-terminus of one or both antibody or antigen-binding fragment heavy chains. In certain embodiments, the antibody or antigen-binding fragment thereof has been modified to include a Q-tag at the C-terminus of both antibody heavy chains.

[0539] The term "antibody" refers to an immunoglobulin molecule and a polymer thereof (e.g., IgM) comprising four polypeptide chains, i.e., two heavy chains (HC) and two light chains (LC), interconnected by disulfide bonds. Preferably, the antibody is an IgG form (e.g., IgG1, IgG2, IgG3, or IgG4 or a variant thereof, such as an IgG4 with an S228P mutation) having two heavy chains and two light chains interconnected by disulfide bonds to form a tetramer with a Y-like shape. See Silva et al., The S228P Mutation Prevents in Vivo and in Vitro IgG4 Fab-arm Exchange as Demonstrated using a Combination of Novel Quantitative Immunoassays and Physiological Matrix Preparation, THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 290, NO. 9, pp. 5462-5469 (2015). In an embodiment of the invention, the antibody or antigen-binding fragment is IgA, IgD, IgE, IgM, IgAl or IgA2 (or variants thereof).The antibody can be conjugated to a payload, for example, via a linker.

[0540] The antibody or antigen-binding fragment can be in any form known to those skilled in the art. In certain embodiments, the antibody or fragment comprises a light chain. In certain embodiments, the light chain is a kappa light chain. In certain embodiments, the light chain is a lambda light chain.

[0541] Each heavy chain comprises a heavy chain variable region (abbreviated herein as HCVR or VH ) and a heavy chain constant region (e.g., a human heavy chain constant region). Each light chain comprises a light chain variable region (abbreviated herein as LCVR or V L ) and a light chain constant region (e.g., a human light chain constant region). V H Area and V L The V domains can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FRs). H and V L It comprises three CDRs and four FRs, arranged in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In various embodiments, the FRs of the antibody (or its antigen-binding portion) may be identical to human germline sequences, or may be naturally or artificially modified. An amino acid consensus sequence may be defined based on a side-by-side analysis of two or more CDRs.

[0542] Antigen-binding fragments of antibodies that specifically bind to GLP1R are also part of the present invention. As used herein, the terms "antigen-binding portion" of an antibody, "antigen-binding fragment" of an antibody, etc. include any naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds to an antigen to form a complex. Antigen-binding fragments of an antibody can be obtained from, for example, antibody molecules using any suitable standard techniques, such as proteolytic digestion or recombinant genetic engineering techniques, including manipulation and expression of DNA encoding antibody variable domains and optionally constant domains. Such DNA is known and / or readily available from, for example, commercial sources, DNA libraries (including, for example, phage antibody libraries), or can be synthesized. The DNA can be sequenced and manipulated chemically or by using molecular biology techniques, for example, to arrange one or more variable domains and / or constant domains into a suitable configuration, or to introduce codons, generate cysteine ​​residues, modify, add, or delete amino acids, etc. The antigen-binding fragment can be conjugated to a payload, for example, via a linker.

[0543] Non-limiting examples of antigen-binding fragments include: (i) Fab fragments; (ii) F(ab')2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single-chain Fv (scFv) or scFv-Fc molecules; (vi) dAb fragments; and (vii) the smallest recognition unit consisting of amino acid residues that mimic the hypervariable region of an antibody (e.g., an isolated complementary determining region (CDR) such as a CDR3 peptide) or a constrained FR3-CDR3-FR4 peptide. In some aspects of the invention, the antibody fragment is, and in some aspects, the antibody fragment is a Fab' fragment. Other engineered molecules, such as domain-specific antibodies, single domain antibodies, domain-deleted antibodies, chimeric antibodies, CDR-grafted antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (e.g., monovalent nanobodies, divalent nanobodies, etc.), small modular immunopharmaceuticals (SMIPs), and shark variable IgNAR domains are also encompassed within the expression "antigen-binding fragment" as used herein.

[0544] The antigen-binding fragment of an antibody may comprise at least one variable domain. The variable domain may have any size or amino acid composition and will generally comprise at least one CDR adjacent to or in frame with one or more framework sequences. L Domain-related V H In the antigen-binding fragment of the structural domain, V H and V L The domains can be positioned relative to each other in any suitable arrangement. For example, the variable region can be a dimer and comprise V H -V H 、V H -V L or V L -V L dimer.

[0545] Alternatively, the antigen-binding fragment of an antibody may contain a monomeric V H or V L domain.

[0546] The antigen-binding fragment of an antibody may contain at least one variable domain covalently linked to at least one constant domain. Non-limiting exemplary configurations of variable and constant domains that may be present in the antigen-binding fragment of an antibody of the present disclosure include: (i) V H -C H 1; (ii) V H -C H 2; (iii) V H -C H3; (iv) V H -C H 1-C H 2; (V)V H -C H 1-C H 2-C H 3; (vi) V H -C H 2-C H 3; (vii) V H -C L ;(viii)V L -C H 1; (ix) V L -C H 2;(x)V L -C H 3; (xi) V L -C H 1-C H 2; (xii) V L -C H 1-C H 2-C H 3;(xiii)V L -C H 2-C H 3; and (xiv) V L -C L In any configuration of variable and constant domains (including any of the exemplary configurations listed herein), the variable and constant domains may be directly linked to each other, or may be linked by a complete or partial hinge or linker region. The hinge region may be composed of at least 2 (e.g., 5, 10, 15, 20, 40, 60 or more) amino acids that result in a flexible or semi-flexible connection between adjacent variable and / or constant domains in a single polypeptide molecule.

[0547] Furthermore, the antigen-binding fragments of the antibodies of the present disclosure may include each other and / or one or more monomeric V H domain or V L A homodimer or heterodimer (or other multimer) of any of the variable and constant domain configurations listed herein in which the domains are non-covalently associated (e.g., through one or more disulfide bonds).

[0548] As with antibodies, antigen-binding fragments can be monospecific or multispecific (e.g., bispecific). A multispecific antigen-binding fragment of an antibody may include at least two different variable domains, each of which is capable of specifically binding to a separate antigen or to a different epitope on the same antigen. Any multispecific antibody format, including the exemplary bispecific antibody formats disclosed herein, can be adapted for use in the context of the antigen-binding fragments of the antibodies of this specification using conventional techniques available in the art.

[0549] In certain embodiments, the antibodies of the present description, such as anti-GLP1R antibodies, are human antibodies. As used herein, the term "human antibody" is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. The human antibodies of the present description may include amino acid residues that are not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random mutagenesis or site-specific mutagenesis in vitro or by somatic mutations in vivo), for example, in CDRs and particularly in CDR3. However, the term "human antibody" as used herein is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species (such as a mouse) have been grafted onto human framework sequences.

[0550] In an embodiment of the present invention, the antibody is a monoclonal antibody. In an embodiment of the present invention, the antibody is a polyclonal antibody. In an embodiment of the present invention, the antibody is a chimeric antibody. In an embodiment of the present invention, the antibody is a humanized antibody.

[0551] In some embodiments, antibody and Fab can be recombinant antibody and Fab.As used herein, term " recombinant " antibody is intended to include the antibody prepared, expressed, produced or separated by recombinant means.For example, recombinant antibodies include those recombinant antibodies expressed using the recombinant expression vector transfected into host cells (for example, Chinese hamster ovary cells), and the recombinant antibodies are optionally separated from the culture medium of host cells and / or host cell growth. Recombinant antibodies include those separated from recombinant combinatorial human antibody libraries, antibodies separated from transgenic animals (such as mice) for human immunoglobulin genes (see, for example, Taylor et al. (1992) Nucl.Acids Res.20:6287-6295) or by including human immunoglobulin gene sequences being spliced ​​to other DNA sequences by any other means, expression, production or separation of antibodies.Such human antibodies have variable regions and constant regions derived from human germline immunoglobulin sequences. However, in certain embodiments, such human antibodies are subjected to in vitro mutagenesis (or, when animals transgenic for human Ig sequences are used, in vivo somatic mutagenesis), and thus the V H and VL The amino acid sequence of the region is such a sequence that, although derived from human germline V H and V L sequence and human germline V H and V L Sequences are related but may not naturally occur in the human antibody germline repertoire in vivo.

[0552] The antibody and Fab of this specification can be separated or purified antibodies. As used herein, "separated antibody" or "purified antibody" means an antibody identified and separated and / or recovered from at least one component of its natural environment. For the purposes of this specification, for example, an antibody separated or taken out from at least one component of an organism or from a naturally occurring or naturally occurring tissue or cell of the antibody is a "separated antibody". In addition, an antibody partially or completely removed from a recombinant host cell in which the antibody is produced is "separated". For example, an antibody purified from at least one component of a reaction or reaction sequence is a "separated" or "purified" antibody. Separated antibodies also include in situ antibodies in recombinant cells. Separated antibodies include those that have undergone at least one purification or separation step. According to certain embodiments, separated antibodies or purified antibodies can be substantially free of other cellular substances and / or chemicals.

[0553] Compared to the corresponding germline sequence from which the antibody is derived, the antibodies and antigen-binding fragments disclosed herein may include one or more amino acid substitutions, insertions and / or deletions in the framework and / or CDR regions of the heavy and light chain variable domains. Such mutations can be easily determined by comparing the amino acid sequences disclosed herein with germline sequences available from, for example, public antibody sequence databases. This specification includes antibodies and antigen-binding fragments thereof derived from any amino acid sequence disclosed herein, wherein one or more amino acids in one or more framework and / or CDR regions are mutated into one or more corresponding residues of the germline sequence from which the antibody is derived, or one or more corresponding residues of another human germline sequence, or one or more corresponding germline residues (such sequence changes are collectively referred to herein as "germline mutations"). One of ordinary skill in the art, starting from a given heavy and light chain variable region sequence, can produce many antibodies and antigen-binding fragments comprising one or more individual germline mutations or combinations thereof. In certain embodiments, V H domain and / or V LAll frameworks and / or CDR residues in the domain are mutated back to the residues present in the original germline sequence from which the antibody is derived. In other embodiments, only some residues are mutated back to the original germline sequence, for example, only the mutated residues present in the first 8 amino acids of FR1 or the last 8 amino acids of FR4, or only the mutated residues present in CDR1, CDR2 or CDR3. In other embodiments, one or more frameworks and / or one or more CDR residues are mutated to one or more corresponding residues of different germline sequences (that is, different from the germline sequence from which the antibody is originally derived).

[0554] In addition, the antibodies and antigen-binding fragments of this specification may contain any combination of two or more germline mutations in the framework and / or CDR regions, for example, wherein some individual residues are mutated to the corresponding residues of a specific germline sequence, while some other residues different from the original germline sequence are maintained or mutated to the corresponding residues of different germline sequences. After acquisition, one or more desired properties of the antibodies and antigen-binding fragments containing one or more germline mutations may be tested, such as improved binding specificity, increased binding affinity, improved or enhanced antagonistic or exciting biological properties (which may be determined on a case-by-case basis), reduced immunogenicity, improved drug to antibody ratios (DAR) of antibody-drug conjugates, etc. Antibodies and antigen-binding fragments obtained in this general manner are encompassed in this specification.

[0555] The present invention includes anti-GLP1R antibodies and antigen-binding fragments thereof that are non-glycosylated (e.g., conjugated to a payload, e.g., via a linker). The term "non-glycosylated" antibody or antigen-binding fragment includes antibodies or fragments that do not include glycosylation sequences that may interfere with transglutamination reactions, such as antibodies that do not have a glycosyl group at N297 on one or more heavy chains. In certain embodiments, the antibody heavy chain has an N297 mutation. According to the EU numbering system disclosed by Kabat et al., the antibody can be mutated to no longer have an asparagine residue at position 297. In certain embodiments, the antibody heavy chain has an N297Q or N297D mutation. Such antibodies can be prepared by site-directed mutagenesis to remove or disable glycosylation sequences, or by site-directed mutagenesis to insert a glutamine residue at a site other than any interfering glycosylation site or any other interfering structure. Such antibodies can also be isolated from natural or artificial sources. Non-glycosylated antibodies and fragments also include antibodies and fragments that include T299 or S298P or other mutations or combinations of mutations that result in a lack of glycosylation. An aglycosylated antibody or antigen-binding fragment may completely lack glycosylation, for example, following expression in a bacterial host cell.

[0556] The present invention includes anti-GLP1R antibodies and antigen-binding fragments thereof that are deglycosylated (e.g., conjugated to a payload, e.g., via a linker). The term "deglycosylated" antibody or antigen-binding fragment refers to an antibody or fragment in which sugar groups are removed to facilitate transglutaminase-mediated conjugation. Sugars include, but are not limited to, N-linked oligosaccharides. In some embodiments, deglycosylation is performed at residue N297. In some embodiments, removal of sugar groups is enzymatic (including, but not limited to, via PNG (Peptide: N-glycosidase, PNGase)).

[0557] The term "epitope" refers to an antigenic determinant (e.g., of GLP1R) that interacts with a specific antigen binding site called a paratope in the variable region of an antibody or antigen-binding fragment. A single antigen can have more than one epitope. Thus, different antibodies can bind to different regions on the antigen and can have different biological effects. Epitopes can be conformational or linear. Conformational epitopes are produced by spatially juxtaposed amino acids from different segments of a linear polypeptide chain. Linear epitopes are epitopes produced by adjacent amino acid residues in a polypeptide chain. In some cases, an epitope can include part of a carbohydrate, a phosphoryl group, or a sulfonyl group on the antigen.

[0558] As used herein, the term "conjugated" protein, antibody, or antigen-binding fragment refers to a protein, antibody, or fragment that is covalently linked to one or more chemical moieties. The chemical moieties may include amine compounds of the present disclosure. Linkers (L) and payloads (P) suitable for use with the present disclosure are described in detail herein.

[0559] The term "drug to antibody ratio" or (DAR) is the average number of therapeutic moieties (eg, drug) conjugated to a binding agent (eg, antibody or antigen-binding fragment) of the disclosure.

[0560] In some embodiments, the term "linker-antibody ratio" or (LAR), also represented by lowercase letters, is the average number of reactive primary amine compounds conjugated to a binding agent of the present disclosure. Such a binding agent, such as an antibody or antigen-binding fragment, can be conjugated to a primary amine compound comprising, for example, a suitable azide or alkyne. The resulting binding agent functionalized with an azide or alkyne can then react with a therapeutic moiety comprising the corresponding azide or alkyne via a 1,3-cycloaddition reaction.

[0561] The phrase "reaction pH" refers to the pH of the reaction after all reaction components or reactants have been added.

[0562] A polypeptide such as an immunoglobulin chain (e.g., REGN7990; REGN9268; REGN15869; REGN18121; REGN18123; REGN8070; REGN8072; REGN9267; REGN7988; REGN5619; REGN7989; REGN8069; REGN8071; REGN9426; REGN5203; REGN5204; REGN5617; REGN5619; REGN7987; REGN9270; REGN9278; REGN9279 or REGN9280) H 、V L, HC, or LC; or CDRs thereof as described herein) are those comprising amino acids that differ from the reference amino acid sequences set forth herein (e.g., SEQ ID NO:26;28;30;32;34;36;38;40;42;44;46;48;50;52;54;56;58;60;62;64;66;68;70;72;74;76;78;80;82;414;416;84;86;88;90; 92;94;96;98;100;102;104;106;108;110;112;114;116;118;120;122;124;126;128;130;132;134;136;138;140;142;144;146;148 ;150;152;154;156;158;160;162;164;166;168;170;172;174;176;178;180;182;184;187;189;191;193;195;197;199;201;203;205;207;209;211;213;215;217;219;221;223;225;227;229;231;233;235;237;239;241;243;245;247;249;251;253;255;257;259; 261;263;265;267;269;271;273;275;277;279;281;283;285;287;289;291;293;295;297;299;301;303;305;307;309;311;313;315;317;319;321;323;325;327;329;331;333;335;337;339;341;343;345;347;349;351;353;355;357;359;361;363;365;367;369;3 %, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, 99.9%, 99.9%, 99.1%, 99.2%, 99.3%, 99.9%, 99.1%, 99.9%, 99.1%, 99.9%, 99.1%, 99.9%, 99.1%, 99.9%, 99.1%, 99.9%, 99.1%, 99.9%, 99.1%, 99.9%, 99.1%, 99.9%, 99.1%, 99.9%, 99.1%, 99.9%, 99.1%, 99.9%, 99.1%, 99.9%, 99.1%, 99.9%, 99.1%, 99.9%, 99.1%, 99.9%, 99.1%, 99.9%, 99.1%, 99.1%, 99.9%, 99.1%, 99.1%, 99.9%) identical or similar amino acid sequences when compared using the BLAST algorithm, wherein the algorithm parameters are selected to give the maximum match between the corresponding sequences over the entire length of the corresponding reference sequences (e.g., expectation threshold: 10; word size: 3; maximum match in query range: 0; BLOSUM 62 matrix; gap cost: existence 11, extension 1; conditional composition scoring matrix adjustment).

[0563] A "variant" of a polynucleotide is one that comprises a sequence that differs from a reference nucleotide sequence set forth herein (e.g., SEQ ID NO: 25; 27; 29; 31; 33; 35; 37; 39; 41; 43; 45; 47; 49; 51; 53; 55; 57; 59; 61; 63; 65; 67; 69; 71; 73; 75; 77; 79; 81; 415; 417; 83; 85; 87; 89; 91; 93; 95; 97; 99; 101; 103; 105; 107; 109; 111; 113; 115; 117; 119; 121; 123; 125; 127; 129; 131; 133; 135; 137; 139; 141; 143; 145; 147; ;149;151;153;155;157;159;161;163;165;167;169;171;173;175;177;179;181;183;186;188;190;192;194;196;198;200;202;204;206;208;210;212;214;216;218;220;222;224;226;228;230;232;234;236;238;240;242;244;246;248;250;252;254;256;258; 260;262;264;266;268;270;272;274;276;278;280;282;284;286;288;290;292;294;296;298;300;302;304;306;308;310;312;314;316;318;320;322;324;326;328;330;332;334;336;338;340;342;344;346;348;350;352;354;356;358;360;362;364;366;368;3 %, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%9%) identical or similar nucleotide sequences when compared using the BLAST algorithm, wherein the algorithm parameters are selected to give the maximum match between the corresponding sequences over the entire length of the corresponding reference sequences (e.g., expectation threshold: 10; word size: 28; maximum match in query range: 0; match / mismatch score: 1, -2; gap cost: linear).

[0564] The following references relate to the BLAST algorithm commonly used for sequence analysis: BLAST ALGORITHMS: Altschul et al. (2005) FEBS J. 272(20):5101-5109; Altschul, SF, et al., (1990) J. Mol. Biol. 215:403-410; Gish, W., et al., (1993) Nature Genet. 3:266-272; Madden, TL, et al., (1996) Meth. Enzymol. 266:131-141; Altschul, SF, et al., (1997) Nucleic Acids Res. 25:3389-3402; Zhang, J., et al., (1997) Genome Res.7:649-656; Wootton, JC, et al., (1993) Comput. Chem. 17:149-163; Hancock, JM, et al., (1994) Comput. Appl. Biosci. 10:67-70; ALIGNMENT SCORING SYSTEMS: Dayhoff, MO, et al., "A model of evolutionary change in proteins." in Atlas of Protein Sequence and Structure, (1978) Vol. 5, Suppl. 3. MO Dayhoff (ed.), pp. 345-352, Natl. Biomed. Res. Found., Washington, DC; Schwartz, RM, et al., "Matrices for detecting distant relationships." in Atlas of Protein Sequence and Structure, (1978) Vol. 5, Suppl. 3. MO Dayhoff (ed.), pp. 353-358, Natl. Biomed. Res. Found., Washington, DC; Altschul, S. F., (1991) J. Mol. Biol. 219:555-565; States, DJ, et al., (1991) Methods 3:66-70; Henikoff, S., et al., (1992) Proc. Natl. Acad. Sci. USA 89:10915-10919; Altschul, S. F., et al., (1993) J. Mol. Evol.36:290-300; ALIGNMENT STATISTICS: Karlin, S., et al., (1990) Proc. Natl. Acad. Sci. USA 87:2264-2268; Karlin, S., et al., (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877; Dembo, A., et al., (1994) Ann. Prob. 22:2022-2039; and Altschul, SF "Evaluating the statistical significance of multiple distinct local alignments." in Theoretical and Computational Methods in Genome Research (S. Suhai, ed.), (1997) pp. 1-14, Plenum, NY.

[0565] In embodiments of the invention, the anti-GLP1R antigen binding proteins of the invention, e.g., antibodies and antigen-binding fragments thereof, comprise a heavy chain immunoglobulin, or a variable region thereof, having at least 70% (e.g., 80%, 85%, 90%, 95%, 99%) amino acid sequence identity to the amino acids set forth in SEQ ID NO: 26, 46, 66, 86, 106, 126, 146, 166, 42, 62, 82, 414, 416, 102, 122, 142, 162, or 182; and / or a light chain immunoglobulin, or a variable region thereof, having at least 70% (e.g., 80%, 85%, 90%, 95%, 99%) amino acid sequence identity to the amino acids set forth in SEQ ID NO: 34, 54, 74, 94, 114, 134, 154, 174, 44, 64, 84, 104, 124, 144, 164, or 184.

[0566] In addition, variants of the polypeptides can comprise an amino acid sequence as set forth herein (e.g., SEQ ID NO: 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 414; 416; 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 169, 170, 171 30, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, or 184), which differ by one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) mutations, such as, for example, missense mutations (e.g., conservative substitutions), nonsense mutations, deletions, or insertions. For example, the present invention includes anti-GLP1R antibodies and antigen-binding fragments thereof comprising an immunoglobulin light chain (or V chain) comprising the amino acid sequence set forth in SEQ ID NO: 34, 54, 74, 94, 114, 134, 154, 174, 44, 64, 84, 104, 124, 144, 164, or 184 but having one or more of such mutations. L ) variants and / or immunoglobulin heavy chains (or V chains) comprising the amino acid sequence set forth in SEQ ID NO: 26, 46, 66, 86, 106, 126, 146, 166, 42, 62, 82, 414, 416, 102, 122, 142, 162 or 182 but having one or more of such mutations H ) variants. In embodiments of the present invention, an anti-GLP1R antibody or antigen-binding fragment thereof comprises an immunoglobulin light chain variant comprising CDR-L1, CDR-L2, and CDR-L3, wherein one or more (e.g., 1 or 2 or 3) of such CDRs have one or more of such mutations (e.g., conservative substitutions) and / or an immunoglobulin heavy chain variant comprising CDR-H1, CDR-H2, and CDR-H3, wherein one or more (e.g., 1 or 2 or 3) of such CDRs have one or more of such CDRs (e.g., conservative substitutions).

[0567] Embodiments of the present invention also include antigen binding proteins, such as anti-GLP1R antibodies and antigen binding fragments thereof, comprising immunoglobulin VH and VL; or HC and LC, comprising variant amino acid sequences having 70% or more (e.g., 80%, 85%, 90%, 95%, 97% or 99%) total amino acid sequence identity or similarity with the amino acid sequences of the corresponding VH, VL, HC or LC specifically listed herein, but wherein the CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2 and CDR-H3 of such immunoglobulins are not variants and comprise the amino acid sequences specifically listed herein. Thus, in such embodiments, the CDRs within the variant antigen binding proteins themselves are not variants.

[0568] For example, "conservatively modified variants" or "conservative substitutions" of immunoglobulin chains listed herein refer to variants in which amino acids in the polypeptide are substituted with other amino acids having similar characteristics (e.g., charge, side chain size, hydrophobicity / hydrophilicity, main chain conformation and rigidity, etc.). Such changes can generally be made without significantly destroying the biological activity of the antibody or fragment. Those skilled in the art recognize that, in general, single amino acid substitutions in non-essential regions of a polypeptide do not substantially alter biological activity (see, e.g., Watson et al. (1987) Molecular Biology of the Gene, The Benjamin / Cummings Pub. Co., 1982, p. 224 (4th ed.)). In addition, substitutions of amino acids that are structurally or functionally similar are unlikely to significantly destroy biological activity. The present invention includes anti-GLP1R antigen binding proteins comprising such conservatively modified variant immunoglobulin chains.

[0569] Examples of amino acid groups with side chains having similar chemical properties include 1) aliphatic side chains: glycine, alanine, valine, leucine, and isoleucine; 2) aliphatic-hydroxy side chains: serine and threonine; 3) amide-containing side chains: asparagine and glutamine; 4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; 5) basic side chains: lysine, arginine, and histidine; 6) acidic side chains: aspartic acid and glutamic acid, and 7) sulfur-containing side chains: cysteine ​​and methionine. Preferred conservative amino acid substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamic acid-aspartic acid, and asparagine-glutamine. Alternatively, a conservative substitution is any change with a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet et al. (1992) Science 256:1443-1445.

[0570] The immunoglobulin chains of the anti-GLP1R antibodies and antigen-binding fragments of the invention are summarized in Tables A and B below.

[0571] Table A. Anti-GLP1R Antibody and Antigen-Binding Fragment Amino Acid Sequence Identifiers

[0572]

[0573]

[0574] HC = immunoglobulin heavy chain; LC = immunoglobulin light chain; HCVR = heavy chain variable region; LCVR = light chain variable region. Optionally, any HCVR and / or LCVR listed herein comprises an N-terminal Q tag, such as LLQGSG (SEQ ID NO: 18). Optionally, any light chain and / or heavy chain listed herein does not comprise an N-terminal Q tag, such as LLQGSG (SEQ ID NO: 18).

[0575] Table B. Nucleotide sequence identifiers of anti-GLP1R antibodies and antigen-binding fragments

[0576]

[0577] HC = immunoglobulin heavy chain; LC = immunoglobulin light chain; HCVR = heavy chain variable region; LCVR = light chain variable region

[0578] REGN9268

[0579] Heavy chain variable region (HCVR; VH) - nucleotide sequence

[0580] GAAGTGCAACTGGTGGAGTCTGGGGGAGGCCTGGTCAAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCATCTTCAGTAGATATAGCATGAACTGGGTCCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCATCCATGAGTAGTAATAGTAAAAACACATACTAC GCAGACTCAGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAAAACTCACTGTTTCTGCAAATGAACACCCTGAGAGCCGAGGACACGGCTGTTTATTACTGTGCGAGAGATGGATACACCCTCAGGGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCA(SEQ ID NO:25)

[0581] Heavy chain variable region (HCVR; V H)-amino acid sequence

[0582] EVQLVESGGGLVKPGGSLRLSCAAS GFIFSRYS MNWVRQAPGKGLEWVSS MSSNSKNT YYADSVKGRFTISRDNAKNSLFLQMNTLRAEDTAVYYC ARDGYTLRAFDI WGQGTMVTVSS (SEQ ID NO: 26)

[0583] CDR-H1-nucleotide sequence

[0584] GGA TTC ATC TTC AGT AGA TAT AGC (SEQ ID NO:27)

[0585] CDR-H1-amino acid sequence

[0586] GFIFSRYS (SEQ ID NO: 28)

[0587] CDR-H2-nucleotide sequence

[0588] ATG AGT AGT AAT AGT AAA AAC ACA(SEQ ID NO:29)

[0589] CDR-H2 - amino acid sequence

[0590] MSSNSKNT (SEQ ID NO: 30)

[0591] CDR-H3-nucleotide sequence

[0592] GCG AGA GAT GGA TAC ACC CTC AGG GCT TTT GAT ATC (SEQ ID NO:31)

[0593] CDR-H3-amino acid sequence

[0594] AR DGYTLR AF DI (SEQ ID NO: 32)

[0595] Light chain variable region (LCVR; V L )-nucleotide sequence

[0596] GAAATTGTGTTGACGCAGTCCAGGCACCCTGTCTCTGTCTCCAGGGGAAAGAGACACCCTCTCCTGCAGGGCCAGTCAGAGTATTGCCGGCAGATACGTAGCCTGGTACCAGCAGAAACCTGGCCAGGCACCCAGACTCCTCATCTACGGTGCATCCAGCAG GGCCACTGGCATCCCAGACAGATTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAATATGGTAGCTCACCTTGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA(SEQ ID NO:33)

[0597] Light chain variable region (LCVR; V L )-amino acid sequence

[0598] EIVLTQSPGTLSLSPGERDTLSCRAS QSIAGRY VAWYQQKPGQAPRLLIY GAS SRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC QQYGSSPWT FGQGTKVEIK (SEQ ID NO: 34)

[0599] CDR-L1-nucleotide sequence

[0600] CAG AGT ATT GCC GGC AGA TAC (SEQ ID NO:35)

[0601] CDR-L1-amino acid sequence

[0602] QSI AG RY (SEQ ID NO: 36)

[0603] CDR-L2-nucleotide sequence

[0604] GGT GCATCC (SEQ ID NO: 37)

[0605] CDR-L2-amino acid sequence

[0606] GAS (SEQ ID NO: 38)

[0607] CDR-L3-nucleotide sequence

[0608] CAG CAATAT GGT AGC TCA CCT TGG ACG (SEQ ID NO:39)

[0609] CDR-L3-amino acid sequence

[0610] QQYGSSPWT (SEQ ID NO: 40)

[0611] Heavy chain (HC)-nucleotide sequence

[0612]

[0613] Heavy chain - Amino acid sequence

[0614] EVQLVESGGGLVKPGGSLRLSCAASGFIFSRYSMNWVRQAPGKGLEWVSSMSSNKNTYYADSVKGRF TISRDNAKNSLFLQMNTLRAEDTAVYYCARDGYTLRAFDIWGQGTMVTVSS ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK(SEQ ID NO:42)

[0615] Light chain (LC) - Nucleotide sequence

[0616] TTACTTCAGGGATCTGGTGAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTCTGTCTCCAGGGGAAAGAGACACCCTCTCCTGCAGGGCCAGTCAGAGTATTGCCGGCAGATACGTAGCCTGGTACCAGCAGAAACCTGGCCAGGCACCCAGACTCCTCATCTACGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGATTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAATATGGTAGCTCACCTTGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG(SEQ ID NO:43) <00029�0>Light chain (LC) - Amino acid sequence

[0618] LLQGSG EIVLTQSPGTLSLSPGERDTLSCRASQSIAGRYVAWYQQKPGQAPRLLIYGASSRATGIPDR FSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLN NFYPREAKVQWKVDNA LQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:44)

[0619] REGN7990

[0620] Heavy chain variable region (HCVR; V H ) - Nucleotide sequence

[0621] It should be noted that there is a possible error in the original text where "<00029�0>" is likely a misrepresentation. It is translated as "

[0617] " here for consistency with the overall translation pattern. If this is not an error, please clarify the correct form for a more accurate translation.GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAATGGGTCTCAGCTATTAGCGGTAGTGGTGGCAGCACATACTACGCA GACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAAAGGCCTTATAGCACCTCGTCCGATGGGCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA(SEQ IDNO:45)

[0622] Heavy chain variable region (HCVR; V H )-amino acid sequence

[0623] EVQLVESGGGLVQPGGSLRLSCAAS GFTFSSYA MSWVRQAPGKGLEWVSA ISGSGGST YYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC AKGLIAPRPMGFDY WGQGTLVTVSS (SEQ ID NO: 46)

[0624] CDR-H1-nucleotide sequence

[0625] GGA TTC ACC TTT AGC AGC TAT GCC (SEQ ID NO:47)

[0626] CDR-H1-amino acid sequence

[0627] GFTFSSYA (SEQ ID NO: 48)

[0628] CDR-H2-nucleotide sequence

[0629] ATT AGC GGT AGT GGT GGC AGC ACA(SEQ ID NO:49)

[0630] CDR-H2 - amino acid sequence

[0631] ISGSGGST (SEQ ID NO: 50)

[0632] CDR-H3-nucleotide sequence

[0633] GCG AAA GGC CTT ATA GCA CCT CGT CCG ATG GGC TTT GAC TAC (SEQ ID NO:51)

[0634] CDR-H3-amino acid sequence

[0635] AKGLIAPRPMGFDY (SEQ ID NO: 52)

[0636] Light chain variable region (LCVR; V L )-nucleotide sequence

[0637] GACATCCAGATGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGTCGGGCGAGTCAGGGTATTAACAGCTGGTTAGCCTGGTATCAGCAGAAACCTGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTG CAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTACTATTGTCACCAGGCTGACAGTTTCCCGTACACTTTTGGCCAGGGGACCAAGCTGGAGATCAAA(SEQ ID NO:53)

[0638] Light chain variable region (LCVR; V L )-amino acid sequence

[0639] DIQMTQSPSSVSASVGDRVTITCRAS QGINSW LAWYQQKPGKAPKLLIY AAS SLQSGVPSRFSGSGSGTDFTLTISSLQPDFATYYC HQADSFPYT FGQGTKLEIK (SEQ ID NO: 54)

[0640] CDR-L1-nucleotide sequence

[0641] CAG GGT ATT AAC AGC TGG (SEQ ID NO:55)

[0642] CDR-L1-amino acid sequence

[0643] QGINSW (SEQ ID NO: 56)

[0644] CDR-L2-nucleotide sequence

[0645] GCT GCA TCC (SEQ ID NO: 57)

[0646] CDR-L2-amino acid sequence

[0647] AAS (SEQ ID NO: 58)

[0648] CDR-L3-nucleotide sequence

[0649] CAC CAG GCT GAC AGT TTC CCG TAC ACT(SEQ ID NO:59)

[0650] CDR-L3-amino acid sequence

[0651] HQADSFPYT (SEQ ID NO: 60)

[0652] Heavy chain-nucleotide sequence

[0653]

[0654] Heavy chain - Amino acid sequence

[0655] EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGLIAPRPMGFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK(SEQ ID NO:62)

[0656] Light chain - Nucleotide sequence<​CTGCTGCAAGGCTCTGGCGACATCCAGATGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGTCGGGCGAGTCAGGGTATTAACAGCTGGTTAGCCTGGTATCAGCAGAAACCTGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTACTATTGTCACCAGGCTGACAGTTTCCCGTACACTTTTGGCCAGGGGACCAAGCTGGAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG(SEQ ID NO:63)

[0658] Light chain - Amino acid sequence

[0659] LLQGSG DIQMTQSPSSSVSASVGDRVTITCRASQGINSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRF SSGSGSGTDFTLTISSLQPEDFATYYCHQADSFPYTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:64)

[0660] REGN15869

[0661] Heavy chain variable region (HCVR; V H ) - Nucleotide sequence

[0662] GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAATGGGTCTCAGCTATTAGCGGTAGTGGTGGCAGCACATACTACGCA GACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAAAGGCCTTATAGCACCTCGTCCGATGGGCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA(SEQ IDNO:65)

[0663] Heavy chain variable region (HCVR; V H )-amino acid sequence

[0664] EVQLVESGGGLVQPGGSLRLSCAAS GFTFSSYA MSWVRQAPGKGLEWVSA ISGSGGST YYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC AKGLIAPRPMGFDY WGQGTLVTVSS (SEQ ID NO: 66)

[0665] CDR-H1-nucleotide sequence

[0666] GGA TTC ACC TTT AGC AGC TAT GCC (SEQ ID NO:67)

[0667] CDR-H1-amino acid sequence

[0668] GFTFSSYA (SEQ ID NO: 68)

[0669] CDR-H2-nucleotide sequence

[0670] ATT AGC GGT AGT GGT GGC AGC ACA(SEQ ID NO:69)

[0671] CDR-H2 - amino acid sequence

[0672] ISGSGGST (SEQ ID NO: 70)

[0673] CDR-H3-nucleotide sequence

[0674] GCG AAA GGC CTT ATA GCA CCT CGT CCG ATG GGC TTT GAC TAC (SEQ ID NO:71)

[0675] CDR-H3-amino acid sequence

[0676] AKGLI AP RPMGFDY(SEQ ID NO:72)

[0677] Light chain variable region (LCVR; V L )-nucleotide sequence

[0678] GACATCCAGATGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGTCGGGCGAGTCAGGGTATTAACAGCTGGTTAGCCTGGTATCAGCAGAAACCTGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTG GAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTACTATTGTCACCAGGCTGACAGTTTCCCGTACACTTTTGGCCAGGGGACCAAGCTGGAGATCAAA(SEQ ID NO:73)

[0679] Light chain variable region (LCVR; V L )-amino acid sequence

[0680] DIQMTQSPSSVSASVGDRVTITCRAS QGINSW LAWYQQKPGKAPKLLIY AAS SLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYC HQADSFPYT FGQGTKLEIK (SEQ ID NO: 74)

[0681] CDR-L1-nucleotide sequence

[0682] CAG GGT ATT AAC AGC TGG (SEQ ID NO:75)

[0683] CDR-L1-amino acid sequence

[0684] QGINSW (SEQ ID NO: 76)

[0685] CDR-L2-nucleotide sequence

[0686] GCT GCA TCC (SEQ ID NO: 77)

[0687] CDR-L2-amino acid sequence

[0688] AAS (SEQ ID NO: 78)

[0689] CDR-L3-nucleotide sequence

[0690] CAC CAG GCT GAC AGT TTC CCG TAC ACT(SEQ ID NO:79)

[0691] CDR-L3-amino acid sequence

[0692] HQADSFPYT (SEQ ID NO: 80)

[0693] Heavy chain-nucleotide sequence

[0694]

[0695] Heavy chain - Amino acid sequence

[0696] EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRF TISRDNSKNTLYLQMNSLRAEDTAVYYCAKGLIAPRPMGFDYWGQGTLVTVSS ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK(SEQ ID NO:82)<00>

[0697] Light chain - Nucleotide sequence

[0698] CTGCTGCAAGGCTCTGGCGACATCCAGATGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGTCGGGCGAGTCAGGGTATTAACAGCTGGTTAGCCTGGTATCAGCAGAAACCTGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTACTATTGTCACCAGGCTGACAGTTTCCCGTACACTTTTGGCCAGGGGACCAAGCTGGAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG(SEQ ID NO:83) <00,03135>Light chain - Amino acid sequence

[0700] LLQGSG DIQMTQSPSSSVSASVGDRVTITCRASQGINSWLAWYQQKPGKAPKLLIYAASSLESGVPSRF SGSGSGTDFTLTISSLQPEDFATYYCHQADSFPYTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:84)

[0701] REGN18121

[0702] Heavy chain variable region (HCVR; V H ) - Nucleotide sequence It should be noted that there seems to be an incorrect format in the original text for the tag <00,03135> which is translated as <00,03135> here. It might be a formatting error in the original. Also, the 7 - digit tags like 2-6 etc. are preserved as per the instruction, but the <00,03135> case might need to be double - checked in the original source for proper correction.

[0703] GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAATGGGTCTCAGCTATTAGCGGTAGTGGTGGCAGCACATACTACGCA GACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAAAGGCCTTATAGCACCTCGTCCGATGGGCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA(SEQ IDNO:65)

[0704] Heavy chain variable region (HCVR; V H )-amino acid sequence

[0705] EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGLIAPRPMGFDYWGQGTLVTVSS(SEQ ID NO:66)

[0706] CDR-H1-nucleotide sequence

[0707] GGA TTC ACC TTT AGC AGC TAT GCC (SEQ ID NO:67)

[0708] CDR-H1-amino acid sequence

[0709] GFTFSSYA (SEQ ID NO: 68)

[0710] CDR-H2-nucleotide sequence

[0711] ATT AGC GGT AGT GGT GGC AGC ACA(SEQ ID NO:69)

[0712] CDR-H2 - amino acid sequence

[0713] ISGSGGST (SEQ ID NO: 70)

[0714] CDR-H3-nucleotide sequence

[0715] GCG AAA GGC CTT ATA GCA CCT CGT CCG ATG GGC TTT GAC TAC (SEQ ID NO:71)

[0716] CDR-H3-amino acid sequence

[0717] AKGLIAPRPMGFDY (SEQ ID NO: 72)

[0718] Light chain variable region (LCVR; V L )-nucleotide sequence

[0719] GACATCCAGATGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGTCGGGCGAGTCAGGGTATTAACAGCTGGTTAGCCTGGTATCAGCAGAAACCTGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTG GAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTACTATTGTCACCAGGCTGACAGTTTCCCGTACACTTTTGGCCAGGGGACCAAGCTGGAGATCAAA(SEQ ID NO:73)

[0720] Light chain variable region (LCVR; V L )-amino acid sequence

[0721] DIQMTQSPSSVSASVGDRVTITCRASQGINSWLAWYQQKPGKAPKLLIYAASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQADSFPYTFGQGTKLEIK(SEQ ID NO:74)

[0722] CDR-L1-nucleotide sequence

[0723] CAG GGT ATT AAC AGC TGG (SEQ ID NO:75)

[0724] CDR-L1-amino acid sequence

[0725] QGINSW (SEQ ID NO: 76)

[0726] CDR-L2-nucleotide sequence

[0727] GCT GCA TCC (SEQ ID NO: 77)

[0728] CDR-L2-amino acid sequence

[0729] AAS (SEQ ID NO: 78)

[0730] CDR-L3-nucleotide sequence

[0731] CAC CAG GCT GAC AGT TTC CCG TAC ACT(SEQ ID NO:79)

[0732] CDR-L3-amino acid sequence

[0733] HQADSFPYT (SEQ ID NO: 80)

[0734] Heavy chain-nucleotide sequence

[0735]

[0736] Heavy chain - Amino acid sequence

[0737] EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRF TISRDNSKNTLYLQMNSLRAEDTAVYYCAKGLIAPRPMGFDYWGQGTLVTVSS ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG (SEQ ID NO:414)

[0738] Light chain - Nucleotide sequence

[0739] CTGCTGCAAGGCTCTGGCGACATCCAGATGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGTCGGGCGAGTCAGGGTATTAACAGCTGGTTAGCCTGGTATCAGCAGAAACCTGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTACTATTGTCACCAGGCTGACAGTTTCCCGTACACTTTTGGCCAGGGGACCAAGCTGGAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG(SEQ ID NO:83) <�

[0740] Light chain - Amino acid sequence

[0741] LLQGSG DIQMTQSPSSVSASVGDRVTITCRASQGINSWLAWYQQKPGKAPKLLIYAASSLESGVPSRF SGSGSGTDFTLTISSLQPEDFATYYCHQADSFPYTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:84)

[0742] REGN18123

[0743] Heavy chain variable region (HCVR; V H ) - Nucleotide sequence It should be noted that there is a small typo in the original text where "<�

[0740] " should probably be "

[0740] ". This has been corrected in the translation.

[0744] GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAATGGGTCTCAGCTATTAGCGGTAGTGGTGGCAGCACATACTACGCA GACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAAAGGCCTTATAGCACCTCGTCCGATGGGCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA(SEQ IDNO:65)

[0745] Heavy chain variable region (HCVR; V H )-amino acid sequence

[0746] EVQLVESGGGLVQPGGSLRLSCAAS GFTFSSYA MSWVRQAPGKGLEWVSA ISGSGGST YYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC AKGLIAPRPMGFDY WGQGTLVTVSS (SEQ ID NO: 66)

[0747] CDR-H1-nucleotide sequence

[0748] GGA TTC ACC TTT AGC AGC TAT GCC (SEQ ID NO:67)

[0749] CDR-H1-amino acid sequence

[0750] GFTFSSYA (SEQ ID NO: 68)

[0751] CDR-H2-nucleotide sequence

[0752] ATT AGC GGT AGT GGT GGC AGC ACA(SEQ ID NO:69)

[0753] CDR-H2 - amino acid sequence

[0754] ISGSGGST (SEQ ID NO: 70)

[0755] CDR-H3-nucleotide sequence

[0756] GCG AAA GGC CTT ATA GCA CCT CGT CCG ATG GGC TTT GAC TAC (SEQ ID NO:71)

[0757] CDR-H3-amino acid sequence

[0758] AKGLIAPRPMGFDY (SEQ ID NO: 72)

[0759] Light chain variable region (LCVR; V L )-nucleotide sequence

[0760] GACATCCAGATGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGTCGGGCGAGTCAGGGTATTAACAGCTGGTTAGCCTGGTATCAGCAGAAACCTGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTG GAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTACTATTGTCACCAGGCTGACAGTTTCCCGTACACTTTTGGCCAGGGGACCAAGCTGGAGATCAAA(SEQ ID NO:73)

[0761] Light chain variable region (LCVR; V L )-amino acid sequence

[0762] DIQMTQSPSSVSASVGDRVTITCRAS QGINSW LAWYQQKPGKAPKLLIY AAS SLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYC HQADSFPYT FGQGTKLEIK (SEQ ID NO: 74)

[0763] CDR-L1-nucleotide sequence

[0764] CAG GGT ATT AAC AGC TGG (SEQ ID NO:75)

[0765] CDR-L1-amino acid sequence

[0766] QGINSW (SEQ ID NO: 76)

[0767] CDR-L2-nucleotide sequence

[0768] GCT GCA TCC (SEQ ID NO: 77)

[0769] CDR-L2-amino acid sequence

[0770] AAS (SEQ ID NO: 78)

[0771] CDR-L3-nucleotide sequence

[0772] CAC CAG GCT GAC AGT TTC CCG TAC ACT(SEQ ID NO:79)

[0773] CDR-L3-amino acid sequence

[0774] HQADSFPYT (SEQ ID NO: 80)

[0775] Heavy chain-nucleotide sequence

[0776]

[0777] Heavy chain - Amino acid sequence

[0778] EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRF TISRDNSKNTLYLQMNSLRAEDTAVYYCAKGLIAPRPMGFDYWGQGTLVTVSS ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSL(SEQ ID NO:416)

[0779] Light chain - Nucleotide sequence

[0780] CTGCTGCAAGGCTCTGGCGACATCCAGATGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGTCGGGCGAGTCAGGGTATTAACAGCTGGTTAGCCTGGTATCAGCAGAAACCTGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTACTATTGTCACCAGGCTGACAGTTTCCCGTACACTTTTGGCCAGGGGACCAAGCTGGAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG(SEQ ID NO:83)

[0781] Light chain - Amino acid sequence

[0782] LLQGSG DIQMTQSPSSVSASVGDRVTITCRASQGINSWLAWYQQKPGKAPKLLIYAASSLESGVPSRF SGSGSGTDFTLTISSLQPEDFATYYCHQADSFPYTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:84)

[0783] REGN8070

[0784] Heavy chain variable region (HCVR, V H ) - Nucleotide sequence

[0785] CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGGCCAGCCTGGGAGGTCCCTGAGACTGTCCTGTGCAGCCTCTGGATTCACCTTCAGCAGGAATGCCATGCACTGGGTCCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTCATATCATATGATGGAAGTAATAAACA CTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGGAAATGAACAGCCTGAGAGTTGAGGACACGGCTGTGTATTATTGTGCGAAAGGGGGGATTCCTTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA(SEQ ID NO:85)

[0786] Heavy chain variable region (HCVR, V H )-amino acid sequence

[0787] QVQLVESGGGVGQPGRSLRLSCAAS GFTFSRNA MHWVRQAPGKGLEWVAV ISYDGSNK HYADSVKGRFTISRDNSKNTLYLEMNSLRVEDTAVYYC AKGGIPFDY WGQGTLVTVSS (SEQ ID NO: 86)

[0788] CDR-H1-nucleotide sequence

[0789] GGA TTC ACC TTC AGC AGG AAT GCC (SEQ ID NO:87)

[0790] CDR-H1-amino acid sequence

[0791] GFTFSRNA (SEQ ID NO:88)

[0792] CDR-H2-nucleotide sequence

[0793] ATA TCA TAT GAT GGA AGT AAT AAA(SEQ ID NO:89)

[0794] CDR-H2 - amino acid sequence

[0795] ISYDGSNK (SEQ ID NO:90)

[0796] CDR-H3-nucleotide sequence

[0797] GCG AAA GGG GGG ATT CCT TTT GAC TAC (SEQ ID NO:91)

[0798] CDR-H3-amino acid sequence

[0799] AKGGIPFDY (SEQ ID NO:92)

[0800] Light chain variable region (LCVR, V L )-nucleotide sequence

[0801] GATATTGTGATGACCCAGTCTCCACTCTCCTCACCTGTCACCCTTGGACAGCCGGCCTCCATCTCCTGCAGGTCTAGTCAAAGCCTCGTACACTTTGATGGAAACACCTACTTGAGTTGGCTTCACCAGAGGCCAGGCCAGCCTCCAAGACTCCTAATTTATAAGATTTC TAACCGCTTCTCTGGGGTCCCAGACAGATTCAGTGGCAGTGGGGCAGGGACAGATTTCACACTGAAAATCAGCAGGTGTGGAACCTGAAGATGTCGGGGTTTATTACTGCATGCATGCTACACAATTTCCGTACACTTTTGGCCAGGGGACCAAGCTGGAGATCAAA(SEQ ID NO:93)

[0802] Light chain variable region (LCVR, V L )-amino acid sequence

[0803] DIVMTQSPLSSPVTLGQPASISCRSS QSLVHFDGNTY LSWLHQRPGQPPRLLIY KIS NRFSGVPDRFSGSGAGTDFTLKISRVEPEDVGVYYC MHATQFPYT FGQGTKLEIK (SEQ ID NO: 94)

[0804] CDR-L1-nucleotide sequence

[0805] CAA AGC CTC GTA CAC TTT GAT GGA AAC ACC TAC (SEQ ID NO:95)

[0806] CDR-L1-amino acid sequence

[0807] QSLVHFDGNTY (SEQ ID NO:96)

[0808] CDR-L2-nucleotide sequence

[0809] AAG ATT TCT (SEQ ID NO: 97)

[0810] CDR-L2-amino acid sequence

[0811] KIS (SEQ ID NO:98)

[0812] CDR-L3-nucleotide sequence

[0813] ATG CAT GCT ACA CAA TTT CCG TAC ACT(SEQ ID NO:99)

[0814] CDR-L3-amino acid sequence

[0815] MHATQFPYT (SEQ ID NO: 100)

[0816]

[0817] Heavy chain - amino acid sequence

[0818] QVQLVESGGGVGQPGRSLRLSCAASGFTFSRNAMHWVRQAPGKGLEWVAVISYDGSNKHYADSVKGRF TISRDNSKNTLYLEMNSLRVEDTAVYYCAKGGIPFDYWGQGTLVTVSS ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK(SEQ ID NO:102)

[0819] Light chain (LC) - nucleotide sequence

[0820] CTGCTGCAAGGCTCTGGCGATATTGTGATGACCCAGTCTCCACTCTCCTCACCTGTCACCCTTGGACAGCCGGCCTCCATCTCCTGCAGGTCTAGTCAAAGCCTCGTACACTTTGATGGAAACACCTACTTGAGTTGGCTTCACCAGAGGCCAGGCCAGCCTCCAAGACTCCTAATTTATAAGATTTCTAACCGCTTCTCTGGGGTCCCAGACAGATTCAGTGGCAGTGGGGCAGGGACAGATTTCACACTGAAAATCAGCAGGGTGGAACCTGAAGATGTCGGGGTTTATTACTGCATGCATGCTACACAATTTCCGTACACTTTTGGCCAGGGGACCAAGCTGGAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG(SEQ ID NO:103)

[0821] Light chain (LC) - Amino acid sequence

[0822] LLQGSG DIVMTQSPLSSPVTLGQPASISCRSSQSLVHFDGNTYLSWLHQRPGQPPRLLIYKISNRFSG VPDRFSGSGAGTDFTLKISRVEPEDVGVYYCMHATQFPYTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:104)

[0823] REGN8072

[0824] Heavy chain variable region (HCVR, V H)-Nucleotide sequence CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGCGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCGCCTTCAGTAGGTCTGCCATGCACTGGGTCCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATAC TATACAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACACCCTGAGAGCTGAGGACACGGCTCTTTATTACTGTGCGAAAATGTATACAACTATGGACTCTTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA(SEQ ID NO:105)

[0825] Heavy chain variable region (HCVR, V H )-amino acid sequence

[0826] QVQLVESGGGVVQPARSLRLSCAAS GFAFSRSA MHWVRQAPGKGLEWVAV ISYDGSNK YYTDSVKGRFTISRDNSKNTLYLQMNTLRAEDTALYYC AKMYTTMDSFDY WGQGTLVTVSS (SEQ ID NO: 106)

[0827] CDR-H1-nucleotide sequence

[0828] GGA TTC GCC TTC AGT AGG TCT GCC (SEQ ID NO:107)

[0829] CDR-H1-amino acid sequence

[0830] GFAFSRSA (SEQ ID NO: 108)

[0831] CDR-H2-nucleotide sequence

[0832] ATA TCA TAT GAT GGA AGT AAT AAA(SEQ ID NO:109)

[0833] CDR-H2 - amino acid sequence

[0834] ISYDGSNK (SEQ ID NO: 110)

[0835] CDR-H3-nucleotide sequence

[0836] GCG AAA ATG TAT ACA ACT ATG GAC TCT TTT GAC TAC (SEQ ID NO:111)

[0837] CDR-H3-amino acid sequence

[0838] AK MYTTMDSFDY (SEQ ID NO: 112)

[0839] Light chain variable region (LCVR, V L )-nucleotide sequence

[0840] GACATCCAGTTGACCCAGTCTCCATCCTTCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCTGGGCCAGTCAGGGCATTAGCAGTTATTTAGCCTGGTATCAGCAAAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCACTTTG CAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACAATCAGCAGCCTGCAGCCTGAAGATTTTGCACTTTATTACTGTCAACAGCTTAATAGTTACCCTCGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA(SEQ ID NO:113)

[0841] Light chain variable region (LCVR, V L )-amino acid sequence

[0842] DIQLTQSPSFLSASVGDRVTITCWAS QGISSY LAWYQQKPGKAPKLLIY AAS TLQSGVPSRFSGSGSGTEFTLTISSLQPEDFALYYC QQLNSYPRT FGQGTKVEIK (SEQ ID NO: 114)

[0843] CDR-L1-nucleotide sequence

[0844] CAG GGC ATT AGC AGT TAT (SEQ ID NO:115)

[0845] CDR-L1-amino acid sequence

[0846] QGISSY (SEQ ID NO: 116)

[0847] CDR-L2-nucleotide sequence

[0848] GCT GCA TCC (SEQ ID NO: 117)

[0849] CDR-L2-amino acid sequence

[0850] AAS (SEQ ID NO: 118)

[0851] CDR-L3-nucleotide sequence

[0852] CAA CAG CTT AAT AGT TAC CCT CGG ACG (SEQ ID NO:119)

[0853] CDR-L3-amino acid sequence

[0854] QQLNSYPRT (SEQ ID NO: 120)

[0855] Heavy chain (HC)-nucleotide sequence

[0856]

[0857] Heavy chain - amino acid sequence

[0858] QVQLVESGGGVVQPARSLRLSCAASGFAFSRSAMHWVRQAPGKGLEWVAVISYDGSNKYYTDSVKGRF TISRDNSKNTLYLQMNTLRAEDTALYYCAKMYTTMDSFDYWGQGTLVTVSS ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK(SEQ ID NO:122)

[0859] Light chain (LC) - nucleotide sequence

[0860] CTGCTGCAAGGCTCTGGCGACATCCAGTTGACCCAGTCTCCATCCTTCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCTGGGCCAGTCAGGGCATTAGCAGTTATTTAGCCTGGTATCAGCAAAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCACTTTGCAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACAATCAGCAGCCTGCAGCCTGAAGATTTTGCACTTTATTACTGTCAACAGCTTAATAGTTACCCTCGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG(SEQ ID NO:123)

[0861] Light chain (LC) - Amino acid sequence

[0862] LLQGSG DIQLTQSPSFLSASVGDRVTITCWASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRF SGSGSGTEFTLTISSLQPEDFALYYCQQLNSYPRTFGQGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:124)

[0863] REGN9267

[0864] Heavy chain variable region (HCVR, V H ) - Nucleotide sequence

[0865] GAAGTGCAACTGGTGGAGTCTGGGGGAGGCCTGGTCAAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCATCTTCAGTAGATATAGCATGAACTGGGTCCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCATCCATGAGTAGTAATAGTAAAAACACATACTAC GCAGACTCAGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAAAACTCACTGTTTCTGCAAATGAACACCCTGAGAGCCGAGGACACGGCTGTTTATTACTGTGCGAGAGATGGATACACCCTCAGGGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCA(SEQ ID NO:125)

[0866] Heavy chain variable region (HCVR, V H )-amino acid sequence

[0867] EVQLVESGGGLVKPGGSLRLSCAAS GFIFSRYS MNWVRQAPGKGLEWVSS MSSNSKNT YYADSVKGRFTISRDNAKNSLFLQMNTLRAEDTAVYYC ARDGYTLRAFDI WGQGTMVTVSS (SEQ ID NO: 126)

[0868] CDR-H1-nucleotide sequence

[0869] GGA TTC ATC TTC AGT AGA TAT AGC (SEQ ID NO:127)

[0870] CDR-H1-amino acid sequence

[0871] GFIFSRYS (SEQ ID NO: 128)

[0872] CDR-H2-nucleotide sequence

[0873] ATG AGT AGT AAT AGT AAA AAC ACA(SEQ ID NO:129)

[0874] CDR-H2 - amino acid sequence

[0875] MSSNSKNT (SEQ ID NO: 130)

[0876] CDR-H3-nucleotide sequence

[0877] GCG AGA GAT GGA TAC ACC CTC AGG GCT TTT GAT ATC (SEQ ID NO:131)

[0878] CDR-H3-amino acid sequence

[0879] ARDGYTLRAFDI (SEQ ID NO: 132)

[0880] Light chain variable region (LCVR, V L )-nucleotide sequence

[0881] GAAATTGTGTTGACGCAGTCCAGGCACCCTGTCTCTGTCTCCAGGGGAAAGAGACACCCTCTCCTGCAGGGCCAGTCAGAGTATTGCCGGCAGATACGTAGCCTGGTACCAGCAGAAACCTGGCCAGGCACCCAGACTCCTCATCTACGGTGCATCCAGCAG GGCCACTGGCATCCCAGACAGATTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAATATGGTAGCTCACCTTGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA(SEQ ID NO:133)

[0882] Light chain variable region (LCVR, V L )-amino acid sequence

[0883] EIVLTQSPGTLSLSPGERDTLSCRAS QSIAGRY VAWYQQKPGQAPRLLIY GAS SRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC QQYGSSPWT FGQGTKVEIK (SEQ ID NO: 134)

[0884] CDR-L1-nucleotide sequence

[0885] CAG AGT ATT GCC GGC AGA TAC (SEQ ID NO:135)

[0886] CDR-L1-amino acid sequence

[0887] QSIAGRY (SEQ ID NO: 136)

[0888] CDR-L2-nucleotide sequence

[0889] GGT GCA TCC (SEQ ID NO: 137)

[0890] CDR-L2-amino acid sequence

[0891] GAS (SEQ ID NO: 138)

[0892] CDR-L3-nucleotide sequence

[0893] CAG CAA TAT GGT AGC TCA CCT TGG ACG (SEQ ID NO:139)

[0894] CDR-L3-amino acid sequence

[0895] QQYGSSPWT (SEQ ID NO: 140)

[0896] Heavy chain (HC)-nucleotide sequence

[0897]

[0898] Heavy chain - amino acid sequence

[0899] LLQGSG EVQLVESGGGLVKPGGSLRLSCAASGFIFSRYSMNWVRQAPGKGLEWVSSMSSNSKNTYYAD SVKGRFTISRDNAKNSLFLQMNTLRAEDTAVYYCARDGYTLRAFDIWGQGTMVTVSS ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK(SEQ ID NO:142)

[0900] Light chain (LC) - nucleotide sequence

[0901] GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTCTGTCTCCAGGGGAAAGAGACACCCTCTCCTGCAGGGCCAGTCAGAGTATTGCCGGCAGATACGTAGCCTGGTACCAGCAGAAACCTGGCCAGGCACCCAGACTCCTCATCTACGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGATTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAATATGGTAGCTCACCTTGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG(SEQ ID NO:143)

[0902] Light chain (LC) - Amino acid sequence

[0903] EIVLTQSPGTLSLSPGERDTLSCRASQSIAGRYVAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGS GTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQID NO:144)

[0904] REGN7988

[0905] Heavy chain variable region (HCVR, V H ) - Nucleotide sequence

[0906] CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTGGCTATGGCATACACTGGGTCCCGCCAGGCTCCAGGCAAGGGACTGGTGTGGGTGGCAGTTATATGGTATGATGGAAGTTTTAAATACTATGCAGACTCC GTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAGATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGGTGATAGCAGCTCGTCCGGACGGTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA(SEQ ID NO:145)

[0907] Heavy chain variable region (HCVR, V H )-amino acid sequence

[0908] QVQLVESGGGVVQPGRSLRLSCAAS GFTFSGYG IHWVRQAPGKGLVWVAV IWYDGSFK YYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC ARGDSSSSGRYYYYGMDV WGQGTTVTVSS (SEQ ID NO: 146)

[0909] CDR-H1-nucleotide sequence

[0910] GGA TTC ACC TTC AGT GGC TAT GGC (SEQ ID NO:147)

[0911] CDR-H1-amino acid sequence

[0912] GFTFSGYG (SEQ ID NO: 148)

[0913] CDR-H2-nucleotide sequence

[0914] ATA TGG TAT GAT GGA AGT TTT AAA(SEQ ID NO:149)

[0915] CDR-H2 - amino acid sequence

[0916] IWYDGSFK (SEQ ID NO: 150)

[0917] CDR-H3-nucleotide sequence

[0918] GCG AGA GGT GAT AGC AGC TCG TCC GGA CGG TAC TAC TAC TAC GGT ATG GACGTC (SEQ ID NO:151)

[0919] CDR-H3-amino acid sequence

[0920] ARGDSSSSGRYYYYGMDV(SEQ ID NO:152)

[0921] Light chain variable region (LCVR, V L )-nucleotide sequence

[0922] GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGGCATTAGAAATGATTTAGGCTGGTATCAGCAGAAACCAGGGACAGCCCCTAAGCGCCTGATCTTTGCTGCATCCAGTT TGCAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACAATCAGCAGCCTGCAGCCTGAAGATTTTGCGACTTATTACTGTCTACAGCATAATAATTACCCTCCCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAA (SEQ ID NO:153)

[0923] Light chain variable region (LCVR, V L )-amino acid sequence

[0924] DIQMTQSPSSLSASVGDRVTITCRAS QGIRND LGWYQQKPGTAPKRLIF AAS SLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYC LQHNNYPPT FGGGTKVEIK (SEQ ID NO: 154)

[0925] CDR-L1-nucleotide sequence

[0926] CAG GGC ATT AGA AAT GAT(SEQ ID NO:155)

[0927] CDR-L1-amino acid sequence

[0928] QGIRND (SEQ ID NO: 156)

[0929] CDR-L2-nucleotide sequence

[0930] GCT GCA TCC (SEQ ID NO: 157)

[0931] CDR-L2-amino acid sequence

[0932] AAS (SEQ ID NO: 158)

[0933] CDR-L3-nucleotide sequence

[0934] CTA CAG CAT AAT AAT TAC CCT CCC ACT(SEQ ID NO:159)

[0935] CDR-L3-amino acid sequence

[0936] LQHNNYPPT (SEQ ID NO: 160)

[0937] Heavy chain (HC)-nucleotide sequence

[0938]

[0939] Heavy chain - Amino acid sequence

[0940] QVQLVESGGGVVQPGRSLRLSCAASGFTFSGYGIHWVRQAPGKGLVWVAVIWYDGSFKYYADSVKGRF TISRDNSKNTLYLQMNSLRAEDTAVYYCARGDSSSSGRYYYYGMDVWGQGTTVTVSS ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO:162)

[0941] Light chain (LC) - Nucleotide sequence

[0942] CTGCTGCAAGGCTCTGGCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGGCATTAGAAATGATTTAGGCTGGTATCAGCAGAAACCAGGGACAGCCCCTAAGCGCCTGATCTTTGCTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACAATCAGCAGCCTGCAGCCTGAAGATTTTGCGACTTATTACTGTCTACAGCATAATAATTACCCTCCCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG(SEQ ID NO:163)

[0943] Light chain (LC) - Amino acid sequence

[0944] LLQGSG DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGTAPKRLIFAASSLQSGVPSRF SGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPPTFGGGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:164)

[0945] REGN5619

[0946] Heavy chain variable region (HCVR, V H ) - Nucleotide sequence

[0947] GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAAACTCTCCTGTGCAGCCTCTGGGTTCACCTTCAGTGGCTCTGCTATGCACTGGGTCCGCCAGGCTTCCGGGAAAGGGCTGGAGTGGGTTGGCCGTATTACAAGCAAAGCTAACAGTTACGCGACAGCATA TGATGCGTCGGTGAAAGGCAGGTTCACCATTCCAGAGATGATTCAAAGAACACGGCGTATCTGCAAATGAACAGCCTGAAAACCGAGGACACGGCCGTGTATTACTGTACTAGGCAACGATTTTTGGAGTTTTTATTCCTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA(SEQ IDNO:165)

[0948] Heavy chain variable region (HCVR, V H )-amino acid sequence

[0949] EVQLVESGGGLVQPGGSLKLSCAAS GFTFSGSA MHWVRQASGKGLEWVGR ITSKANSYAT AYDASVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYC TRQRFLEFLFLDY WGQGTLVTVSS (SEQ ID NO: 166)

[0950] CDR-H1-nucleotide sequence

[0951] GGG TTC ACC TTC AGT GGC TCT GCT(SEQ ID NO:167)

[0952] CDR-H1-amino acid sequence

[0953] GFTFSGSA (SEQ ID NO: 168)

[0954] CDR-H2-nucleotide sequence

[0955] ATT ACA AGC AAA GCT AAC AGT TAC GCG ACA (SEQ ID NO:169)

[0956] CDR-H2 - amino acid sequence

[0957] ITSKANSYAT (SEQ ID NO: 170)

[0958] CDR-H3-nucleotide sequence

[0959] ACT AGG CAA CGA TTT TTG GAG TTT TTA TTC CTT GAC TAC (SEQ ID NO:171)

[0960] CDR-H3-amino acid sequence

[0961] TRQRFLEFLFLDY (SEQ ID NO: 172)

[0962] Light chain variable region (LCVR, V L )-nucleotide sequence

[0963] GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTTACAGTACCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAA(SEQ ID NO:173)

[0964] Light chain variable region (LCVR, V L )-amino acid sequence

[0965] DIQMTQSPSSLSASVGDRVTITCRAS QSISSY LNWYQQKPGKAPKLLIY AAS SLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQSYSTPPIT FGQGTRLEIK (SEQ ID NO: 174)

[0966] CDR-L1-nucleotide sequence

[0967] CAG AGC ATT AGC AGC TAT(SEQ ID NO:175)

[0968] CDR-L1-amino acid sequence

[0969] QSISSY (SEQ ID NO: 176)

[0970] CDR-L2-nucleotide sequence

[0971] GCT GCA TCC (SEQ ID NO: 177)

[0972] CDR-L2-amino acid sequence

[0973] AAS (SEQ ID NO: 178)

[0974] CDR-L3-nucleotide sequence

[0975] CAA CAG AGT TAC AGT ACC CCT CCG ATC ACC(SEQ ID NO:179)

[0976] CDR-L3-amino acid sequence

[0977] QQSYSTPPIT (SEQ ID NO: 180)

[0978] Heavy chain (HC)-nucleotide sequence

[0979]

[0980] Heavy chain - Amino acid sequence

[0981] EVQLVESGGGLVQPGGSLKLSCAASGFTFSGSAMHWVRQASGKGLEWVGRITSKANSYATAYDASVKG RFTISRDDSKNTAYLQMNSLKTEDTAVYYCTRQRFLEFLFLDYWGQGTLVTVSS ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK(SEQ ID NO:182)

[0982] Light chain (LC) - Nucleotide sequence

[0983] CTGCTGCAAGGCTCTGGCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCAAAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTTACAGTACCCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG(SEQ ID NO:183)

[0984] Light chain (LC) - Amino acid sequence

[0985] LLQGSG DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRF SGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:184)

[0986] REGN7989

[0987] Heavy chain variable region (HCVR, V H ) - Nucleotide sequence

[0988] GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAATGGGTCTCAGCTATTAGCGGTAGTGGTGGCAGCACATACTACGCA GACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAAAGGCCTTATAGCACCTCGTCCGATGGGCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA(SEQ IDNO:186)

[0989] Heavy chain variable region (HCVR, V H )-amino acid sequence

[0990] EVQLVESGGGLVQPGGSLRLSCAAS GFTFSSYA MSWVRQAPGKGLEWVSA ISGSGGST YYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC AKGLIAPRPMGFDY WGQGTLVTVSS (SEQ ID NO: 187)

[0991] CDR-H1-nucleotide sequence

[0992] GGA TTC ACC TTT AGC AGC TAT GCC (SEQ ID NO:188)

[0993] CDR-H1-amino acid sequence

[0994] GFTFSSYA (SEQ ID NO: 189)

[0995] CDR-H2-nucleotide sequence

[0996] ATT AGC GGT AGT GGT GGC AGC ACA(SEQ ID NO:190)

[0997] CDR-H2 - amino acid sequence

[0998] ISGSGGST (SEQ ID NO: 191)

[0999] CDR-H3-nucleotide sequence

[1000] GCG AAA GGC CTT ATA GCA CCT CGT CCG ATG GGC TTT GAC TAC (SEQ ID NO:192)

[1001] CDR-H3-amino acid sequence

[1002] AKGLIAPRPMGFDY (SEQ ID NO: 193)

[1003] Light chain variable region (LCVR, V L )-nucleotide sequence

[1004] GACATCCAGATGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGTCGGGCGAGTCAGGGTATTAACAGCTGGTTAGCCTGGTATCAGCAGAAACCTGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTG CAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTACTATTGTCACCAGGCTGACAGTTTCCCGTACACTTTTGGCCAGGGGACCAAGCTGGAGATCAAA(SEQ ID NO:194)

[1005] Light chain variable region (LCVR, V L )-amino acid sequence

[1006] DIQMTQSPSSVSASVGDRVTITCRAS QGINSW LAWYQQKPGKAPKLLIY AAS SLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYC HQADSFPYT FGQGTKLEIK (SEQ ID NO: 195)

[1007] CDR-L1-nucleotide sequence

[1008] CAG GGT ATT AAC AGC TGG (SEQ ID NO:196)

[1009] CDR-L1-amino acid sequence

[1010] QGINSW (SEQ ID NO: 197)

[1011] CDR-L2-nucleotide sequence

[1012] GCT GCA TCC (SEQ ID NO: 198)

[1013] CDR-L2-amino acid sequence

[1014] AAS (SEQ ID NO: 199)

[1015] CDR-L3-nucleotide sequence

[1016] CAC CAG GCT GAC AGT TTC CCG TAC ACT(SEQ ID NO:200)

[1017] CDR-L3-amino acid sequence

[1018] HQADSFPYT (SEQ ID NO: 201)

[1019] Heavy chain (HC)-nucleotide sequence

[1020]

[1021] Heavy chain - amino acid sequence

[1022] LLQGSG EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYAD SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGLIARPMGFDYWGQGTLVTVSS ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK(SEQ ID NO:203)

[1023] Light chain (LC) - nucleotide sequence

[1024] GACATCCAGATGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGTCGGGCGAGTCAGGGTATTAACAGCTGGTTAGCCTGGTATCAGCAGAAACCTGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTACTATTGTCACCAGGCTGACAGTTTCCCGTACACTTTTGGCCAGGGGACCAAGCTGGAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG(SEQ ID NO:204)

[1025] Light chain (LC) - Amino acid sequence

[1026] DIQMTQSPSSVSASVGDRVTITCRASQGINSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSG TDFTLTISSLQPEDFATYYCHQADSFPYTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ IDNO:205)

[1027] REGN8069

[1028] Heavy chain variable region (HCVR, V H ) - Nucleotide sequence

[1029] CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGGCCAGCCTGGGAGGTCCCTGAGACTGTCCTGTGCAGCCTCTGGATTCACCTTCAGCAGGAATGCCATGCACTGGGTCCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTCATATCATATGATGGAAGTAATAAACA CTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGGAAATGAACAGCCTGAGAGTTGAGGACACGGCTGTGTATTATTGTGCGAAAGGGGGGATTCCTTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA(SEQ ID NO:206)

[1030] Heavy chain variable region (HCVR, V H )-amino acid sequence

[1031] VQLVESGGGVGQPGRSLRLSCAAS GFTFSRNA MHWVRQAPGKGLEWVAV ISYDGSNK HYADSVKGRFTISRDNSKNTLYLEMNSLRVEDTAVYYC AKGGIPFDY WGQGTLVTVSS (SEQ ID NO: 207)

[1032] CDR-H1-nucleotide sequence

[1033] GGA TTC ACC TTC AGC AGG AAT GCC (SEQ ID NO:208)

[1034] CDR-H1-amino acid sequence

[1035] GFTFSRNA; (SEQ ID NO: 209)

[1036] CDR-H2-nucleotide sequence

[1037] ATA TCA TAT GAT GGA AGT AAT AAA(SEQ ID NO:210)

[1038] CDR-H2 - amino acid sequence

[1039] ISYDGSNK; (SEQ ID NO: 211)

[1040] CDR-H3-nucleotide sequence

[1041] GCG AAA GGG GGG ATT CCT TTT GAC TAC (SEQ ID NO:212)

[1042] CDR-H3-amino acid sequence

[1043] AKGGIPFDY; (SEQ ID NO: 213)

[1044] Light chain variable region (LCVR, V L )-nucleotide sequence

[1045] GATATTGTGATGACCCAGTCTCCACTCTCCTCACCTGTCACCCTTGGACAGCCGGCCTCCATCTCCTGCAGGTCTAGTCAAAGCCTCGTACACTTTGATGGAAACACCTACTTGAGTTGGCTTCACCAGAGGCCAGGCCAGCCTCCAAGACTCCTAATTTATAAGATTTC TAACCGCTTCTCTGGGGTCCCAGACAGATTCAGTGGCAGTGGGGCAGGGACAGATTTCACACTGAAAATCAGCAGGTGTGGAACCTGAAGATGTCGGGGTTTATTACTGCATGCATGCTACACAATTTCCGTACACTTTTGGCCAGGGGACCAAGCTGGAGATCAAA(SEQ ID NO:214)

[1046] Light chain variable region (LCVR, V L )-amino acid sequence

[1047] DIVMTQSPLSSPVTLGQPASISCRSS QSLVHFDGNTY LSWLHQRPGQPPRLLIY KIS NRFSGVPDRFSGSGAGTDFTLKISRVEPEDVGVYYC MHATQFPYT FGQGTKLEIK (SEQ ID NO: 215)

[1048] CDR-L1-nucleotide sequence

[1049] CAA AGC CTC GTA CAC TTT GAT GGA AAC ACC TAC (SEQ ID NO:216)

[1050] CDR-L1-amino acid sequence

[1051] QSLVHFDGNTY (SEQ ID NO: 217)

[1052] CDR-L2-nucleotide sequence

[1053] AAG ATT TCT (SEQ ID NO: 218)

[1054] CDR-L2-amino acid sequence

[1055] KIS (SEQ ID NO: 219)

[1056] CDR-L3-nucleotide sequence

[1057] ATG CAT GCT ACA CAA TTT CCG TAC ACT(SEQ ID NO:220)

[1058] CDR-L3-amino acid sequence

[1059] MHATQFPYT (SEQ ID NO: 221)

[1060] Heavy chain (HC)-nucleotide sequence

[1061]

[1062] Heavy chain - amino acid sequence

[1063] LLQGSG QVQLVESGGGVGQPGRSLRLSCAASGFTFSRNAMHWVRQAPGKGLEWVAVISYDGSNKHYAD SVKGRFTISRDNSKNTLYLEMNSLRVEDTAVYYCAKGGIPFDYWGQGTLVTVSS ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK(SEQ ID NO:223)

[1064] Light chain (LC) - nucleotide sequence

[1065] GATATTGTGATGACCCAGTCTCCACTCTCCTCACCTGTCACCCTTGGACAGCCGGCCTCCATCTCCTGCAGGTCTAGTCAAAGCCTCGTACACTTTGATGGAAACACCTACTTGAGTTGGCTTCACCAGAGGCCAGGCCAGCCTCCAAGACTCCTAATTTATAAGATTTCTAACCGCTTCTCTGGGGTCCCAGACAGATTCAGTGGCAGTGGGGCAGGGACAGATTTCACACTGAAAATCAGCAGGGTGGAACCTGAAGATGTCGGGGTTTATTACTGCATGCATGCTACACAATTTCCGTACACTTTTGGCCAGGGGACCAAGCTGGAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG(SEQ ID NO:224)

[1066] Light chain (LC) - Amino acid sequence

[1067] DIVMTQSPLSSPVTLGQPASISCRSSQSLVHFDGNTYLSWLHQRPGQPPRLLIYKISNRFSGVPDRFS GSGAGTDFTLKISRVEPEDVGVYYCMHATQFPYTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:225)

[1068] REGN8071

[1069] Heavy chain variable region (HCVR, V H ) - Nucleotide sequence

[1070] CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGCGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCGCCTTCAGTAGGTCTGCCATGCACTGGGTCCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACT ATACAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACACCCTGAGAGCTGAGGACACGGCTCTTTATTACTGTGCGAAAATGTATACAACTATGGACTCTTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA (SEQ ID NO:226)

[1071] Heavy chain variable region (HCVR, V H )-amino acid sequence QVQLVESGGGVVQPARSLRLSCAAS GFAFSRSA MHWVRQAPGKGLEWVAV ISYDGSNK YYTDSVKGRFTISRDNSKNTLYLQMNTLRAEDTALYYC AKMYTTMDSFDY WGQGTLVTVSS (SEQ ID NO: 227)

[1072] CDR-H1-nucleotide sequence

[1073] GGA TTC GCC TTC AGT AGG TCT GCC (SEQ ID NO:228)

[1074] CDR-H1-amino acid sequence

[1075] GFAFSRSA (SEQ ID NO: 229)

[1076] CDR-H2-nucleotide sequence

[1077] ATA TCA TAT GAT GGA AGT AAT AAA (SEQ ID NO:230)

[1078] CDR-H2 - amino acid sequence

[1079] ISYDGSNK (SEQ ID NO: 231)

[1080] CDR-H3-nucleotide sequence

[1081] GCG AAA ATG TAT ACA ACT ATG GAC TCT TTT GAC TAC (SEQ ID NO:232)

[1082] CDR-H3-amino acid sequence

[1083] AKMYTTMDSFDY (SEQ ID NO: 233)

[1084] Light chain variable region (LCVR, V L )-nucleotide sequence

[1085] GACATCCAGTTGACCCAGTCTCCATCCTTCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCTGGGCCAGTCAGGGCATTAGCAGTTATTTAGCCTGGTATCAGCAAAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCACTTTG CAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACAATCAGCAGCCTGCAGCCTGAAGATTTTGCACTTTATTACTGTCAACAGCTTAATAGTTACCCTCGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA(SEQ ID NO:234)

[1086] Light chain variable region (LCVR, V L )-amino acid sequence

[1087] DIQLTQSPSFLSASVGDRVTITCWAS QGISSY LAWYQQKPGKAPKLLIY AAS TLQSGVPSRFSGSGSGTEFTLTISSLQPEDFALYYC QQLNSYPRT FGQGTKVEIK (SEQ ID NO: 235)

[1088] CDR-L1-nucleotide sequence

[1089] CAG GGC ATT AGC AGT TAT(SEQ ID NO:236)

[1090] CDR-L1-amino acid sequence

[1091] QGISSY (SEQ ID NO: 237)

[1092] CDR-L2-nucleotide sequence

[1093] GCT GCA TCC (SEQ ID NO: 238)

[1094] CDR-L2-amino acid sequence

[1095] AAS (SEQ ID NO: 239)

[1096] CDR-L3-nucleotide sequence

[1097] CAA CAG CTT AAT AGT TAC CCT CGG ACG (SEQ ID NO:240)

[1098] CDR-L3-amino acid sequence

[1099] QQLNSYPRT (SEQ ID NO: 241)

[1100] Heavy chain (HC)-nucleotide sequence

[1101]

[1102] Heavy chain - Amino acid sequence

[1103] LLQGSG QVQLVESGGGVVQPARSLRLSCAASGFAFSRSAMHWVRQAPGKGLEWVAVISYDGSNKYYTD SVKGRFTISRDNSKNTLYLQMNTLRAEDTALYYCAKMYTTMDSFDYWGQGTLVTVSS ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK(SEQ ID NO:243)

[1104] Light chain (LC) - Nucleotide sequence

[1105] GACATCCAGTTGACCCAGTCTCCATCCTTCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCTGGGCCAGTCAGGGCATTAGCAGTTATTTAGCCTGGTATCAGCAAAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCACTTTGCAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACAATCAGCAGCCTGCAGCCTGAAGATTTTGCACTTTATTACTGTCAACAGCTTAATAGTTACCCTCGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG(SEQ ID NO:244)

[1106] Light chain (LC) - Amino acid sequence

[1107] DIQLTQSPSFLSASVGDRVTITCWASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSG TEFTLTISSLQPEDFALYYCQQLNSYPRTFGQGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ IDNO:245)

[1108] REGN9426

[1109] Heavy chain variable region (HCVR, V H ) - Nucleotide sequence

[1110] GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAAACTCTCCTGTGCAGCCTCTGGGTTCACCTTCAGTGGCTCTGCTATGCACTGGGTCCGCCAGGCTTCCGGGAAAGGGCTGGAGTGGGTTGGCCGTATTACAAGCAAAGCTAACAGTTACGCGACAGCATA TGATGCGTCGGTGAAAGGCAGGTTCACCATTCCAGAGATGATTCAAAGAACACGGCGTATCTGCAAATGAACAGCCTGAAAACCGAGGACACGGCCGTGTATTACTGTACTAGGCAACGATTTTTGGAGTTTTTATTCCTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA(SEQ IDNO:246)

[1111] Heavy chain variable region (HCVR, V H )-amino acid sequence

[1112] EVQLVESGGGLVQPGGSLKLSCAAS GFTFSGSA MHWVRQASGKGLEWVGR ITSKANSYAT AYDASVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYC TRQRFLEFLFLDY WGQGTLVTVSS (SEQ ID NO: 247)

[1113] CDR-H1-nucleotide sequence

[1114] GGG TTC ACC TTC AGT GGC TCT GCT; (SEQ ID NO:248)

[1115] CDR-H1-amino acid sequence

[1116] GFTFSGSA (SEQ ID NO: 249)

[1117] CDR-H2-nucleotide sequence

[1118] ATT ACA AGC AAA GCT AAC AGT TAC GCG ACA(SEQ ID NO:250)

[1119] CDR-H2 - amino acid sequence

[1120] ITSKANSY AT (SEQ ID NO: 251)

[1121] CDR-H3-nucleotide sequence

[1122] ACT AGG CAA CGA TTT TTG GAG TTT TTA TTC CTT GAC TAC; (SEQ ID NO: 252)

[1123] CDR-H3-amino acid sequence

[1124] TRQRFLEFLFLDY (SEQ ID NO: 253)

[1125] Light chain variable region (LCVR, V L )-nucleotide sequence

[1126] GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTTACAGTACCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAA(SEQ ID NO:254)

[1127] Light chain variable region (LCVR, V L )-amino acid sequence

[1128] DIQMTQSPSSLSASVGDRVTITCRAS QSISSY LNWYQQKPGKAPKLLIY AAS SLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQSYSTPPIT FGQGTRLEIK (SEQ ID NO: 255)

[1129] CDR-L1-nucleotide sequence

[1130] CAG AGC ATT AGC AGC TAT(SEQ ID NO:256)

[1131] CDR-L1-amino acid sequence

[1132] QSISSY (SEQ ID NO: 257)

[1133] CDR-L2-nucleotide sequence

[1134] GCT GCA TCC (SEQ ID NO: 258)

[1135] CDR-L2-amino acid sequence

[1136] AAS (SEQ ID NO: 259)

[1137] CDR-L3-nucleotide sequence

[1138] CAA CAG AGT TAC AGT ACC CCT CCG ATC ACC(SEQ ID NO:260)

[1139] CDR-L3-amino acid sequence

[1140] QQSYSTPPIT (SEQ ID NO: 261)

[1141] Heavy chain (HC)-nucleotide sequence

[1142]

[1143] Heavy chain - Amino acid sequence

[1144] LLQGSG EVQLVESGGGLVQPGGSLKLSCAASGFTFSGSAMHWVRQASGKGLEWVGRITSKANSYATAY DASVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCTRQRFLEFLFLDYWGQGTLVTVSS ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK(SEQ ID NO:263)

[1145] Light chain (LC) - Nucleotide sequence

[1146] GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCAAAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTTACAGTACCCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAG CAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG(SEQ ID NO:264)

[1147] Light chain (LC) - Amino acid sequence<0004***

[1148] DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSG TDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQID NO:265)

[1149] REGN5203

[1150] Heavy chain (HC) - Nucleotide sequence

[1151] It should be noted that there seems to be an error in the original text where "***" appears in the middle of the translation of item . Please check and correct it if necessary.

[1152] Heavy chain - amino acid sequence

[1153] LLQGSGQVTLKESGPGILQPSQTLSLTCSFSGFSLSTSGTGVGWIRQPSGKGLEWLSHIWWDDVKRYNPALKSRLTISRDTSYSQVFLRIASVDTADTATYYCARILDGTGPMDYWGQGTSVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK(SEQ ID NO:267)

[1154] Light chain (LC) - nucleotide sequence

[1155] CAAATTGTTCTTACTCAATCTCCTGCTATTATGTCTGCTAGCCCTGGTGAAAAAGTTACTATGACTTGTTCTGCTTCTTCTCGTGTTACTTATATGCATTGGTATCAACAACGTTCTGGTACTTCTCCTAAACGTTGGATTTATGATACTTCTAAACTTGCTTCTGGTGTTCCTGCTCGTTTTTCTGGTTCTGGTTCTGGTACTTCTTATTCTCTTACTATTTCTTCTATGGAAGCTGAAGATGCTGCTACTTATTATTGTCAACAATGGGGTAATAATCCTCAATATACTTTTGGTGGTGGTACTCGTCTTGAAATTAAACGTCGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG(SEQ ID NO:268)

[1156] [[ID=*3*]]Light chain (LC) - Amino acid sequence

[1157] [[ID=*6*]]QIVLTQSPAIMSASPGEKVTMTCSASSRVTYMHWYQQRSGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWGNNPQYTFGGGTRLEIKRRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQID NO:269)

[1158] REGN5204

[1159] Heavy chain (HC)-nucleotide sequence

[1160]

[1161] Heavy chain - amino acid sequence

[1162] QVTLKESGPGILQPSQTLSLTCSFSGFSLSTSGTGVGWIRQPSGKGLEWLSHIWWDDVKRYNPALKSRLTISRDTSYSQVFLRIASVDTADTATYYCARILDGTGPMDYWGQGTSVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK(SEQ ID NO:271)

[1163] Light chain (LC) - nucleotide sequence

[1164] TTACTTCAGGGATCTGGTCAAATTGTTCTTACTCAATCTCCTGCTATTATGTCTGCTAGCCCTGGTGAAAAAGTTACTATGACTTGTTCTGCTTCTTCTCGTGTTACTTATATGCATTGGTATCAACAACGTTCTGGTACTTCTCCTAAACGTTGGATTTATGATACTTCTAAACTTGCTTCTGGTGTTCCTGCTCGTTTTTCTGGTTCTGGTTCTGGTACTTCTTATTCTCTTACTATTTCTTCTATGGAAGCTGAAGATGCTGCTACTTATTATTGTCAACAATGGGGTAATAATCCTCAATATACTTTTGGTGGTGGTACTCGTCTTGAAATTAAACGTCGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG(SEQ ID NO:272)

[1165] Light chain (LC) - Amino acid sequence

[1166] LLQGSGQIVLTQSPAIMSASPGEKVTMTCSASSRVTYMHWYQQRSGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWGNNPQYTFGGGTRLEIKRRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:273)

[1167] REGN5617

[1168] Heavy chain variable region (HCVR, V H )-nucleotide sequence

[1169] GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCTCTAGGTACTGGATGACCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAAGCAAGATGGCAGTGGGAAAAACTATGT GGACTCTGTGATGGGCCGATACACCATCTCCAGAGACAACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGATGGATAGCACCAGATTTCCCCGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA(SEQ ID NO:274)

[1170] Heavy chain variable region (HCVR, V H )-amino acid sequence

[1171] EVQLVESGGGLVQPGGSLRLSCAAS GFTFSRYW MTWVRQAPGKGLEWVAN IKQDGSGK NYVDSVMGRYTISRDNAKNSLYLQMNSLRAEDTAVYYC ARWIAPDFPGMDV WGQGTTVTVSS (SEQ ID NO: 275)

[1172] CDR-H1—nucleotide sequence

[1173] GGA TTC ACC TTC TCT AGG TAC TGG (SEQ ID NO:276)

[1174] CDR-H1-amino acid sequence

[1175] GFTFSRYW (SEQ ID NO: 277)

[1176] CDR-H2-nucleotide sequence

[1177] ATA AAG CAA GAT GGC AGT GGG AAA(SEQ ID NO:278)

[1178] CDR-H2 - amino acid sequence

[1179] IKQDGSGK (SEQ ID NO: 279)

[1180] CDR-H3-nucleotide sequence

[1181] GCG AGA TGG ATA GCA CCA GAT TTC CCC GGT ATG GAC GTC (SEQ ID NO:280)

[1182] CDR-H3-amino acid sequence

[1183] ARWIAPDFPGMDV (SEQ ID NO: 281)

[1184] Light chain variable region (LCVR, V L )-nucleotide sequence

[1185] GACATCCAGTTGACCCAGTCTCCATCCTTCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCTGGGCCAGTCAGGGCATTAGCAGTTATTTAGCCTGGTATCAGCAAAAACCAGGAAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCACTTTG CAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACAATCAGCAGCCTGCAGCCTGCAGATTTTGCAACTTATTACTGTCAACAGCTTAATAGTTACCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAA(SEQ ID NO:282)

[1186] Light chain variable region (LCVR, V L )-amino acid sequence

[1187] DIQLTQSPSFLSASVGDRVTITCWAS QGISSY LAWYQQKPGKAPKLLIY AAS TLQSGVPSRFSGSGSGTEFTLTISSLQPADFATYYC QQLNSYPLT FGGGTKVEIK (SEQ ID NO: 283)

[1188] CDR-L1-nucleotide sequence

[1189] CAG GGC ATT AGC AGT TAT(SEQ ID NO:284)

[1190] CDR-L1-amino acid sequence

[1191] QGISSY (SEQ ID NO: 285)

[1192] CDR-L2-nucleotide sequence

[1193] GCT GCA TCC (SEQ ID NO: 286)

[1194] CDR-L2-amino acid sequence

[1195] AAS (SEQ ID NO: 287)

[1196] CDR-L3-nucleotide sequence

[1197] CAA CAG CTT AAT AGT TAC CCG CTC ACT(SEQ ID NO:288)

[1198] CDR-L3-amino acid sequence

[1199] QQLNSYPLT (SEQ ID NO: 289)

[1200] Heavy chain (HC)-nucleotide sequence

[1201]

[1202] Heavy chain - Amino acid sequence

[1203] EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMTWVRQAPGKGLEWVANIKQDGSGKNYVDSVMGRY TISRDNAKNSLYLQMNSLRAEDTAVYYCARWIAPDFPGMDVWGQGTTVTVSS ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK(SEQ ID NO:291)

[1204] Light chain (LC) - Nucleotide sequence

[1205] CTGCTGCAAGGCTCTGGCGACATCCAGTTGACCCAGTCTCCATCCTTCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCTGGGCCAGTCAGGGCATTAGCAGTTATTTAGCCTGGTATCAGCAAAAACCAGGAAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCACTTTGCAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACAATCAGCAGCCTGCAGCCTGCAGATTTTGCAACTTATTACTGTCAACAGCTTAATAGTTACCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG(SEQ ID NO:292)

[1206] Light chain (LC) - Amino acid sequence

[1207] LLQGSG DIQLTQSPSFLSASVGDRVTITCWASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRF SGSGSGTEFTLTISSLQPADFATYYCQQLNSYPLTFGGGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:293)

[1208] REGN5619

[1209] Heavy chain variable region (HCVR, V H ) - Nucleotide sequence

[1210] GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAAACTCTCCTGTGCAGCCTCTGGGTTCACCTTCAGTGGCTCTGCTATGCACTGGGTCCGCCAGGCTTCCGGGAAAGGGCTGGAGTGGGTTGGCCGTATTACAAGCAAAGCTAACAGTTACGCGACAGCATA TGATGCGTCGGTGAAAGGCAGGTTCACCATTCCAGAGATGATTCAAAGAACACGGCGTATCTGCAAATGAACAGCCTGAAAACCGAGGACACGGCCGTGTATTACTGTACTAGGCAACGATTTTTGGAGTTTTTATTCCTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA(SEQ IDNO:294)

[1211] Heavy chain variable region (HCVR, V H )-amino acid sequence

[1212] EVQLVESGGGLVQPGGSLKLSCAAS GFTFSGSA MHWVRQASGKGLEWVGR ITSKANSYAT AYDASVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYC TRQRFLEFLFLDY WGQGTLVTVSS (SEQ ID NO: 295)

[1213] CDR-H1-nucleotide sequence

[1214] GGG TTC ACC TTC AGT GGC TCT GCT(SEQ ID NO:296)

[1215] CDR-H1-amino acid sequence

[1216] GFTFSGSA (SEQ ID NO: 297)

[1217] CDR-H2-nucleotide sequence

[1218] ATT ACA AGC AAA GCT AAC AGT TAC GCG ACA(SEQ ID NO:298)

[1219] CDR-H2 - amino acid sequence

[1220] ITSKANSY AT (SEQ ID NO: 299)

[1221] CDR-H3-nucleotide sequence

[1222] ACT AGG CAA CGA TTT TTG GAG TTT TTA TTC CTT GAC TAC (SEQ ID NO:300)

[1223] CDR-H3-amino acid sequence

[1224] TRQRFLEFLFLDY (SEQ ID NO: 301)

[1225] Light chain variable region (LCVR, V L )-nucleotide sequence

[1226] GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTTACAGTACCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAA(SEQ ID NO:302)

[1227] Light chain variable region (LCVR, V L )-amino acid sequence

[1228] DIQMTQSPSSLSASVGDRVTITCRAS QSISSY LNWYQQKPGKAPKLLIY AAS SLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQSYSTPPIT FGQGTRLEIK (SEQ ID NO: 303)

[1229] CDR-L1-nucleotide sequence

[1230] CAG AGC ATT AGC AGC TAT (SEQ ID NO:304)

[1231] CDR-L1-amino acid sequence

[1232] QSISSY (SEQ ID NO: 305)

[1233] CDR-L2-nucleotide sequence

[1234] GCT GCA TCC (SEQ ID NO: 306)

[1235] CDR-L2-amino acid sequence

[1236] AAS (SEQ ID NO: 307)

[1237] CDR-L3-nucleotide sequence

[1238] CAA CAG AGT TAC AGT ACC CCT CCG ATC ACC; (SEQ ID NO:308)

[1239] CDR-L3-amino acid sequence

[1240] QQSYSTPPIT (SEQ ID NO: 309)

[1241] Heavy chain (HC)-nucleotide sequence

[1242]

[1243] Heavy chain - Amino acid sequence

[1244] EVQLVESGGGLVQPGGSLKLSCAASGFTFSGSAMHWVRQASGKGLEWVGRITSKANSYATAYDASVKG RFTISRDDSKNTAYLQMNSLKTEDTAVYYCTRQRFLEFLFLDYWGQGTLVTVSS ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK(SEQ ID NO:311)

[1245] Light chain (LC) - Nucleotide sequence

[1246] CTGCTGCAAGGCTCTGGCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCAAAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTTACAGTACCCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG(SEQ ID NO:312)

[1247] Light chain (LC) - Amino acid sequence

[1248] LLQGSG DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRF SGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:313)

[1249] REGN7987

[1250] Heavy chain variable region (HCVR, V H ) - Nucleotide sequence

[1251] CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTGGCTATGGCATACACTGGGTCCCGCCAGGCTCCAGGCAAGGGACTGGTGTGGGTGGCAGTTATATGGTATGATGGAAGTTTTAAATACTATGCAGACTCC GTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAGATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGGTGATAGCAGCTCGTCCGGACGGTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA(SEQ ID NO:314)

[1252] Heavy chain variable region (HCVR, V H )-amino acid sequence

[1253] QVQLVESGGGVVQPGRSLRLSCAAS GFTFSGYG IHWVRQAPGKGLVWVAV IWYDGSFK YYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC ARGDSSSSGRYYYYGMDV WGQGTTVTVSS; (SEQ ID NO: 315)

[1254] CDR-H1-nucleotide sequence

[1255] GA TTC ACC TTC AGT GGC TAT GGC (SEQ ID NO:316)

[1256] CDR-H1-amino acid sequence

[1257] GFTFSGYG (SEQ ID NO: 317)

[1258] CDR-H2-nucleotide sequence

[1259] ATA TGG TAT GAT GGA AGT TTT AAA(SEQ ID NO:318)

[1260] CDR-H2 - amino acid sequence

[1261] IWYDGSFK (SEQ ID NO: 319)

[1262] CDR-H3-nucleotide sequence

[1263] GCG AGA GGT GAT AGC AGC TCG TCC GGA CGG TAC TAC TAC TAC GGT ATG GACGTC(SEQ ID NO:320)

[1264] CDR-H3-amino acid sequence

[1265] ARGDSSSSGRYYYYGMDV(SEQ ID NO:321)

[1266] Light chain variable region (LCVR, V L )-nucleotide sequence

[1267] GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGGCATTAGAAATGATTTAGGCTGGTATCAGCAGAAACCAGGGACAGCCCCTAAGCGCCTGATCTTTGCTGCATCCAGTTTG CAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACAATCAGCAGCCTGCAGCCTGAAGATTTTGCGACTTATTACTGTCTACAGCATAATAATTACCCTCCCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAA(SEQ ID NO:322)

[1268] Light chain variable region (LCVR, V L )-amino acid sequence

[1269] DIQMTQSPSSLSASVGDRVTITCRAS QGIRND LGWYQQKPGTAPKRLIF AAS SLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYC LQHNNYPPT FGGGTKVEIK (SEQ ID NO: 323)

[1270] CDR-L1-nucleotide sequence

[1271] CAG GGC ATT AGA AAT GAT(SEQ ID NO:324)

[1272] CDR-L1-amino acid sequence

[1273] QGIRND (SEQ ID NO: 325)

[1274] CDR-L2-nucleotide sequence

[1275] GCT GCA TCC (SEQ ID NO: 326)

[1276] CDR-L2-amino acid sequence

[1277] AAS (SEQ ID NO: 327)

[1278] CDR-L3-nucleotide sequence

[1279] CTA CAG CAT AAT AAT TAC CCT CCC ACT(SEQ ID NO:328)

[1280] CDR-L3-amino acid sequence

[1281] LQHNNYPPT (SEQ ID NO: 329)

[1282] Heavy chain (HC)-nucleotide sequence

[1283]

[1284] Heavy chain - Amino acid sequence

[1285] LLQGSG QVQLVESGGGVVQPGRSLRLSCAASGFTFSGYGIHWVRQAPGKGLVWVAVIWYDGSFKYYAD SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDSSSSGRYYYYGMDVWGQGTTVTVSS ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK(SEQ ID NO:331)

[1286] Light chain (LC) - Nucleotide sequence

[1287] GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGGCATTAGAAATGATTTAGGCTGGTATCAGCAGAAACCAGGGACAGCCCCTAAGCGCCTGATCTTTGCTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACAATCAGCAGCCTGCAGCCTGAAGATTTTGCGACTTATTACTGTCTACAGCATAATAATTACCCTCCCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG;(SEQ ID NO:332)

[1288] Light chain (LC) - Amino acid sequence

[1289] DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGTAPKRLIFAASSLQSGVPSRFSGSGSG TEFTLTISSLQPEDFATYYCLQHNNYPPTFGGGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ IDNO:333)

[1290] REGN9270

[1291] Heavy chain variable region (HCVR, V H ) - Nucleotide sequence

[1292] CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCGCTGTCTATGGTGGGTCCTTCAGTGGTTACTACTGGAGCTGGATCCGCCAGCCCCCAGGAAAGGGGCTGGAGTGGATTGGGGAAATCAATCATGCTGGAAGCACCAACTACAACCCGTCCCT CAAGAGTCGAATCACCATATCAGTGGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGTTCTGTGACCGCCGCGGACACGGCTGTGTATTACTGTGCGAGAGGATGTGTACTATGGTTCGGGGAGTTATCACCGAAACTGGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA(SEQ ID NO:334)

[1293] Heavy chain variable region (HCVR, V H )-amino acid sequence

[1294] QVQLQQWGAGLLKPSETLSLTCAVY GGSFSGYY WSWIRQPPGKGLEWIGE INHAGST NYNPSLKSRITISVDTSKNQFSLKLSSVTAADTAVYYC ARGWYYGSGSYHRNWFDP WGQGTLVTVSS (SEQ ID NO: 335)

[1295] CDR-H1-nucleotide sequence

[1296] GGT GGG TCC TTC AGT GGT TAC TAC (SEQ ID NO:336)

[1297] CDR-H1-amino acid sequence

[1298] GGSFSGYY (SEQ ID NO: 337)

[1299] CDR-H2-nucleotide sequence

[1300] ATC AAT CAT GCT GGAAGC ACC(SEQ ID NO:338)

[1301] CDR-H2 - amino acid sequence

[1302] INHAGST (SEQ ID NO: 339)

[1303] CDR-H3-nucleotide sequence

[1304] GCG AGA GGA TGG TAC TAT GGT TCG GGG AGT TAT CAC CGA AAC TGG TTC GACCCC (SEQ ID NO:340)

[1305] CDR-H3-amino acid sequence

[1306] ARGWYYGSGSYHRNWFDP(SEQ ID NO:341)

[1307] Light chain variable region (LCVR, V L )-nucleotide sequence

[1308] GAAATTGTATTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTTATTACAGCTACTTAGCCTGGTATCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAACAG GGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAACTCACCTTGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA(SEQ ID NO:342)

[1309] Light chain variable region (LCVR, V L )-amino acid sequence

[1310] EIVLTQSPGTLSLSPGERATLSCRAS QSVYYSY LAWYQQKPGQAPRLLIY GAS NRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC QQYGNSPWT FGQGTKVEIK (SEQ ID NO: 343)

[1311] CDR-L1-nucleotide sequence

[1312] CAG AGT GTT TAT TAC AGC TAC (SEQ ID NO:344)

[1313] CDR-L1-amino acid sequence

[1314] QSVYYSY (SEQ ID NO: 345)

[1315] CDR-L2-nucleotide sequence

[1316] GGT GCA TCC (SEQ ID NO: 346)

[1317] CDR-L2-amino acid sequence

[1318] GAS (SEQ ID NO: 347)

[1319] CDR-L3-nucleotide sequence

[1320] CAG CAG TAT GGT AAC TCA CCT TGG ACG (SEQ ID NO:348)

[1321] CDR-L3-amino acid sequence

[1322] QQYGNSPWT (SEQ ID NO: 349)

[1323] Heavy chain (HC)-nucleotide sequence

[1324]

[1325] Heavy chain - Amino acid sequence

[1326] LLQGSG QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHAGSTNYNPS LKSRITISVDTSKNQFSLKLSSVTAADTAVYYCARGWYYGSGSYHRNWFDPWGQGTLVTVSS ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK(SEQ ID NO:351)

[1327] Light chain (LC) - Nucleotide sequence

[1328] GAAATTGTATTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTTATTACAGCTACTTAGCCTGGTATCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAACAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAACTCACCTTGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG(SEQ ID NO:352)

[1329] Light chain (LC) - Amino acid sequence

[1330] EIVLTQSPGTLSLSPGERATLSCRASQSVYYSYLAWYQQKPGQAPRLLIYGASNRATGIPDRFSGSGS GTDFTLTISRLEPEDFAVYYCQQYGNSPWTFGQGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQID NO:353)

[1331] REGN9278

[1332] Heavy chain variable region (HCVR, V H ) - Nucleotide sequence

[1333] CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCGCTGTCTATGGTGGGTCCTTCAGTGGTTACTACTGGAGCTGGATCCGCCAGCCCCCAGGAAAGGGGCTGGAGTGGATTGGGGAAATCAATCATGCTGGAAGCACCAACTACAACCCGTCCCT CAAGAGTCGAATCACCATATCAGTGGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGTTCTGTGACCGCCGCGGACACGGCTGTGTATTACTGTGCGAGAGGATGTGTACTATGGTTCGGGGAGTTATCACCGAAACTGGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA(SEQ ID NO:354)

[1334] Heavy chain variable region (HCVR, V H )-amino acid sequence

[1335] QVQLQQWGAGLLKPSETLSLTCAVY GGSFSGYY WSWIRQPPGKGLEWIGE INHAGST NYNPSLKSRITISVDTSKNQFSLKLSSVTAADTAVYYC ARGWYYGSGSYHRNWFDP WGQGTLVTVSS (SEQ ID NO: 355)

[1336] CDR-H1-nucleotide sequence

[1337] GGT GGG TCC TTC AGT GGT TAC TAC (SEQ ID NO:356)

[1338] CDR-H1-amino acid sequence

[1339] GGSFSGYY (SEQ ID NO: 357)

[1340] CDR-H2-nucleotide sequence

[1341] ATC AAT CAT GCT GGAAGC ACC(SEQ ID NO:358)

[1342] CDR-H2 - amino acid sequence

[1343] INHAGST (SEQ ID NO: 359)

[1344] CDR-H3-nucleotide sequence

[1345] GCG AGA GGA TGG TAC TAT GGT TCG GGG AGT TAT CAC CGA AAC TGG TTC GACCCC (SEQ ID NO:360)

[1346] CDR-H3-amino acid sequence

[1347] ARGWYYGSGSYHRNWFDP(SEQ ID NO:361)

[1348] Light chain variable region (LCVR, V L )-nucleotide sequence

[1349] GAAATTGTATTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTTATTACAGCTACTTAGCCTGGTATCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAACAG GGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAACTCACCTTGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA(SEQ ID NO:362)

[1350] Light chain variable region (LCVR, V L )-amino acid sequence

[1351] EIVLTQSPGTLSLSPGERATLSCRAS QSVYYSY LAWYQQKPGQAPRLLIY GAS NRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC QQYGNSPWT FGQGTKVEIK (SEQ ID NO: 363)

[1352] CDR-L1-nucleotide sequence

[1353] CAG AGT GTT TAT TAC AGC TAC (SEQ ID NO:364)

[1354] CDR-L1-amino acid sequence

[1355] QSVYYSY (SEQ ID NO: 365)

[1356] CDR-L2-nucleotide sequence

[1357] GGT GCA TCC (SEQ ID NO: 366)

[1358] CDR-L2-amino acid sequence

[1359] GAS (SEQ ID NO: 367)

[1360] CDR-L3-nucleotide sequence

[1361] CAG CAG TAT GGT AAC TCA CCT TGG ACG (SEQ ID NO:368)

[1362] CDR-L3-amino acid sequence

[1363] QQYGNSPWT (SEQ ID NO: 369)

[1364] Heavy chain (HC)-nucleotide sequence

[1365]

[1366] Heavy chain - Amino acid sequence

[1367] QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHAGSTNYNPSLKSRIT ISVDTSKNQFSLKLSSVTAADTAVYYCARGWYYGSGSYHRNWFDPWGQGTLVTVSS ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK(SEQ ID NO:371)

[1368] Light chain (LC) - Nucleotide sequence

[1369] TTACTTCAGGGATCTGGTGAAATTGTATTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTTATTACAGCTACTTAGCCTGGTATCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAACAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAACTCACCTTGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG(SEQ ID NO:372)

[1370] Light chain (LC) - Amino acid sequence

[1371] LLQGSG EIVLTQSPGTLSLSPGERATLSCRASQSVYYSYLAWYQQKPGQAPRLLIYGASNRATGIPDR FSGSGSGTDFTLTISRLEPEDFAVYYCQQYGNSPWTFGQGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:373)

[1372] REGN9279

[1373] Heavy chain variable region (HCVR, V H ) - Nucleotide sequence

[1374] GAAGTGCAGGTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGCAGGTCCCTGAGACTCTCCTGTACAGCCTCTGGATTCACCTTTGATGATTATGCCATGTTTTGGGTCCGGCAAGGTCCAGGGAAGGGCCTGGAGTGGGTCTCAGGTATTAGTTGGAATAGTGGTAGCATAGGCTATGCGGACTCTGT AAAGGGCCGCTTCACCACCTCCAGAGACAACGCCAAGAACTCCCTATATTTACAAATGAACAGTCTGAGAACTGAAGACACGGCCTTGTATTACTGTGCAAAAGATTATCGACCCCGTAGTGGGAACCACTATAACAACTACGGTATGGACGTCTGGGGCCCAGGGACCACGGTCACCGTCTCCTCA(SEQ ID NO:374)

[1375] Heavy chain variable region (HCVR, V H )-amino acid sequence

[1376] EVQVVESGGGLVQPGRSLRLSCTAS GFTFDDYA MFWVRQGPGKGLEWVSG ISWNSGSI GYADSVKGRFTTSRDNAKNSLYLQMNSLRTEDTALYYC AKDYRPRSGNHYNNYGMDV WGPGTTVTVSS (SEQ ID NO: 375)

[1377] CDR-H1-nucleotide sequence

[1378] GGA TTC ACC TTT GAT GAT TAT GCC(SEQ ID NO:376)

[1379] CDR-H1-amino acid sequence

[1380] GFTFDDYA (SEQ ID NO: 377)

[1381] CDR-H2-nucleotide sequence

[1382] ATT AGT TGG AAT AGT GGT AGC ATA(SEQ ID NO:378)

[1383] CDR-H2 - amino acid sequence

[1384] ISWNSGSI (SEQ ID NO: 379)

[1385] CDR-H3-nucleotide sequence

[1386] GCA AAA GAT TAT CGA CCC CGT AGT GGG AAC CAC TAT AAC AAC TAC GGT ATGGAC GTC (SEQ ID NO:380)

[1387] CDR-H3-amino acid sequence

[1388] AKDYRPRSGNHYNNYGMDV(SEQ ID NO:381)

[1389] Light chain variable region (LCVR, V L )-nucleotide sequence

[1390] GAGATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTTTTCGCGGCAACTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGACTCCTCATCTATGGTGCATCCAGCAG GGCCACTGGCATCCCAGACAGGTTCAGGGGGCAGTGGGTCTGGGACAGACTTCACGCTCACCATCAGCAGACTGGAGCCTGAGGATTTTGCAGTATATTACTGTCACCAGTATGGTAGGTCACCTTGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA(SEQ ID NO:382)

[1391] Light chain variable region (LCVR, V L )-amino acid sequence

[1392] EIVLTQSPGTLSLSPGERATLSCRAS QSFRGNY LAWYQQKPGQAPRLLIY GAS SRATGIPDRFRGSGSGTDFTLTISRLEPEDFAVYYC HQYGRSPWT FGQGTKVEIK (SEQ ID NO: 383)

[1393] CDR-L1-nucleotide sequence

[1394] CAG AGT TTT CGC GGC AAC TAC (SEQ ID NO:384)

[1395] CDR-L1-amino acid sequence

[1396] QSFRGNY (SEQ ID NO: 385)

[1397] CDR-L2-nucleotide sequence

[1398] GGT GCA TCC (SEQ ID NO: 386)

[1399] CDR-L2-amino acid sequence

[1400] GAS (SEQ ID NO: 387)

[1401] CDR-L3-nucleotide sequence

[1402] CAC CAG TAT GGT AGG TCA CCT TGG ACG (SEQ ID NO:388)

[1403] CDR-L3-amino acid sequence

[1404] HQYGRSPWT (SEQ ID NO: 389)

[1405] Heavy chain (HC)-nucleotide sequence

[1406]

[1407] Heavy chain - Amino acid sequence

[1408] LLQGSG EVQVVESGGGLVQPGRSLRLSCTASGFTFDDYAMFWVRQGPGKGLEWVSGISWNSGSIGYAD SVKGRFTTSRDNAKNSLYLQMNSLRTEDTALYYCAKDYRPRSGNHYNNYGMDVWGPGTTVTVSS ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK(SEQ ID NO:391)

[1409] Light chain (LC) - Nucleotide sequence

[1410] GAGATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTTTTCGCGGCAACTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGACTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGGGGCAGTGGGTCTGGGACAGACTTCACGCTCACCATCAGCAGACTGGAGCCTGAGGATTTTGCAGTATATTACTGTCACCAGTATGGTAGGTCACCTTGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG(SEQ ID NO:392)

[1411] Light chain (LC) - Amino acid sequence

[1412] EIVLTQSPGTLSLSPGERATLSCRASQSFRGNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFRGSGS GTDFTLTISRLEPEDFAVYYCHQYGRSPWTFGQGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQID NO:393)

[1413] REGN9280

[1414] Heavy chain variable region (HCVR, V H ) - Nucleotide sequence

[1415] GAAGTGCAGGTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGCAGGTCCCTGAGACTCTCCTGTACAGCCTCTGGATTCACCTTTGATGATTATGCCATGTTTTGGGTCCGGCAAGGTCCAGGGAAGGGCCTGGAGTGGGTCTCAGGTATTAGTTGGAATAGTGGTAGCATAGGCTATGCGGACTCTGT AAAGGGCCGCTTCACCACCTCCAGAGACAACGCCAAGAACTCCCTATATTTACAAATGAACAGTCTGAGAACTGAAGACACGGCCTTGTATTACTGTGCAAAAGATTATCGACCCCGTAGTGGGAACCACTATAACAACTACGGTATGGACGTCTGGGGCCCAGGGACCACGGTCACCGTCTCCTCA(SEQ ID NO:394)

[1416] Heavy chain variable region (HCVR, V H )-amino acid sequence

[1417] EVQVVESGGGLVQPGRSLRLSCTAS GFTFDDYA MFWVRQGPGKGLEWVSG ISWNSGSI GYADSVKGRFTTSRDNAKNSLYLQMNSLRTEDTALYYC AKDYRPRSGNHYNNYGMDV WGPGTTVTVSS (SEQ ID NO: 395)

[1418] CDR-H1-nucleotide sequence

[1419] GGA TTC ACC TTT GAT GAT TAT GCC (SEQ ID NO:396)

[1420] CDR-H1-amino acid sequence

[1421] GFTFDDYA (SEQ ID NO: 397)

[1422] CDR-H2-nucleotide sequence

[1423] ATT AGT TGG AAT AGT GGT AGC ATA(SEQ ID NO:398)

[1424] CDR-H2 - amino acid sequence

[1425] ISWNSGSI (SEQ ID NO: 399)

[1426] CDR-H3-nucleotide sequence

[1427] GCA AAA GAT TAT CGA CCC CGT AGT GGG AAC CAC TAT AAC AAC TAC GGT ATGGAC GTC(SEQ ID NO:400)

[1428] CDR-H3-amino acid sequence

[1429] AKDYRPRSGNHYNNYGMDV(SEQ ID NO:401)

[1430] Light chain variable region (LCVR, V L )-nucleotide sequence

[1431] GAGATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTTTTCGCGGCAACTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGACTCCTCATCTATGGTGCATCCAGCAG GGCCACTGGCATCCCAGACAGGTTCAGGGGGCAGTGGGTCTGGGACAGACTTCACGCTCACCATCAGCAGACTGGAGCCTGAGGATTTTGCAGTATATTACTGTCACCAGTATGGTAGGTCACCTTGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA(SEQ ID NO:402)

[1432] Light chain variable region (LCVR, V L )-amino acid sequence

[1433] EIVLTQSPGTLSLSPGERATLSCRAS QSFRGNY LAWYQQKPGQAPRLLIY GAS SRATGIPDRFRGSGSGTDFTLTISRLEPEDFAVYYC HQYGRSPWT FGQGTKVEIK (SEQ ID NO: 403)

[1434] CDR-L1-nucleotide sequence

[1435] CAG AGT TTT CGC GGC AAC TAC (SEQ ID NO:404)

[1436] CDR-L1-amino acid sequence

[1437] QSFRGNY (SEQ ID NO:405)

[1438] CDR-L2-nucleotide sequence

[1439] GGT GCA TCC (SEQ ID NO: 406)

[1440] CDR-L2-amino acid sequence

[1441] GAS (SEQ ID NO: 407)

[1442] CDR-L3-nucleotide sequence

[1443] CAC CAG TAT GGT AGG TCACCT TGG ACG (SEQ ID NO:408)

[1444] CDR-L3-amino acid sequence

[1445] HQYGRSPWT (SEQ ID NO: 409)

[1446] Heavy chain (HC)-nucleotide sequence

[1447]

[1448] Heavy chain - amino acid sequence

[1449] EVQVVESGGGLVQPGRSLRLSCTASGFTFDDYAMFWVRQGPGKGLEWVSGISWNSGSIGYADSVKGRF TTSRDNAKNSLYLQMNSLRTEDTALYYCAKDYRPRSGNHYNNYGMDVWGPGTTVTVSS ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK(SEQ ID NO:411)

[1450] Light chain (LC) - nucleotide sequence

[1451] TTACTTCAGGGATCTGGTGAGATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTTTTCGCGGCAACTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGACTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGGGGCAGTGGGTCTGGGACAGACTTCACGCTCACCATCAGCAGACTGGAGCCTGAGGATTTTGCAGTATATTACTGTCACCAGTATGGTAGGTCACCTTGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG(SEQ ID NO:412)

[1452] Light chain (LC) - Amino acid sequence

[1453] LLQGSG EIVLTQSPGTLSLSPGERATLSCRASQSFRGNYLAWYQQKPGQAPRLLIYGASSRATGIPDR FRGSGSGTDFTLTISRLEPEDFAVYYCHQYGRSPWTFGQGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:413)

[1454] In some embodiments, the heavy chains of the ATDCs disclosed herein may optionally lack a C-terminal lysine (K) or glycine-lysine (GK). The C-terminal lysine can facilitate transglutaminase-mediated cross-linking of an antibody to another antibody, thereby generating a high molecular weight species.

[1455] In embodiments of the invention, the ATDC of the invention (e.g., REGN7990; REGN9268; REGN15869; REGN18121; REGN18123; REGN8070; REGN8072; REGN9267; REGN7988; REGN5619; REGN7989; REGN8069; REGN8071; REGN9426; REGN5203; REGN5204; REGN5617; REGN5619; REGN7987; REGN9270; REGN9278; REGN9279 or REGN9280) is characterized by one or more of the following:

[1456] An anti-GLP1R antibody or antigen-binding fragment without a payload binds to GLP1R, but is not an agonist antibody or fragment;

[1457] Causing weight loss in obese mice expressing human GLP1R instead of mouse GLP1R administered (e.g., subcutaneously) ATDC (e.g., about 25 mg / kg or 100 mg / kg, e.g., twice weekly for 4 weeks), e.g., by about 3, 7, 14, 28, 38, or 42 days after the first administration; and / or

[1458] Obese mice expressing human GLP1R instead of mouse GLP1R that are administered (e.g., subcutaneously) ATDC (e.g., about 25 mg / kg or 100 mg / kg, e.g., twice a week for 4 weeks) cause weight loss, e.g., by about 3, 7, 14, 21, and 42 days after the first administration; in embodiments of the invention, no reduction occurs when about 25 mg / kg of ATDC is administered.

[1459] "REGN7990", "REGN9268", "REGN15869", "REGN18121", "REGN18123", "REGN8070", "REGN8072", "REGN9267", "REGN7988", "REGN5619", "REGN7989", "REGN8069", "REGN8071", "REGN9426", "REGN5203", "REGN5204", "REGN5617", "REGN5619", "REGN7987", "REGN9270", "REGN9278", "REGN9279" or "REGN9280" refers to an antigen binding protein, such as an antibody and antigen binding fragments thereof (including multispecific antigen binding proteins), that specifically binds to GLP1R, which comprises SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 1109, SEQ ID NO: 111 The immunoglobulin heavy chain (or its variable region) of NO: 42, 62, 82, 414, 416, 102, 122, 142, 162 or 182 (V H ), wherein the variable region is SEQ ID NO: 26, 46, 66, 86, 106, 126, 146 or 166 (or a variant thereof); and an immunoglobulin light chain (or its variable region) comprising SEQ ID NO: 44, 64, 84, 104, 124, 144, 164 or 184, respectively (V L ), wherein the variable region is SEQ ID NO: 34, 54, 74, 94, 114, 134, 154 or 174 (or a variant thereof); or it comprises a heavy chain or V chain comprising the corresponding CDRs (CDR-H1 (or a variant thereof), CDR-H2 (or a variant thereof) and CDR-H3 (or a variant thereof)). H and / or a light chain or V chain containing the corresponding CDRs (CDR-L1 (or its variant), CDR-L2 (or its variant) and CDR-L3 (or its variant)) L , for example, wherein the immunoglobulin chain, variable region and / or CDR comprises a specific amino acid sequence as described herein. In an embodiment of the invention, V H Linked to IgG constant heavy chain domain (e.g. IgG1 or IgG4) and / or V LLinked to a lambda or kappa constant light chain domain. "REGN7990"; "REGN9268"; "REGN15869"; "REGN18121"; "REGN18123"; "REGN8070"; "REGN8072"; "REGN9267"; "REGN7988"; "REGN5619"; "REGN7989"; "REGN8069"; "REGN8071"; "REGN9426"; "REGN5203"; "REGN5204"; "REGN5617"; "REGN5619"; "REGN7987"; "REGN9270"; "REGN9278"; "REGN9279" or "REGN9280" also include such antibodies or antigen-binding fragments having the immunoglobulins discussed herein but lacking the N-terminal sequence LLQGSG (SEQ ID NO: 18) on the light chain. "REGN7990"; "REGN9268"; "REGN15869"; "REGN18121"; "REGN18123"; "REGN8070"; "REGN8072"; REGN9267"; "REGN7988"; "REGN5619"; "REGN7989"; "REGN8069"; "REGN8071"; "REGN9426"; "REGN5 "REGN5204"; "REGN5617"; "REGN5619"; "REGN7987"; "REGN9270"; "REGN9278"; "REGN9279" or "REGN9280" also include antibody-tethered drug conjugates comprising an immunoglobulin discussed herein tethered, for example, via a linker to a drug payload such as a GLP1 peptide mimetic (e.g., LP11, LP30, or LP32)."REGN7990"; "REGN9268"; "REGN15869"; "REGN18121"; "REGN18123"; "REGN8070"; "REGN8072"; "REGN9267 "; "REGN7988"; "REGN5619"; "REGN7989"; "REGN8069"; "REGN8071"; "REGN9426"; "REGN5203"; "REGN5204"; "REGN5617"; "REGN5619"; "REGN7987"; "REGN9270"; "REGN9278"; "REGN9279" or "REGN9280" (which have a given payload or linker payload, such as LP11, LP30 or LP32) (e.g., ATDC) may be specifically named, for example, "REGN7990-LP30", "REGN9268-LP32" or "REGN15869-LP11".

[1460] In one aspect, the present disclosure provides antibodies and antigen-binding fragments that specifically bind to GLP1R conjugated to one or more GLP1 peptidomimetics via a non-cleavable linker.Illustrative, non-limiting examples of ATDCs of the present invention include Formula (I) or (A) described herein.

[1461] In some embodiments of the present invention, the non-cleavable linker in the ATDC of the present disclosure is stable after the ATDC is administered into the body (e.g., a human body). For example, the non-cleavable linker can be stable in plasma, such as in human plasma, stable when bound to a cell surface, or stable when an antibody binds to its target antigen and / or a GLP1 peptide mimetic binds to a GLP1R. In some embodiments, the non-cleavable linker is more stable in vivo than the payload or antibody under the same physiological conditions. In some embodiments of the present invention, the ATDC can be degraded in lysosomes to release the payload, linker-payload, and / or its ATDC metabolites / catabolites, which in certain embodiments are effective for local or systemic GLP1R activation.

[1462] In some embodiments, ATDC is stable in plasma and degraded in lysosomes. In some embodiments, ATDC is stable in plasma and does not degrade in lysosomes.

[1463] The present invention provides an ATDC comprising a structure of formula (A):

[1464] BA-(LP)m(A),

[1465] in:

[1466] BA is REGN7990; EGN8069; REGN8071; REGN9426; REGN5203; REGN5204; REGN5617; REGN5619; REGN7987;

[1467] L is a non-cleavable linker;

[1468] P is a payload having a structure selected from the group consisting of:

[1469]

[1470]

[1471] in is the attachment point where the payload is attached to L;

[1472] X1 is selected from H;

[1473] X2 is selected from

[1474] X3 is selected from a bond, -(CH2) 2-6 -NH-, -(CH2) 2-6 -Tr- and -(CH2) 2-6 -Tr-(CH2) 1-6 -NH, wherein Tr is a triazole moiety;

[1475] n is 0 or 1;

[1476] X4 is selected from -NH2, -OH and -N(H)(phenyl);

[1477] X5 is selected from -OH, -NH2, -NH-OH and

[1478] X6, at each occurrence, is independently selected from H, -OH, -CH3, and -CH2OH;

[1479] X7 is selected from H,

[1480]

[1481] X8 is selected from H, -OH, -NH2 and

[1482] Ar is selected from

[1483] X9 is selected from -NH2, and

[1484] m is an integer from 1 to 4;

[1485] or a pharmaceutically acceptable salt thereof.

[1486] In one embodiment, m is 1. In one embodiment, m is an integer from 2 to 4. In one embodiment, m is 2.

[1487] The present invention provides an ATDC comprising a structure of formula (I):

[1488] BA-LP(I),

[1489] in:

[1490] BA is REGN7990; EGN8069; REGN8071; REGN9426; REGN5203; REGN5204; REGN5617; REGN5619; REGN7987;

[1491] L is a non-cleavable linker;

[1492] P is a payload having a structure selected from the group consisting of:

[1493]

[1494] in is the attachment point where the payload is attached to L;

[1495] X1 is selected from H;

[1496] X2 is selected from

[1497] X3 is selected from -(CH2) 2-6 -NH- and -(CH2) 2-6 -Tr-, wherein Tr is a triazole moiety;

[1498] n is 0 or 1;

[1499] X4 is selected from H and phenyl;

[1500] X5 is selected from -OH, -NH2, -NH-OH and

[1501] X6, at each occurrence, is independently selected from H, -OH, -CH3, and -CH2OH;

[1502] X7 is selected from H,

[1503] X8 is selected from H, -OH, -NH2 and

[1504] or a pharmaceutically acceptable salt thereof.

[1505] In one embodiment of the invention, linker L is a non-cleavable linker, i.e., a stable linker, and provides a covalent linkage between the antibody or antigen-binding fragment (e.g., REGN7990; REGN9268; REGN15869; REGN18121; REGN18123; REGN8070; REGN8072; REGN9267; REGN7988; REGN5619; REGN7989; REGN8069; REGN8071; REGN9426; REGN5203; REGN5204; REGN5617; REGN5619; REGN7987; REGN9270; REGN9278; REGN9279 or REGN9280) and the drug, e.g., between an anti-GLP1R antibody or fragment according to the present disclosure and a GLP1 peptidomimetic payload P. In some embodiments of the present invention, the non-cleavable linker L of the present disclosure is stable after the ATDC is administered into the body (e.g., a human body). For example, the linker L can be stable in plasma, such as in human plasma, stable when bound to a cell surface, or stable when an antibody binds to its target antigen and / or a GLP1 peptide mimetic binds to a GLP1R. In some embodiments of the present invention, the linker L is more stable in vivo than the payload or antibody under the same physiological conditions.

[1506] In one embodiment, the linker L has the structure of formula (L'):

[1507] -La-Y-Lp-(L'),

[1508] wherein La is a first linker covalently attached to the antibody or antigen-binding fragment thereof;

[1509] Y is a group comprising a triazole, a Diels-Alder adduct, or a thiol-maleimide adduct, and

[1510] Lp is absent or is a second linker covalently attached to a payload P according to the present disclosure, wherein when Lp is absent, Y is also absent.

[1511] In one embodiment, Y is a triazole-containing group.

[1512] In another embodiment, Y is a group comprising a Diels-Alder adduct.

[1513] In one embodiment, the linker L has the structure of formula (L'):

[1514] -La-Y-Lp-(L'),

[1515] wherein La is a first linker covalently attached to the antibody or antigen-binding fragment thereof;

[1516] Y is a triazole-containing group, and

[1517] Lp is absent or is a second linker covalently attached to the payload P according to the present disclosure.

[1518] In one embodiment, La comprises C 1-6 Alkyl, phenyl, -NH-, -C(O)-, -(CH2) u -NH-C(O)-, -(CH2) u -C(O)-NH-, -(CH2-CH2-O) v -、-(CH2) u -(O-CH2-CH2) v -C(O)-NH-, a peptide unit comprising 2 to 4 amino acids, or a combination thereof, each of which can be optionally substituted by one or more of -S-, -S(O2)-, -C(O)-, -C(O2)- and CO2H, wherein the subscripts u and v are independently integers from 1 to 8.

[1519] In one embodiment, La is selected from the group consisting of:

[1520]

[1521] where R A is a group including alkynes, azides, tetrazines, trans-cyclooctene, maleimides, amines, ketones, aldehydes, carboxylic acids, esters, thiols, sulfonic acids, tosylates, halides, silanes, cyano groups, carbohydrate groups, biotin groups, lipid residues, and wherein the subscripts x, n, p, and q are independently integers from 0 to 12, and combinations thereof.

[1522] In one embodiment, -La- is selected from the group consisting of:

[1523]

[1524]

[1525] in is an amino group attachment point to a residue (e.g., a glutamine residue) of an antibody and / or antigen-containing fragment thereof. In one embodiment, -La- is In another embodiment, -La- is selected from the group consisting of:

[1526]

[1527]

[1528] in It is an amino group attachment point to a residue (e.g., a glutamine residue) of the antibody and / or antigen-containing fragment thereof.

[1529] In some embodiments of the present invention, La comprises a polyethylene glycol (PEG) segment having 1 to 36 -CH2CH2O-(EG) units. In some embodiments of the present invention, the PEG segment comprises 4 EG units, or 8 EG units, or 12 EG units, or 24 EG units. In some embodiments of the present invention, the PEG segment comprises 8 EG units. In some embodiments, La has a structure selected from the group consisting of

[1530]

[1531] In some embodiments of the present invention, La comprises one or more amino acids selected from glycine, threonine, serine, glutamine, glutamic acid, alanine, valine, leucine and proline and combinations thereof. In some embodiments of the present invention, La comprises 1 to 10 glycines and 1 to 6 serines. In some embodiments of the present invention, La comprises 4 glycines and 1 serine. In some embodiments of the present invention, La is selected from the group consisting of Gly-Gly-Gly-Gly-Ser (G4S) (SEQ ID NO: 1), Ser-Gly-Gly-Gly-Gly (SG4) (SEQ ID NO: 2), Gly-Gly-Ser-Gly-Gly-Ser-Gly-Gly (G2S-G2S-G2) and Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly (G4S-G4) (SEQ ID NO: 3).

[1532] In some embodiments of the invention, La comprises a PEG segment having 1 to 36 EG units and a combination of one or more amino acids selected from glycine, threonine, serine, glutamine, glutamic acid, alanine, valine, leucine and proline, and combinations thereof. In some embodiments of the invention, La is selected from the group consisting of:

[1533]

[1534]

[1535] In some embodiments, La comprises -(CH2) 2-24 -chain. In some embodiments of the present invention, La comprises -(CH2) 2-24 -chain, a PEG segment having 1 to 36 EG units and one or more amino acids selected from glycine, threonine, serine, glutamine, glutamic acid, alanine, valine, leucine and proline, and combinations thereof. La is selected from the group consisting of:

[1536] In one embodiment of the present invention, Y has a structure selected from the group consisting of:

[1537] Wherein Q is C or N.

[1538] In one embodiment of the present invention, the linker L or the first linker La or the second linker Lp comprises a polyethylene glycol (PEG) segment having 1 to 36 -CH2CH2O-(EG) units.

[1539] In one embodiment of the invention, the PEG segment comprises between 2 and 30 EG units or between 4 and 24 EG units. In one embodiment, the PEG segment comprises 2 EG units, or 4 EG units, or 6 EG units, or 8 EG units, or 10 EG units, or 12 EG units, or 14 EG units, or 16 EG units, or 18 EG units, or 20 EG units, or 22 EG units, or 24 EG units.

[1540] In one embodiment of the invention, the PEG segment comprises 4 EG units. In one embodiment, the PEG segment comprises 8 EG units. In one embodiment, the PEG segment comprises 12 EG units. In one embodiment, the PEG segment comprises 24 EG units.

[1541] In one embodiment of the invention, the PEG segment comprises 4 to 8 EG units. In one embodiment, the PEG segment comprises 4 EG units or 8 EG units.

[1542] In one embodiment of the invention, La comprises a PEG segment having 3 EG units.

[1543] In one embodiment of the invention, Lp comprises a PEG segment comprising 4 EG units. In one embodiment, Lp comprises a PEG segment comprising 8 EG units.

[1544] In one embodiment of the present invention, Y-Lp has a structure selected from the group consisting of:

[1545]

[1546] Wherein p is an integer from 1 to 36.

[1547] In one embodiment of the present invention, Y-Lp has a structure selected from the group consisting of:

[1548]

[1549] or a triazole positional isomer thereof,

[1550] Wherein p is an integer from 1 to 36.

[1551] In another embodiment of the present invention, the linker L or the first linker La or the second linker Lp comprises one or more amino acids selected from the group consisting of glycine, serine, glutamic acid, alanine, valine and proline, and combinations thereof.

[1552] In one embodiment of the present invention, the linker L or the first linker La or the second linker Lp comprises 1 to 10 glycines or 1 glycine or 2 glycines or 3 glycines or 4 glycines or 5 glycines or 6 glycines or 7 glycines or 8 glycines or 9 glycines or 10 glycines.

[1553] In one embodiment of the present invention, the linker L or the first linker La or the second linker Lp comprises 1 to 6 serines or 1 serine or 2 serines or 3 serines or 4 serines or 5 serines or 6 serines.

[1554] In one embodiment of the present invention, the linker L or the first linker La or the second linker Lp comprises 1 to 10 glycines and 1 to 6 serines.

[1555] In one embodiment of the present invention, the linker L or the first linker La or the second linker Lp comprises 4 glycines and 1 serine.

[1556] In one embodiment of the present invention, the linker L or the first linker La or the second linker Lp is selected from the group consisting of: Gly-Gly-Gly-Gly-Ser(G4S) (SEQ ID NO: 1), Ser-Gly-Gly-Gly-Gly(SG4) (SEQ ID NO: 2) and Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser(G4S-G4S) (SEQ ID NO: 3).

[1557] In some embodiments of the invention, one or more serine residues comprises a carbohydrate group, such as a glucose group.

[1558] In one embodiment of the present invention, the linker L or the first linker La or the second linker Lp comprises 1 to 10 glutamic acids and 1 to 10 glycines.

[1559] In some embodiments of the present invention, the linker L or the first linker La or the second linker Lp comprises a polyethylene glycol (PEG) segment having 1 to 36 -CH2CH2O-(EG) units and a combination of one or more amino acids selected from glycine, serine, glutamic acid, alanine, valine and proline, and combinations thereof.

[1560] In one embodiment of the present invention, the linker L or the first linker La or the second linker Lp comprises a combination of a PEG segment having 1 to 36 EG units and 1 to 10 glycines. In one embodiment of the present invention, the linker L or the first linker La or the second linker Lp comprises a PEG segment having 1 to 36 EG units and a combination of a group selected from the group consisting of Gly-Gly-Gly-Gly-Gly-Ser (G4S) (SEQ ID NO: 1), Ser-Gly-Gly-Gly-Gly (SG4) (SEQ ID NO: 2) and Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser (G4S-G4S) (SEQ ID NO: 3).

[1561] In one embodiment of the present invention, the linker L or the first linker La or the second linker Lp has a structure selected from the group consisting of:

[1562]

[1563] wherein Y is a triazole-containing group, for example, as shown above, and P is a payload, and wherein Rc is selected from hydrogen (H) and glucose, g is an integer from 1 to 10, and s is an integer from 0 to 4.

[1564] In one embodiment of the present invention, Y-Lp has a structure selected from the group consisting of:

[1565]

[1566]

[1567] In one embodiment of the invention, the linker L comprises a cyclodextrin moiety.

[1568] In some embodiments of the invention, the linker L is attached to the antibody or antigen-binding fragment thereof via a glutamine residue (e.g., REGN7990; REGN9268; REGN15869; REGN18121; REGN18123; REGN8070; REGN8072; REGN9267; REGN7988; REGN5619; REGN7989; REGN8069; REGN8071; REGN9426; REGN5203; REGN5204; REGN5617; REGN5619; REGN7987; REGN9270; REGN9278; REGN9279 or REGN9280). In some embodiments of the invention, the linker L is attached to the antibody or antigen-binding fragment thereof via a lysine residue. In some embodiments of the invention, the linker L is attached to the antibody or antigen-binding fragment thereof via a cysteine ​​residue.

[1569] In one aspect of the invention, the payload P according to the present disclosure has a structure of a formula selected from the group consisting of Formula (P-IB), Formula (P-IIB), and Formula (P-IIIB):

[1570]

[1571]

[1572] in:

[1573] X1 is selected from H;

[1574] X2 is selected from

[1575] X3 is selected from -CH3, -(CH2) 2-6 -NH2, -(CH2)2-6 -N3 and -(CH2) 2-6 -Tr-(CH2) 1-6 -NH2, wherein Tr is a triazole moiety;

[1576] n is 0 or 1;

[1577] X4 is selected from -NH2, -OH and -N(H)(phenyl);

[1578] X5 is selected from -OH, -NH2, -NH-OH and

[1579] X6, at each occurrence, is independently selected from H, -OH, -CH3, and -CH2OH;

[1580] X7 is selected from H,

[1581] X8 is selected from H, -OH, -NH2 and

[1582] Ar is selected from

[1583] X9 is selected from -NH2, and

[1584] m is an integer from 1 to 4;

[1585] or a pharmaceutically acceptable salt thereof.

[1586] In one embodiment of the present invention, the payload P according to the present disclosure has the structure of formula (II):

[1587]

[1588] in:

[1589] X1 is selected from H;

[1590] X2 is selected from

[1591] X3 is selected from -(CH2) 2-6 -NH2, -(CH2) 2-6 -N3 and -CH3, provided that when X3 is -CH3, n is 1, and Ra is selected from -(CH2) in at least one occurrence 2-6 -NH2 and -(CH2) 2-6 -N3;

[1592] n is 0 or 1;

[1593] m is an integer from 0 to 3;

[1594] Ra is independently selected at each occurrence from -CH3, -(CH2) 2-6 -NH2 and -(CH2) 2-6 -N3;

[1595] X4 is selected from H and phenyl;

[1596] X5 is selected from -OH, -NH2, -NH-OH and

[1597] X6, at each occurrence, is independently selected from H, -OH, -CH3, and -CH2OH;

[1598] X7 is selected from H,

[1599] X8 is selected from H, -OH, -NH2 and

[1600] and pharmaceutically acceptable salts thereof.

[1601] In one embodiment of the present invention, the payload P has a structure selected from the group consisting of:

[1602] in Indicates the attachment point to the connector.

[1603] In one embodiment of the present invention, the payload has the structure of Formula (PI) shown above, wherein

[1604] X1 is H; X2 is X3 is selected from -(CH2) 2-6 -NH- and -(CH2) 2-6 -Tr-, wherein Tr is a triazole moiety; n is 1, and X4 is H;

[1605] X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1; X4 is H, and X5 is selected from -OH, -NH2, -NH-OH and

[1606] X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1, and X4 is H;

[1607] X1 is X2 is X3 is -(CH2) 2-6-NH-; n is 1; X4 is H; X6 at each occurrence is independently selected from H and -CH2OH, and X7 is H;

[1608] X1 is X2 is X3 is -(CH2) 2-6 -Tr-, wherein Tr is a triazole moiety; n is 1; X4 is H, and X5 is

[1609] X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1; X4 is H; X6 is independently selected at each occurrence from H and -CH3; X7 is and X8 is -NH2;

[1610] X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1; X4 is H, and X8 is H;

[1611] X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1; X4 is H; X6 is H at every occurrence; X7 is and X8 is H;

[1612] X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1; X4 is H; X6 is independently selected at each occurrence from H and -CH3; X7 is And X8 is

[1613] X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1, and X4 is H;

[1614] X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1, and X4 is H;

[1615] X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1; X4 is H; X6 is independently selected at each occurrence from H and -CH3, and X7 is

[1616] X1 is H; X2 is X3 is -(CH2) 2-6 -NH-; n is 1, and X4 is H;

[1617] X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1; X4 is H, and X5 is

[1618] X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 0; X4 is phenyl, and X5 is and

[1619] X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1; X4 is phenyl, and X5 is

[1620] In one embodiment, the payload has the structure of Formula (P-II) as shown above, wherein X1 is X2 is X3 is -(CH2) 2-6 -NH-; X4 is H, and X5 is

[1621] In one embodiment of the present invention, the payload P according to the present disclosure has a structure selected from the group consisting of:

[1622]

[1623]

[1624]

[1625]

[1626]

[1627]

[1628]

[1629] In one embodiment of the present invention, the payload as described above has the following characteristics:

[1630]

[1631]

[1632]

[1633] In some embodiments of the invention, the payloads of the present disclosure are suitable for conjugation to a binding agent (e.g., an antibody or antigen-binding fragment thereof, e.g., REGN7990; REGN9268; REGN15869; REGN18121; REGN18123; REGN8070; REGN8072; REGN9267; REGN7988; REGN5619; REGN7989; REGN8069; REGN8071; REGN9426; REGN5203; REGN5204; REGN5617; REGN5619; REGN7987; REGN9270; REGN9278; REGN9279 or REGN9280).

[1634] In one embodiment of the invention, the disclosure provides a reactive linker-payload (LP) comprising a payload P as described above and a linker capable of covalent attachment to an antibody or antigen-binding fragment thereof (e.g., REGN7990; REGN9268; REGN15869; REGN18121; REGN18123; REGN8070; REGN8072; REGN9267; REGN7988; REGN5619; REGN7989; REGN8069; REGN8071; REGN9426; REGN5203; REGN5204; REGN5617; REGN5619; REGN7987; REGN9270; REGN9278; REGN9279 or REGN9280).

[1635] In one embodiment of the present invention, the linker-payload according to the present disclosure has the structure of formula (C):

[1636]

[1637] in:

[1638] L p The linker is absent or includes one or more of the following: Carbamate group; cyclodextrin; polyethylene glycol (PEG) segment having 1 to 36 -CH2CH2O-(EG) units; -(CH2) 2-24-chain; triazole; one or more amino acids selected from glycine, serine, glutamic acid, alanine, valine and proline and combinations thereof;

[1639] Q is selected from -NH2, -N3, wherein A is C or N;

[1640] X1 is selected from H;

[1641] X2 is selected from

[1642] X3 is selected from -CH3, -(CH2) 2-6 -NH2, -(CH2) 2-6 -N3 and -(CH2) 2-6 -Tr-(CH2) 1-6 -NH2, wherein Tr is a triazole moiety;

[1643] n is 0 or 1;

[1644] X4 is selected from -NH2, -OH and -N(H)(phenyl);

[1645] X5 is selected from -OH, -NH2, -NH-OH and

[1646] X6, at each occurrence, is independently selected from H, -OH, -CH3, and -CH2OH;

[1647] X7 is selected from H,

[1648] X8 is selected from H, -OH, -NH2 and

[1649] Ar is selected from

[1650] X9 is selected from -NH2, and

[1651] m is an integer from 1 to 4;

[1652] or a pharmaceutically acceptable salt thereof.

[1653] In one embodiment, a linker-payload according to the present disclosure has the structure of formula (III):

[1654]

[1655] in:

[1656] Lp is absent or includes one or more of the following linkers: a carbamate group; a cyclodextrin; a polyethylene glycol (PEG) segment having 1 to 36 -CH2CH2O-(EG) units; one or more amino acids selected from glycine, serine, glutamic acid, alanine, valine, and proline, and combinations thereof;

[1657] Q is selected from -N3, wherein A is C or N;

[1658] X1 is selected from H;

[1659] X2 is selected from

[1660] X3 is selected from -(CH2) 2-6 -NH2, -(CH2) 2-6 -N3 and -CH3, provided that when X3 is -CH3, n is 1, and Ra is selected from -(CH2) in at least one occurrence 2-6 -NH2 and -(CH2) 2-6 -N3;

[1661] n is 0 or 1;

[1662] Ra is independently selected at each occurrence from H, -CH3, -(CH2) 2-6 -NH2 and -(CH2) 2-6 -N3;

[1663] X4 is selected from H and phenyl;

[1664] X5 is selected from -OH, -NH2, -NH-OH and

[1665] X6, at each occurrence, is independently selected from H, -OH, -CH3, and -CH2OH;

[1666] X7 is selected from H,

[1667] X8 is selected from H, -OH, -NH2 and

[1668] and pharmaceutically acceptable salts thereof.

[1669] In one embodiment of the invention, the linker-payload LP comprises a cyclodextrin moiety. In some embodiments of the invention, the linker-payload LP comprising a cyclodextrin moiety exhibits GLP1R agonistic activity.

[1670] In one embodiment of the present invention, the linker-payload LP according to the present disclosure has a structure selected from the group consisting of:

[1671]

[1672]

[1673]

[1674]

[1675]

[1676]

[1677]

[1678]

[1679]

[1680]

[1681]

[1682] In one embodiment of the invention, the linker-payload as described above has the following properties:

[1683]

[1684]

[1685]

[1686] In the present disclosure, an antibody can be any antibody deemed suitable by a practitioner in the art. In some embodiments of the present invention, a linker or linker-payload is attached to one or both heavy chains of an antibody or antigen-binding fragment thereof. In some embodiments, a linker or linker-payload is attached to one or both heavy chain variable domains of an antibody or antigen-binding fragment thereof.

[1687] In an embodiment of the present invention, the linker or linker-payload is attached to the N-terminus of one or two heavy chain variable domains of an antibody or antigen-binding fragment thereof; the N-terminus of two heavy chain variable domains of an antibody or antigen-binding fragment thereof; one or two light chains of an antibody or antigen-binding fragment thereof; one or two light chain variable domains of an antibody or antigen-binding fragment thereof; the N-terminus of one or two light chain variable domains of an antibody or antigen-binding fragment thereof; the N-terminus of two light chain variable domains of an antibody or antigen-binding fragment thereof; the C-terminus of one or two heavy chain variable domains of an antibody or antigen-binding fragment thereof; the C-terminus of two heavy chain variable domains of an antibody or antigen-binding fragment thereof; the C-terminus of one or two light chain variable domains of an antibody or antigen-binding fragment thereof; and / or the C-terminus of two light chain variable domains of an antibody or antigen-binding fragment thereof.

[1688] In embodiments of the present invention, the antibody or antigen-binding fragment comprises at least one glutamine residue in at least one polypeptide chain sequence. In embodiments of the present invention, the antibody or antigen-binding fragment comprises one or more Gln295 residues. Generally, the Gln295 residue is conserved in the heavy chain and in the context of EEQYNS or EEQFNS. See Mindt et al., Modification of different IgG1 antibodies via glutamine and lysine using bacterial and human tissue transglutaminase. Bioconjug Chem 2008;19:271-8; and Jeger et al., Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase, Angew Chem Int Ed Engl 2010;49:9995-7. However, the "Gln295" discussed herein may not be the 295th residue in the heavy chain. See, for example, SEQ ID NO:42 herein. In embodiments of the present invention, the antibody or antigen-binding fragment comprises two heavy chain polypeptides, each having a Gln295 residue. In embodiments of the present invention, the antibody or antigen-binding fragment comprises one or more glutamine residues at sites other than Gln295 of the heavy chain. Such antibodies and antigen-binding fragments can be isolated from natural sources or engineered to comprise one or more glutamine residues. Techniques for engineering glutamine residues into antibody or antigen-binding fragment polypeptide chains are within the skill of practitioners in the art. In embodiments of the present invention, the glutamine residue is introduced at the N-terminus of the antibody or antigen-binding fragment polypeptide chain. In embodiments of the present invention, the glutamine residue is introduced at the N-terminus of one or both heavy chains of the antibody or antigen-binding fragment. In embodiments of the present invention, the glutamine residue is introduced at the N-terminus of both heavy chains of the antibody or antigen-binding fragment. In embodiments of the present invention, the glutamine residue is introduced at the N-terminus of one or both light chains of the antibody or antigen-binding fragment. In embodiments of the present invention, the glutamine residue is introduced at the N-terminus of both light chains of the antibody or antigen-binding fragment. In an embodiment of the invention, a glutamine residue is introduced at the N-terminus of one or both heavy chains and one or both light chains of the antibody or antigen-binding fragment. In an embodiment of the invention, Gln295 (Q295) is in the context of an EEQFNS (amino acids 292-297 of SEQ ID NO: 42) motif.

[1689] In an embodiment of the present invention, a glutamine residue is introduced into the C-terminus of an antibody or antigen-binding fragment polypeptide chain. In an embodiment of the present invention, a glutamine residue is introduced into the C-terminus of one or both heavy chains of an antibody or antigen-binding fragment. In an embodiment of the present invention, a glutamine residue is introduced into the C-terminus of both heavy chains of an antibody or antigen-binding fragment. In an embodiment of the present invention, a glutamine residue is introduced into the C-terminus of one or both light chains of an antibody or antigen-binding fragment. In an embodiment of the present invention, a glutamine residue is introduced into the C-terminus of both light chains of an antibody or antigen-binding fragment. In an embodiment of the present invention, a glutamine residue is introduced into the C-terminus of one or both heavy chains and one or both light chains of an antibody or antigen-binding fragment.

[1690] Examples of anti-GLP1R antibodi...

Claims

1. An antibody-tethered drug conjugate (ATDC) having a structure of formula (A): BA-(LP)m(A), in: BA is an antibody or an antigen-binding fragment thereof that specifically binds to GLP1R, wherein the antibody or an antigen-binding fragment thereof that specifically binds to GLP1R: (i) comprising a heavy chain immunoglobulin or a variable region thereof, said heavy chain immunoglobulin or a variable region thereof comprising a CDR-H1, CDR-H2 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO:26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411; or a variant thereof; and / or A light chain immunoglobulin or a variable region thereof, comprising a CDR-L1, CDR-L2 and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373;393 or 413; or a variant thereof; (ii) is an antibody or antigen-binding fragment thereof that competes with the antibody or fragment of (i) for binding to GLP1R; and / or (iii) an antibody or antigen-binding fragment thereof that binds to the same epitope of GLP1R as the antibody or fragment of (i); L is a non-cleavable linker; Optionally, wherein the heavy chain immunoglobulin of the BA does not comprise a C-terminal lysine or a lysine and a glycine; Optionally, wherein said light chain immunoglobulin and / or heavy chain immunoglobulin of BA comprises an N-terminal Q tag conjugated to said non-cleavable linker; P is a payload having a structure selected from the group consisting of: in is the attachment point where the payload is attached to L; X1 is selected from H; X2 is selected from X3 is selected from a bond, -(CH2) 2-6 -NH-, -(CH2) 2-6 -Tr- and -(CH2) 2-6 -Tr-(CH2) 1-6 –NH, where Tr is a triazole moiety; n is 0 or 1; X4 is selected from -NH2, -OH and -N(H)(phenyl); X5 is selected from -OH, -NH2, -NH-OH and X6, at each occurrence, is independently selected from H, -OH, -CH3, and -CH2OH; X7 is selected from H, X8 is selected from H, -OH, -NH2 and Ar is selected from X9 is selected from -NH2, and m is an integer from 1 to 4; or a pharmaceutically acceptable salt thereof.

2. An antibody-tethered drug conjugate having the structure of formula (I): BA-LP(I), in: BA is an antibody or an antigen-binding fragment thereof that specifically binds to GLP1R, wherein the antibody or an antigen-binding fragment thereof that specifically binds to GLP1R: (i) comprising a heavy chain immunoglobulin or a variable region thereof, said heavy chain immunoglobulin or a variable region thereof comprising a CDR-H1, CDR-H2 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO:26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411; or a variant thereof; and / or A light chain immunoglobulin or a variable region thereof, comprising a CDR-L1, CDR-L2 and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373;393 or 413; or a variant thereof; (ii) is an antibody or antigen-binding fragment thereof that competes with the antibody or fragment of (i) for binding to GLP1R; (iii) an antibody or antigen-binding fragment thereof that binds to the same epitope of GLP1R as the antibody or fragment of (i); L is a non-cleavable linker; Optionally, wherein the heavy chain immunoglobulin of the BA does not comprise a C-terminal lysine or a lysine and a glycine; Optionally, wherein said light chain immunoglobulin and / or heavy chain immunoglobulin of BA comprises an N-terminal Q tag conjugated to said non-cleavable linker; P is a payload having a structure selected from the group consisting of: in is the attachment point where the payload is attached to L; X1 is selected from H; X2 is selected from X3 is selected from -(CH2) 2-6 -NH- and -(CH2) 2-6 -Tr-, wherein Tr is a triazole moiety; n is 0 or 1; X4 is selected from H and phenyl; X5 is selected from -OH, -NH2, -NH-OH and X6, at each occurrence, is independently selected from H, -OH, -CH3, and -CH2OH; X7 is selected from H, X8 is selected from H, -OH, -NH2 and Optionally, wherein the light chain immunoglobulin comprises an N-terminal Q tag, or a pharmaceutically acceptable salt thereof.

3. An antibody-tethered drug conjugate comprising an antibody or an antigen-binding fragment thereof targeting glucagon-like peptide-1 receptor (GLP1R), wherein: (i) comprising a heavy chain immunoglobulin or a variable region thereof, said heavy chain immunoglobulin or a variable region thereof comprising a CDR-H1, CDR-H2 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO:26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411; or a variant thereof; and / or A light chain immunoglobulin or a variable region thereof, comprising a CDR-L1, CDR-L2 and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373;393 or 413; or a variant thereof; (ii) is an antibody or antigen-binding fragment thereof that competes with the antibody or fragment of (i) for binding to GLP1R; or (iii) an antibody or antigen-binding fragment thereof that binds to the same epitope of GLP1R as the antibody or fragment of (i); Optionally, wherein the heavy chain immunoglobulin does not comprise a C-terminal lysine or a lysine and a glycine; Optionally, the N-terminus of the light chain immunoglobulin and / or heavy chain immunoglobulin of the antibody or fragment comprises a Q tag; Optionally, wherein the antibody or fragment is conjugated to a payload having a structure selected from the group consisting of: or a pharmaceutically acceptable salt thereof.

4. An antibody-tethered drug conjugate comprising an antibody or an antigen-binding fragment thereof targeting glucagon-like peptide-1 receptor (GLP1R) and a payload, wherein the antibody or the antigen-binding fragment thereof: (i) comprising a heavy chain immunoglobulin or a variable region thereof, wherein the heavy chain immunoglobulin or a variable region thereof comprises CDR-H1, CDR-H2 and CDR-H3 of a heavy chain immunoglobulin or a variable region thereof comprising: SEQ ID NO:26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411; or a variant thereof; and / or a light chain immunoglobulin or its variable region, the light chain immunoglobulin or its variable region comprising the following light chain immunoglobulin or its variable region CDR-L1, CDR-L2 and CDR-L3: SEQ ID NO: NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373; the amino acid sequence listed in 393 or 413; or a variant thereof; (ii) is an antibody or antigen-binding fragment thereof that competes with the antibody or fragment of (i) for binding to GLP1R; or (iii) an antibody or antigen-binding fragment thereof that binds to the same epitope of GLP1R as the antibody or fragment of (i); Optionally, wherein the heavy chain immunoglobulin does not comprise a C-terminal lysine or a lysine and a glycine; The payload has the following structure: in is the point of attachment where the payload is attached to the antibody or antigen-binding fragment thereof directly or through a linker.

5. The antibody-tethered drug conjugate of claim 4, wherein the payload has the following structure:

6. An antibody-tethered drug conjugate comprising an antibody or an antigen-binding fragment thereof targeting glucagon-like peptide-1 receptor (GLP1R) and a linker-payload, wherein the antibody or the antigen-binding fragment thereof: (i) comprising a heavy chain immunoglobulin or a variable region thereof, wherein the heavy chain immunoglobulin or a variable region thereof comprises CDR-H1, CDR-H2 and CDR-H3 of a heavy chain immunoglobulin or a variable region thereof comprising: SEQ ID NO:26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411; or a variant thereof; and / or a light chain immunoglobulin or its variable region, the light chain immunoglobulin or its variable region comprising the following light chain immunoglobulin or its variable region CDR-L1, CDR-L2 and CDR-L3: SEQ ID NO: NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373; the amino acid sequence listed in 393 or 413; or a variant thereof; (ii) is an antibody or antigen-binding fragment thereof that competes with the antibody or fragment of (i) for binding to GLP1R; or (iii) an antibody or antigen-binding fragment thereof that binds to the same epitope of GLP1R as the antibody or fragment of (i); Optionally, wherein the heavy chain immunoglobulin does not comprise a C-terminal lysine or a lysine and a glycine; The linker-payload has the following structure: in is the attachment point of the linker-payload to the Q tag of the antibody or antigen-binding fragment thereof; wherein the attachment of the linker-payload to the Q tag is an amination product.

7. The antibody-tethered drug conjugate of claim 6, wherein the linker-payload has the following structure:

8. An antibody-tethered drug conjugate comprising an antibody or an antigen-binding fragment thereof targeting glucagon-like peptide-1 receptor (GLP1R), wherein the antibody or the antigen-binding fragment thereof comprises: (a) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:42, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:44; (b) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:62, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:64; (c) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:82, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:84; (d) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 102, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 104; (e) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 122, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 124; (f) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 142, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 144; (g) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 162, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 164; and / or (h) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 182, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 184; (i) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 203, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 205; (j) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 223, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 225; (k) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 243, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 245; (1) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 263, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 265; (m) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 267, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 269; (n) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 271, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 273; (o) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 291, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 293; (p) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:311, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:313; (q) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 331, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 333; (r) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:351, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:353; (s) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 371, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 373; (t) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 391, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 393; (u) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:411, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:413; (v) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:414, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:84; or (w) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:416, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:84; Optionally, wherein the heavy chain immunoglobulin does not comprise a C-terminal lysine or a lysine and a glycine; wherein the structure of the linker-payload conjugated to amino acid 3 (Gln) of SEQ ID NO: 44, 64, 84, 104, 124, 144, 164, 184, 205, 225, 245, 265, 269, 273, 293, 313, 333, 353, 373, 393 or 413 is represented by: in The attachment point is amino acids 1-6 (LLQGSG) of SEQ ID NO: 44, 64, 84, 104, 124, 144, 164, 184, 205, 225, 245, 265, 269, 273, 293, 313, 333, 353, 373, 393 or 413 attached to amino acid 7.

9. An antibody-tethered drug conjugate comprising an antibody or an antigen-binding fragment thereof targeting glucagon-like peptide-1 receptor (GLP1R), wherein the antibody or the antigen-binding fragment thereof comprises: (a) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:42, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:44; (b) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:62, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:64; (c) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:82, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:84; (d) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 102, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 104; (e) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 122, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 124; (f) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 142, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 144; (g) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 162, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 164; and / or (h) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 182, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 184; (i) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 203, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 205; (j) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 223, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 225; (k) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 243, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 245; (1) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 263, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 265; (m) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 267, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 269; (n) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 271, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 273; (o) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 291, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 293; (p) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:311, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:313; (q) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 331, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 333; (r) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:351, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:353; (s) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 371, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 373; (t) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 391, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 393; (u) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:411, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:413; (v) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:414, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:84; or (w) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:416, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:84; wherein the structure of the linker-payload conjugated to amino acid 3 (Gln) of SEQ ID NOS: 44, 64, 84, 104, 124, 144, 164, 184, 205, 225, 245, 265, 269, 273, 293, 313, 333, 353, 373, 393 or 413 is represented by:

10. An isolated antibody or antigen-binding fragment thereof that specifically binds to GLP1R, wherein: (i) comprising a heavy chain immunoglobulin or a variable region thereof, said heavy chain immunoglobulin or a variable region thereof comprising a CDR-H1, CDR-H2 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO:26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411; or a variant thereof; and / or a light chain immunoglobulin or a variable region thereof, the light chain immunoglobulin or its variable region comprising a CDR-L1, CDR-L2 and CDR-L3 comprising a light chain immunoglobulin or its variable region comprising the amino acid sequence set forth in SEQ ID NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373;393 or 413; or a variant thereof, optionally wherein the light chain immunoglobulin lacks the N-terminal residues LLQGSG (SEQ ID NO:18); (ii) is an antibody or antigen-binding fragment thereof that competes with the antibody or fragment of (i) for binding to GLP1R; (iii) an antibody or antigen-binding fragment thereof that binds to the same epitope of GLP1R as the antibody or fragment of (i); Optionally, wherein the heavy chain immunoglobulin does not comprise a C-terminal lysine or a lysine and a glycine; and Optionally, wherein the antibody or antigen-binding fragment is conjugated to a payload or linker-payload.

11. The antibody-tethered drug conjugate of any one of claims 1-9, wherein the linker L is attached to one or both heavy chains of the BA.

12. The antibody-tethered drug conjugate of any one of claims 1-9, wherein the linker L is attached to one or both heavy chain variable domains of the BA.

13. The antibody-tethered drug conjugate of any one of claims 1-9, wherein the linker L is attached to one or both light chains of the BA.

14. The antibody-tethered drug conjugate of any one of claims 1-9, wherein the linker L is attached to one or two light chain variable domains of the BA.

15. The antibody-tethered drug conjugate according to any one of claims 1-9 and 11-14, wherein the linker L is attached to BA via a glutamine residue.

16. The antibody-tethered drug conjugate according to claim 15, wherein the glutamine residue is introduced into the N-terminus of one or both heavy chains of the BA.

17. The antibody-tethered drug conjugate according to any one of claims 15-16, wherein the glutamine residue is introduced to the N-terminus of one or both light chains of the BA.

18. The antibody-tethered drug conjugate of claim 15, wherein the glutamine residue naturally occurs in the CH2 domain or the CH3 domain of the BA.

19. The antibody-tethered drug conjugate according to any one of claims 15 to 17, wherein the glutamine residue is introduced into the BA by modifying one or more amino acids.

20. The antibody-tethered drug conjugate according to any one of claims 15-19, wherein the glutamine residue is Q295 or is mutated from N297 to Q297 (N297Q).

21. The antibody-tethered drug conjugate according to any one of claims 1-9 and 11-14, wherein the linker L is attached to BA via a lysine residue.

22. The antibody-tethered drug conjugate of any one of claims 1-9 and 11-21, wherein the antibody or antigen-binding fragment thereof is non-glycosylated.

23. The antibody-tethered drug conjugate of any one of claims 1-9 and 11-21, wherein the antibody or antigen-binding fragment thereof is deglycosylated.

24. The antibody-tethered drug conjugate of any one of claims 1-9 and 11-23, wherein the antigen binding fragment is a Fab fragment.

25. The antibody-tethered drug conjugate of claim 1, wherein m is 1.

26. The antibody-tethered drug conjugate of claim 1, wherein m is an integer from 2 to 4.

27. The antibody-tethered drug conjugate of claim 1, wherein m is 2.

28. The antibody-tethered drug conjugate according to any one of claims 1-9 and 11-27, wherein the linker L has a structure of formula (L'): -La-Y-Lp-(L'), wherein La is a first linker covalently attached to said BA; Y is a triazole-containing group, and Lp is absent or is covalently attached to a second linker of said P, wherein when Lp is absent, Y is also absent.

29. The antibody-tethered drug conjugate of claim 28, wherein Y-Lp is absent.

30. The antibody-tethered drug conjugate of claim 28, wherein Y has a structure selected from the group consisting of: Wherein Q is C or N.

31. The antibody-tethered drug conjugate of any one of claims 28-30, wherein Lp comprises a polyethylene glycol (PEG) segment having 1 to 36 -CH2CH2O-(EG) units.

32. The antibody-tethered drug conjugate of claim 31, wherein the PEG segment comprises between 2 and 30 EG units.

33. The antibody-tethered drug conjugate of any one of claims 31-32, wherein the PEG segment comprises between 4 and 24 EG units.

34. The antibody-tethered drug conjugate of any one of claims 31-32, wherein the PEG segment comprises 4 EG units, or 8 EG units, or 12 EG units, or 24 EG units.

35. The antibody-tethered drug conjugate of any one of claims 31-34, wherein the PEG segment comprises 4 EG units.

36. The antibody-tethered drug conjugate of any one of claims 31-34, wherein the PEG segment comprises 8 EG units.

37. The antibody-tethered drug conjugate of claim 28, wherein Y-Lp has a structure selected from the group consisting of: or a triazole positional isomer thereof, Wherein p is an integer from 1 to 36.

38. The antibody-tethered drug conjugate of any one of claims 28-37, wherein the Lp comprises one or more amino acids selected from glycine, serine, glutamic acid, alanine, valine and proline, and combinations thereof.

39. The antibody-tethered drug conjugate of claim 38, wherein the Lp comprises 1 to 10 glycines.

40. The antibody-tethered drug conjugate of claim 38, wherein the Lp comprises 1 to 6 serines.

41. The antibody-tethered drug conjugate of claim 38, wherein the Lp comprises 1 to 10 glycines and 1 to 6 serines.

42. The antibody-tethered drug conjugate of any one of claims 38-41, wherein the Lp comprises 4 glycines and 1 serine.

43. The antibody-tethered drug conjugate of any one of claims 38-42, wherein the Lp is selected from the group consisting of Gly-Gly-Gly-Gly-Gly-Ser(G4S) (SEQ ID NO: 1), Ser-Gly-Gly-Gly-Gly-Gly(SG4) (SEQ ID NO: 2), and Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser(G4S-G4S) (SEQ ID NO: 3).

44. The antibody-tethered drug conjugate of any one of claims 28-43, wherein the Lp comprises a PEG segment having 1 to 36 EG units and a combination of one or more amino acids selected from glycine, serine, glutamic acid, alanine, valine and proline, and combinations thereof.

45. The antibody-tethered drug conjugate of any one of claims 38 and 40-44, wherein the serine residue comprises a carbohydrate group.

46. ​​The antibody-tethered drug conjugate of any one of claims 38 and 40-45, wherein the serine residue comprises a glucose group.

47. The antibody-tethered drug conjugate of any one of claims 28-46, wherein Lp has a structure selected from the group consisting of: wherein Y is a triazole-containing group, and P is a payload, and wherein Rc is selected from H and glucose, g is an integer from 1 to 10, and s is an integer from 0 to 4.

48. The antibody-tethered drug conjugate of any one of claims 28-47, wherein Y-Lp has a structure selected from the group consisting of: or a triazole positional isomer thereof.

49. The antibody-tethered drug conjugate of any one of claims 28-48, wherein La comprises a polyethylene glycol (PEG) segment having 1 to 36 -CH2CH2O-(EG) units.

50. The antibody-tethered drug conjugate of claim 48, wherein the PEG segment comprises 4 EG units, or 8 EG units, or 12 EG units, or 24 EG units.

51. The antibody-tethered drug conjugate of claim 50, wherein the PEG segment comprises 8 EG units.

52. The antibody-tethered drug conjugate of any one of claims 28-51, wherein La has a structure selected from the group consisting of:

53. The antibody-tethered drug conjugate of any one of claims 28-50, wherein La comprises one or more amino acids selected from glycine, threonine, serine, glutamine, glutamic acid, alanine, valine, leucine and proline, and combinations thereof.

54. The antibody-tethered drug conjugate of claim 53, wherein the La comprises 1 to 10 glycines and 1 to 6 serines.

55. The antibody-tethered drug conjugate of any one of claims 53-54, wherein the La comprises 4 glycines and 1 serine.

56. The antibody-tethered drug conjugate of any one of claims 53-55, wherein the La is selected from the group consisting of Gly-Gly-Gly-Gly-Ser(G4S) (SEQ ID NO: 1), Ser-Gly-Gly-Gly-Gly(SG4) (SEQ ID NO: 2), Gly-Gly-Ser-Gly-Gly-Ser-Gly-Gly(G2S-G2S-G2), and Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly(G4S-G4) (SEQ ID NO: 3).

57. The antibody-tethered drug conjugate of any one of claims 53-56, wherein La comprises a PEG segment having 1 to 36 EG units and a combination of one or more amino acids selected from glycine, threonine, serine, glutamine, glutamic acid, alanine, valine, leucine and proline, and combinations thereof.

58. The antibody-tethered drug conjugate according to any one of claims 53-57, wherein said La is selected from the group consisting of:

59. The antibody-tethered drug conjugate of any one of claims 28-58, wherein La comprises -(CH2) 2-24 -chain.

60. The antibody-tethered drug conjugate of claim 59, wherein La comprises -(CH2) 2-24 A combination of a -chain, a PEG segment having 1 to 36 EG units, and one or more amino acids selected from the group consisting of glycine, threonine, serine, glutamine, glutamic acid, alanine, valine, leucine and proline, and combinations thereof.

61. The antibody-tethered drug conjugate of claim 60, wherein said La is selected from the group consisting of:

62. The antibody-tethered drug conjugate of any one of claims 1-9 and 11-61, wherein P has the structure 63. The antibody-tethered drug conjugate of any one of claims 1-9 and 11-62, wherein X1 is H; X2 is X3 is selected from -(CH2) 2-6 -NH- and -(CH2) 2-6 -Tr-, wherein Tr is a triazole moiety; n is 1, and X4 is H.

64. The antibody-tethered drug conjugate of any one of claims 1-9 and 11-62, wherein X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1; X4 is H, and X5 is selected from -OH, -NH2, -NH-OH and 65. The antibody-tethered drug conjugate of any one of claims 1-9 and 11-62, wherein X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1, and X4 is H.

66. The antibody-tethered drug conjugate of any one of claims 1-9 and 11-62, wherein X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1; X4 is H; X6 at each occurrence is independently selected from H and -CH2OH, and X7 is H.

67. The antibody-tethered drug conjugate of any one of claims 1-9 and 11-62, wherein X1 is X2 is X3 is -(CH2) 2-6 -Tr-, wherein Tr is a triazole moiety; n is 1; X4 is H, and X5 is 68. The antibody-tethered drug conjugate of any one of claims 1-9 and 11-62, wherein X1 is X2 is X3 is -(CH2) 2-6-NH-; n is 1; X4 is H; X6 is independently selected at each occurrence from H and -CH3; X7 is And X8 is -NH2.

69. The antibody-tethered drug conjugate of any one of claims 1-9 and 11-62, wherein X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1; X4 is H, and X8 is H.

70. The antibody-tethered drug conjugate of any one of claims 1-9 and 11-62, wherein X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1; X4 is H; X6 is H at each occurrence; X7 is And X8 is H.

71. The antibody-tethered drug conjugate of any one of claims 1-9 and 11-62, wherein X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1; X4 is H; X6 is independently selected at each occurrence from H and -CH3; X7 is And X8 is 72. The antibody-tethered drug conjugate of any one of claims 1-9 and 11-62, wherein X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1, and X4 is H.

73. The antibody-tethered drug conjugate of any one of claims 1-9 and 11-62, wherein X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1, and X4 is H.

74. The antibody-tethered drug conjugate of any one of claims 1-9 and 11-62, wherein X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1; X4 is H; X6 is independently selected at each occurrence from H and -CH3, and X7 is 75. The antibody-tethered drug conjugate of any one of claims 1-9 and 11-62, wherein X1 is H; X2 is X3 is -(CH2) 2-6 -NH-; n is 1, and X4 is H.

76. The antibody-tethered drug conjugate of any one of claims 1-9 and 11-62, wherein X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1; X4 is H, and X5 is 77. The antibody-tethered drug conjugate of any one of claims 1-9 and 11-62, wherein X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 0; X4 is phenyl, and X5 is 78. The antibody-tethered drug conjugate of any one of claims 1-9 and 11-62, wherein X1 is X2 is X3 is -(CH2) 2-6 -NH-; n is 1; X4 is phenyl, and X5 is 79. The antibody-tethered drug conjugate of any one of claims 1-9 and 11-62, wherein P has the structure 80. The antibody-tethered drug conjugate of any one of claims 1-9 and 11-62, wherein X1 is X2 is X3 is -(CH2) 2-6 -NH-; X4 is H, and X5 is 81. The antibody-tethered drug conjugate of any one of claims 1-81, wherein P has a structure selected from the group consisting of:

82. The antibody-tethered drug conjugate of any one of claims 1-9 and 11-82, wherein the antibody-tethered drug conjugate has a half-life in plasma of longer than 7 days.

83. The antibody-tethered drug conjugate of any one of claims 1-9 and 11-82, wherein the antibody-tethered drug conjugate does not bind to a G protein coupled receptor (GPCR) other than GLP1R.

84. The antibody-tethered drug conjugate of any one of claims 1-9 and 11-84, comprising a payload conjugated to a linker, wherein the linker is conjugated to one or both of the two immunoglobulin heavy chains or variable regions thereof and / or one or both of the two immunoglobulin light chains or variable regions thereof of an antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof (i) comprising a heavy chain immunoglobulin or a variable region thereof, said heavy chain immunoglobulin or a variable region thereof comprising a CDR-H1, CDR-H2 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO:26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411; or a variant thereof; and / or A light chain immunoglobulin or a variable region thereof, comprising a CDR-L1, CDR-L2 and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373;393 or 413; or a variant thereof; (ii) is an antibody or antigen-binding fragment thereof that competes with the antibody or fragment of (i) for binding to GLP1R; (iii) is an antibody or antigen-binding fragment thereof that binds to the same epitope of GLP1R as the antibody or fragment of (i); having the following structure: in Immunoglobulin is the immunoglobulin chain of said antibody or fragment; CapAib is 3-((2-(1H-imidazol-5-yl)ethyl)amino)-2,2-dimethyl-3-oxopropanoic acid; E* is (S)-2-amino-3-(2H-tetrazol-5-yl)propanoic acid; G is glycine; T is threonine; F* is (S)-2-amino-3-(2-fluorophenyl)-2-methylpropanoic acid; S is serine; D is aspartic acid; AA2 is (S)-2-amino-3-(4'-(4-(4-(25-amino-2,5,8,11,14,17,20,23-octaoxacosyl)-1H-1,2,3-triazol-1-yl)butoxy)-2'-ethyl-[1,1'-biphenyl]-4-yl)propanoic acid [AA2 includes the linker]; and AA1 = (S)-2-amino-5-(3,5-dimethylphenyl)pentanamide.

85. The antibody-tethered drug conjugate of any one of claims 1-9 and 11-85, wherein the linker is conjugated to the immunoglobulin heavy chain and / or light chain or variable region thereof via a Q tag.

86. The antibody-tethered drug conjugate of claim 86, wherein the Q tag comprises the amino acid sequence LLQGG (SEQ ID NO:6), LLQG (SEQ ID NO:7), LSLSQG (SEQ ID NO:8), GGGLLQGG (SEQ ID NO:9), GLLQG (SEQ ID NO:10), LLQ, GSPLAQSHGG (SEQ ID NO:11), GLLQGGG (SEQ ID NO:12), GLLQGG (SEQ ID NO:13), GLLQ (SEQ ID NO:14), LLQLLQGA (SEQ ID NO:15), LLQGA (SEQ ID NO:16), LLQYQGA (SEQ ID NO:17), LLQGSG (SEQ ID NO:18), LLQYQG (SEQ ID NO:19), LLQLLQG (SEQ ID NO:20), SLLQG (SEQ ID NO:21), LLQLQ (SEQ ID NO:22), LLQLLQ (SEQ ID NO:23). ID NO:23), LLQGSGSG (SEQ ID NO:185) and / or LLQGR (SEQ ID NO:24).

87. The antibody-tethered drug conjugate of any one of claims 1-9 and 11-87, wherein the linker is conjugated to the immunoglobulin heavy chain and / or light chain or its variable region via the glutamine (Q) of the Q tag, the Q tag comprising the following amino acid sequence: LLQGG (SEQ ID NO: 6), LLQG (SEQ ID NO: 7), LSLSQG (SEQ ID NO: 8), GGGLLQGG (SEQ ID NO: 9), GLLQG (SEQ ID NO: 10), LLQ, GSPLAQSHGG (SEQ ID NO: 11), GLLQGGG (SEQ ID NO: 12), GLLQGG (SEQ ID NO: 13), GLLQ (SEQ ID NO: 14), LLQLLQGA (SEQ ID NO: 15), LLQGA (SEQ ID NO: 16), LLQYQGA (SEQ ID NO: 17), LLQGSG (SEQ ID NO: 18), LLQYQG (SEQ ID NO: 19), LLQLLQG (SEQ ID NO: 20), NO:20), SLLQG (SEQ ID NO:21), LLQLQ (SEQ ID NO:22), LLQLLQ (SEQ ID NO:23), LLQGSGSG (SEQ ID NO:185) and / or LLQGR (SEQ ID NO:24).

88. The antibody-tethered drug conjugate of any one of claims 1-9 and 11-88, wherein the linker is conjugated to each of the two immunoglobulin light chains through the glutamine (Q) of the Q tag, the Q tag comprising the amino acid sequence LLQGSG (SEQ ID NO: 18).

89. The antibody or antigen-binding fragment thereof according to claim 10 or the antibody-tethered drug conjugate according to any one of claims 1-9 and 11-89, wherein: (a) the heavy chain immunoglobulin or its variable region comprises an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411; and / or (b) the light chain immunoglobulin or its variable region comprises an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence listed in SEQ ID NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373;393 or 413.

90. The antibody or antigen-binding fragment thereof according to claim 10 or the antibody-tethered drug conjugate according to any one of claims 1-9 and 11-89, wherein: (a) the heavy chain immunoglobulin or its variable region comprises a heavy chain immunoglobulin or its variable region comprising the following CDR-H1, CDR-H2 and CDR-H3: the amino acid sequence listed in SEQ ID NO:26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411, and the amino acid sequence of SEQ ID NO: at least 90% amino acid sequence identity to the amino acid sequence set forth in NO:26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411; and / or (b) the light chain immunoglobulin or its variable region comprises a CDR-L1, CDR-L2 and CDR-L3 comprising the following light chain immunoglobulin or its variable region: the amino acid sequence listed in SEQ ID NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373;393 or 413, and the amino acid sequence of SEQ ID NO: at least 90% amino acid sequence identity to the amino acid sequence set forth in NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373;393 or 413.

91. The antibody or antigen-binding fragment thereof according to claim 10 or the antibody-tethered drug conjugate according to any one of claims 1-9 and 11-89, wherein: The heavy chain immunoglobulin or its variable region comprises: (i) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO:28 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO:30 or a variant thereof; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO:32 or a variant thereof; (ii) CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO:48 or a variant thereof; CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO:50 or a variant thereof; CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO:52 or a variant thereof; (iii) CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO:68 or a variant thereof; CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO:70 or a variant thereof; CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO:72 or a variant thereof; (iv) CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO:88 or a variant thereof; CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO:90 or a variant thereof; CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO:92 or a variant thereof; (v) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 108 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 110 or a variant thereof; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 112 or a variant thereof; (vi) CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 128 or a variant thereof; CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 130 or a variant thereof; CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 132 or a variant thereof; (vii) CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 148 or a variant thereof; CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 150 or a variant thereof; CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 152 or a variant thereof; (viii) CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 168 or a variant thereof; CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 170 or a variant thereof; CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 172 or a variant thereof; (ix) CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 189 or a variant thereof; CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 191 or a variant thereof; CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 193 or a variant thereof; (x) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 209 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 211 or a variant thereof; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 213 or a variant thereof; (xi) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 229 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 231 or a variant thereof; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 233 or a variant thereof; (xii) CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 249 or a variant thereof; CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 251 or a variant thereof; CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 253 or a variant thereof; (xiii) CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 277 or a variant thereof; CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 279 or a variant thereof; CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 281 or a variant thereof; (xiv) CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 297 or a variant thereof; CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 299 or a variant thereof; CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 301 or a variant thereof; (xv) CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 317 or a variant thereof; CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 319 or a variant thereof; CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 321 or a variant thereof; (xvi) CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 337 or a variant thereof; CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 339 or a variant thereof; CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 341 or a variant thereof; (xvii) CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 357 or a variant thereof; CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 359 or a variant thereof; CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 361 or a variant thereof; and / or (xviii) CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 377 or a variant thereof; CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 379 or a variant thereof; CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 381 or a variant thereof; (xix) CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 397 or a variant thereof; CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 399 or a variant thereof; CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 401 or a variant thereof; and / or The light chain immunoglobulin or its variable region comprises: (a) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO:36 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO:38 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:40 or a variant thereof; (b) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO:56 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO:58 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:60 or a variant thereof; (c) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 76 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 78 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 80 or a variant thereof; (d) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 96 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 98 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 100 or a variant thereof; (e) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 116 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 118 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 120 or a variant thereof; (f) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 136 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 138 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 140 or a variant thereof; (g) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 156 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 158 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 160 or a variant thereof; (h) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 176 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 178 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 180 or a variant thereof; (i) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 197 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 199 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 201 or a variant thereof; (j) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 217 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 219 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 221 or a variant thereof; (k) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 237 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 239 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 241 or a variant thereof; (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 257 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 259 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 261 or a variant thereof; (m) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 285 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 287 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 289 or a variant thereof; (n) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 305 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 307 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 309 or a variant thereof; (o) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 325 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 327 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 329 or a variant thereof; (p) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 345 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 347 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 349 or a variant thereof; (q) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 365 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 367 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 369 or a variant thereof; (r) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 385 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 387 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 389 or a variant thereof; and / or (s) CDR-L1 comprising the amino acid sequence listed in SEQ ID NO:405 or a variant thereof; CDR-L2 comprising the amino acid sequence listed in SEQ ID NO:407 or a variant thereof; CDR-L3 comprising the amino acid sequence listed in SEQ ID NO:409 or a variant thereof.

92. The antibody or antigen-binding fragment thereof according to claim 10 or the antibody-tethered drug conjugate according to any one of claims 1-9 and 11-89, wherein: (1) the heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 28 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 30 or a variant thereof; and a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 32; and The light chain immunoglobulin or its variable region comprises a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO:36 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO:38 or a variant thereof; and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:40 or a variant thereof; (2) the heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO:48 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO:50 or a variant thereof; and a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO:52; and The light chain immunoglobulin or its variable region comprises a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO:56 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO:58 or a variant thereof; and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:60 or a variant thereof; (3) the heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 68 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 70 or a variant thereof; and a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 72; and The light chain immunoglobulin or its variable region comprises a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 76 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 78 or a variant thereof; and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 80 or a variant thereof; (4) the heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 88 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 90 or a variant thereof; and a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 92; and The light chain immunoglobulin or its variable region comprises a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 96 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 98 or a variant thereof; and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 100 or a variant thereof; (5) the heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 108 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 110 or a variant thereof; and a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 112; and The light chain immunoglobulin or its variable region comprises a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 116 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 118 or a variant thereof; and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 120 or a variant thereof; (6) the heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 128 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 130 or a variant thereof; and a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 132; and The light chain immunoglobulin or its variable region comprises a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 136 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 138 or a variant thereof; and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 140 or a variant thereof; (7) the heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 148 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 150 or a variant thereof; and a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 152; and The light chain immunoglobulin or its variable region comprises a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 156 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 158 or a variant thereof; and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 160 or a variant thereof; (8) the heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 168 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 170 or a variant thereof; and a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 172; The light chain immunoglobulin or its variable region comprises a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 176 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 178 or a variant thereof; and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 180 or a variant thereof; (9) the heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 189 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 191 or a variant thereof; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 193 or a variant thereof; and the light chain immunoglobulin or its variable region comprises a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 197 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 199 or a variant thereof; and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 201 or a variant thereof; (10) the heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 209 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 211 or a variant thereof; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 213 or a variant thereof; and the light chain immunoglobulin or its variable region comprises a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 217 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 219 or a variant thereof; and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 221 or a variant thereof; (11) the heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 229 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 231 or a variant thereof; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 233 or a variant thereof; and the light chain immunoglobulin or its variable region comprises a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 237 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 239 or a variant thereof; and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 241 or a variant thereof; (12) the heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 249 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 251 or a variant thereof; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 253 or a variant thereof; and the light chain immunoglobulin or its variable region comprises a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 257 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 259 or a variant thereof; and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 261 or a variant thereof; (13) the heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 277 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 279 or a variant thereof; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 281 or a variant thereof; and the light chain immunoglobulin or its variable region comprises a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 285 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 287 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 289 or a variant thereof; (14) the heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 297 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 299 or a variant thereof; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 301 or a variant thereof; and the light chain immunoglobulin or its variable region comprises a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 305 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 307 or a variant thereof; and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 309 or a variant thereof; (15) the heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 317 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 319 or a variant thereof; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 321 or a variant thereof; and the light chain immunoglobulin or its variable region comprises a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 325 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 327 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 329 or a variant thereof; (16) the heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 337 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 339 or a variant thereof; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 341 or a variant thereof; and the light chain immunoglobulin or its variable region comprises a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 345 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 347 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 349 or a variant thereof; (17) the heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 357 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 359 or a variant thereof; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 361 or a variant thereof; and the light chain immunoglobulin or its variable region comprises a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 365 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 367 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 369 or a variant thereof; (18) the heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 377 or a variant thereof; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 379 or a variant thereof; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 381 or a variant thereof; and the light chain immunoglobulin or its variable region comprises a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 385 or a variant thereof; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 387 or a variant thereof; a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 389 or a variant thereof; or (19) The heavy chain immunoglobulin or its variable region comprises a CDR-H1 comprising the amino acid sequence listed in SEQ ID NO: 397 or a variant thereof; a CDR-H2 comprising the amino acid sequence listed in SEQ ID NO: 399 or a variant thereof; a CDR-H3 comprising the amino acid sequence listed in SEQ ID NO: 401 or a variant thereof; and the light chain immunoglobulin or its variable region comprises a CDR-L1 comprising the amino acid sequence listed in SEQ ID NO: 405 or a variant thereof; a CDR-L2 comprising the amino acid sequence listed in SEQ ID NO: 407 or a variant thereof; and a CDR-L3 comprising the amino acid sequence listed in SEQ ID NO: 409 or a variant thereof.

93. The antibody or antigen-binding fragment thereof according to claim 10 or the antibody-tethered drug conjugate according to any one of claims 1-9 and 11-89, wherein: (a) the heavy chain immunoglobulin or its variable region comprises the amino acid sequence listed in SEQ ID NO:26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411 or a variant thereof; and / or (b) the light chain immunoglobulin or its variable region comprises the amino acid sequence listed in SEQ ID NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373;393 or 413 or a variant thereof.

94. The antibody or antigen-binding fragment thereof according to claim 10 or the antibody-tethered drug conjugate according to any one of claims 1-9 and 11-89, wherein: (a) the heavy chain immunoglobulin variable region comprises the amino acid sequence EVQLVESGGGLVKPGGSLRLSCAASGFIFSRYSMNWVRQAPGKGLEWVSSMSSNSKNTYYADSVKGRFTISRDNAKNSLFLQMNTLRAEDTAVYYCARDGYTLRAFDIWGQGTMVTVSS (SEQ ID NO: 26), and the light chain immunoglobulin variable region comprises the amino acid sequence LLQGSGEIVLTQSPGTLSLSPGERDTLSCRASQSIAGRYVAWYQQKPGQAPRLLIYGASSRAT GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK (SEQ ID NO: 34); (b) the heavy chain immunoglobulin variable region comprises the amino acid sequence of EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGLIAPRPMGFDYWGQGTLVTVSS (SEQ ID NO:46), and the light chain immunoglobulin variable region comprises the amino acid sequence of LLQGSGDIQMTQSPSSVSASVGDRVTITCRASQGINSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQADSFPYTFGQGTKLEIK (SEQ ID NO:54); (c) the heavy chain immunoglobulin variable region comprises the amino acid sequence of EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGLIAPRPMGFDYWGQGTLVTVSS (SEQ ID NO:66), and the light chain immunoglobulin variable region comprises the amino acid sequence of LLQGSGDIQMTQSPSSVSASVGDRVTITCRASQGINSWLAWYQQKPGKAPKLLIYAASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQADSFPYTFGQGTKLEIK (SEQ ID NO:74); (d) the heavy chain immunoglobulin variable region comprises the amino acid sequence of QVQLVESGGGVGQPGRSLRLSCAASGFTFSRNAMHWVRQAPGKGLEWVAVISYDGSNKH YADSVKGRFTISRDNSKNTLYLEMNSLRVEDTAVYYCAKGGIPFDYWGQGTLVTVSS (SEQ ID NO: 86), and the light chain immunoglobulin variable region comprises the amino acid sequence of LLQGSGDIVMTQSPLSSPVTLGQPASISCRSSQSLVHFDGNTYLSWLHQRPGQPPRLLIYKISNRFSGVPDRFSGSGAGTDFTLKISRVEPEDVGVYYCMHATQFPYTFGQGTKLEIK (SEQ ID NO: 94); (e) the heavy chain immunoglobulin variable region comprises the amino acid sequence of QVQLVESGGGVVQPARSLRLSCAASGFAFSRSAMHWVRQAPGKGLEWVAVISYDGSNKYY TDSVKGRFTISRDNSKNTLYLQMNTLRAEDTALYYCAKMYTTMDSFDYWGQGTLVTVSS (SEQ ID NO: 106), and the light chain immunoglobulin variable region comprises the amino acid sequence of LLQGSGDIQLTQSPSFLSASVGDRVTITCWASQGISSYLAWYQQKPGKAPKLLIYAASTLQSG VPSRFSGSGSGTEFTLTISSLQPEDFALYYCQQLNSYPRTFGQGTKVEIK (SEQ ID NO: 114); (f) the heavy chain immunoglobulin variable region comprises the amino acid sequence of LLQGSGEVQLVESGGGLVKPGGSLRLSCAASGFIFSRYSMNWVRQAPGKGLEWVSSMSSN SKNTYYADSVKGRFTISRDNAKNSLFLQMNTLRAEDTAVYYCARDGYTLRAFDIWGQGTM VTVSS (SEQ ID NO: 126), and the light chain immunoglobulin variable region comprises the amino acid sequence of EIVLTQSPGTLSLSPGERDTLSCRASQSIAGRYVAWYQQKPGQAPRLLIYGASSRATGIPDRF SGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK (SEQ ID NO: 134); (g) the heavy chain immunoglobulin variable region comprises the amino acid sequence of QVQLVESGGGVVQPGRSLRLSCAASGFTFSGYGIHWVRQAPGKGLVWVAVIWYDGSFKYY ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDSSSSGRYYYYGMDVWGQGT TVTVSS (SEQ ID NO: 146), and the light chain immunoglobulin variable region comprises the amino acid sequence of LLQGSGDIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGTAPKRLIFAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPPTFGGGTKVEIK (SEQ ID NO: 154); (h) the heavy chain immunoglobulin variable region comprises the amino acid sequence EVQLVESGGGLVQPGGSLKLSCAASGFTFSGSAMHWVRQASGKGLEWVGRITSKANSYATAYDASVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCTRQRFLEFLFLDYWGQGTLVTVSS (SEQ ID NO: 166), and the light chain immunoglobulin variable region comprises the amino acid sequence LLQGSGDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK (SEQ ID NO: 174); (i) the heavy chain immunoglobulin variable region comprises the amino acid sequence of LLQGSGEVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSG GSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGLIAPRPMGFDYWGQGTLVTVSS (SEQ ID NO: 187), and the light chain immunoglobulin variable region comprises the amino acid sequence of DIQMTQSPSSVSASVGDRVTITCRASQGINSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRF SGSGSGTDFTLTISSLQPEDFATYYCHQADSFPYTFGQGTKLEIK (SEQ ID NO: 195); (j) the heavy chain immunoglobulin variable region comprises the amino acid sequence of LLQGSGQVQLVESGGGVGQPGRSLRLSCAASGFTFSRNAMHWVRQAPGKGLEWVAVISYD GSNKHYADSVKGRFTISRDNSKNTLYLEMNSLRVEDTAVYYCAKGGIPFDYWGQGTLVTVSS (SEQ ID NO: 207), and the light chain immunoglobulin variable region comprises the amino acid sequence of DIVMTQSPLSSPVTLGQPASISCRSSQSLVHFDGNTYLSWLHQRPGQPPRLLIYKISNRFSGVPDRFSGSGAGTDFTLKISRVEPEDVGVYYCMHATQFPYTFGQGTKLEIK (SEQ ID NO: 215); (k) the heavy chain immunoglobulin variable region comprises the amino acid sequence of LLQGSGQVQLVESGGGVVQPARSLRLSCAASGFAFSRSAMHWVRQAPGKGLEWVAVISYD GSNKYYTDSVKGRFTISRDNSKNTLYLQMNTLRAEDTALYYCAKMYTTMDSFDYWGQGTLVTVSS (SEQ ID NO: 227), and the light chain immunoglobulin variable region comprises the amino acid sequence of DIQLTQSPSFLSASVGDRVTITCWASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFS GSGSGTEFTLTISSLQPEDFALYYCQQLNSYPRTFGQGTKVEIK (SEQ ID NO: 235); (1) the heavy chain immunoglobulin variable region comprises the amino acid sequence of LLQGSGEVQLVESGGGLVQPGGSLKLSCAASGFTFSGSAMHWVRQASGKGLEWVGRITSKANSYATAYDASVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCTRQRFLEFLFLDYWGQGTLVTVSS (SEQ ID NO: 247), and the light chain immunoglobulin variable region comprises the amino acid sequence of DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK (SEQ ID NO: 255); (m) the heavy chain immunoglobulin variable region comprises the amino acid sequence of EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMTWVRQAPGKGLEWVANIKQDGSGKN YVDSVMGRYTISRDNAKNSLYLQMNSLRAEDTAVYYCARWIAPDFPGMDVWGQGTTVTV SS (SEQ ID NO: 275), and the light chain immunoglobulin variable region comprises the amino acid sequence of LLQGSGDIQLTQSPSFLSASVGDRVTITCWASQGISSYLAWYQQKPGKAPKLLIYAASTLQSG VPSRFSGSGSGTEFTLTISSLQPADFATYYCQQLNSYPLTFGGGTKVEIK (SEQ ID NO: 283); (n) the heavy chain immunoglobulin variable region comprises the amino acid sequence of EVQLVESGGGLVQPGGSLKLSCAASGFTFSGSAMHWVRQASGKGLEWVGRITSKANSYATAYDASVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCTRQRFLEFLFLDYWGQGTLVTVSS (SEQ ID NO: 295), and the light chain immunoglobulin variable region comprises the amino acid sequence of LLQGSGDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK (SEQ ID NO: 303); (o) the heavy chain immunoglobulin variable region comprises the amino acid sequence of LLQGSGQVQLVESGGGVVQPGRSLRLSCAASGFTFSGYGIHWVRQAPGKGLVWVAVIWYD GSFKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDSSSSGRYYYYGMDV WGQGTTVTVSS (SEQ ID NO: 315), and the light chain immunoglobulin variable region comprises the amino acid sequence of DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGTAPKRLIFAASSLQSGVPSRFS GSGSGTEFTLTISSLQPEDFATYYCLQHNNYPPTFGGGTKVEIK (SEQ ID NO: 323); (p) the heavy chain immunoglobulin variable region comprises the amino acid sequence of LLQGSGQVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHA GSTNYNPSLKSRITISVDTSKNQFSLKLSSVTAADTAVYYCARGWYYGSGSYHRNWFDPWGQGTLVTVSS (SEQ ID NO:335), and the light chain immunoglobulin variable region comprises the amino acid sequence of EIVLTQSPGTLSLSPGERATLSCRASQSVYYSYLAWYQQKPGQAPRLLIYGASNRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGNSPWTFGQGTKVEIK (SEQ ID NO:343); (q) the heavy chain immunoglobulin variable region comprises the amino acid sequence of QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHAGSTNYNPSLKSRITISVDTSKNQFSLKLSSVTAADTAVYYCARGWYYGSGSYHRNWFDPWGQGTLVT VSS (SEQ ID NO:355), and the light chain immunoglobulin variable region comprises the amino acid sequence of LLQGSGEIVLTQSPGTLSLSPGERATLSCRASQSVYYSYLAWYQQKPGQAPRLLIYGASNRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGNSPWTFGQGTKVEIK (SEQ ID NO:363); (r) the heavy chain immunoglobulin variable region comprises the amino acid sequence of LLQGSGEVQVVESGGGLVQPGRSLRLSCTASGFTFDDYAMFWVRQGPGKGLEWVSGISWN SGSIGYADSVKGRFTTSRDNAKNSLYLQMNSLRTEDTALYYCAKDYRPRSGNHYNNYGMD VWGPGTTVTVSS (SEQ ID NO: 375), and the light chain immunoglobulin variable region comprises the amino acid sequence of EIVLTQSPGTLSLSPGERATLSCRASQSFRGNYLAWYQQKPGQAPRLLIYGASSRATGIPDRF RGSGSGTDFTLTISRLEPEDFAVYYCHQYGRSPWTFGQGTKVEIK (SEQ ID NO: 383); and / or (s) the heavy chain immunoglobulin variable region comprises the amino acid sequence EVQVVESGGGLVQPGRSLRLSCTASGFTFDDYAMFWVRQGPGKGLEWVSGISWNSGSIGY ADSVKGRFTTSRDNAKNSLYLQMNSLRTEDTALYYCAKDYRPRSGNHYNNYGMDVWGP GTTVTVSS (SEQ ID NO:395), and the light chain immunoglobulin variable region comprises the amino acid sequence LLQGSGEIVLTQSPGTLSLSPGERATLSCRASQSFRGNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFRGSGSGTDFTLTISRLEPEDFAVYYCHQYGRSPWTFGQGTKVEIK (SEQ ID NO:403).

95. The antibody or antigen-binding fragment thereof according to claim 10 or the antibody-tethered drug conjugate according to any one of claims 1-9 and 11-89, wherein: (a) The heavy-chain immunoglobulin comprises the amino acid sequence EVQLVESGGGLVKPGGSLRLSCAASGFIFSRYSMNWVRQAPGKGLEWVSSMSSNSKNTYYADSVKGRFTISRDNAKNSLFLQMNTLRAEDTAVYYCARDGYTLRAFDIWGQGTMVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO:42), and the light-chain immunoglobulin comprises the amino acid sequence LLQGSGEIVLTQSPGTLSLSPGERDTLSCRASQSIAGRYVAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:44); (b) The heavy chain immunoglobulin comprises the amino acid sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGLIAPRPMGFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO:62), and the light chain immunoglobulin comprises the amino acid sequence LLQGSGDIQMTQSPSSVSASVGDRVTITCRASQGINSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQADSFPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:64); (c) The heavy chain immunoglobulin comprises the amino acid sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGLIAPRPMGFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO:82), and the light chain immunoglobulin comprises the amino acid sequence LLQGSGDIQMTQSPSSVSASVGDRVTITCRASQGINSWLAWYQQKPGKAPKLLIYAASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQADSFPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:84); (d) The heavy-chain immunoglobulin comprises the amino acid sequence QVQLVESGGGVGQPGRSLRLSCAASGFTFSRNAMHWVRQAPGKGLEWVAVISYDGSNKHYADSVKGRFTISRDNSKNTLYLEMNSLRVEDTAVYYCAKGGIPFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO: 102), and the light-chain immunoglobulin comprises the amino acid sequence LLQGSGDIVMTQSPLSSPVTLGQPASISCRSSQSLVHFDGNTYLSWLHQRPGQPPRLLIYKISNRFSGVPDRFSGSGAGTDFTLKISRVEPEDVGVYYCMHATQFPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 104); (e) The heavy chain immunoglobulin comprises the amino acid sequence QVQLVESGGGVVQPARSLRLSCAASGFAFSRSAMHWVRQAPGKGLEWVAVISYDGSNKYYTDSVKGRFTISRDNSKNTLYLQMNTLRAEDTALYYCAKMYTTMDSFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO: 122), and the light chain immunoglobulin comprises the amino acid sequence LLQGSGDIQLTQSPSFLSASVGDRVTITCWASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFALYYCQQLNSYPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 124); (f) The heavy-chain immunoglobulin comprises the amino acid sequence LLQGSGEVQLVESGGGLVKPGGSLRLSCAASGFIFSRYSMNWVRQAPGKGLEWVSSMSSNSKNTYYADSVKGRFTISRDNAKNSLFLQMNTLRAEDTAVYYCARDGYTLRAFDIWGQGTMVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO: 142), and the light-chain immunoglobulin comprises the amino acid sequence EIVLTQSPGTLSLSPGERDTLSCRASQSIAGRYVAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 144); (g) The heavy-chain immunoglobulin comprises the amino acid sequence QVQLVESGGGVVQPGRSLRLSCAASGFTFSGYGIHWVRQAPGKGLVWVAVIWYDGSFKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDSSSSGRYYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO:162), and the light-chain immunoglobulin comprises the amino acid sequence LLQGSGDIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGTAPKRLIFAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:164); (h) The heavy-chain immunoglobulin comprises the amino acid sequence EVQLVESGGGLVQPGGSLKLSCAASGFTFSGSAMHWVRQASGKGLEWVGRITSKANSYATAYDASVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCTRQRFLEFLFLDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO:182), and the light-chain immunoglobulin comprises the amino acid sequence LLQGSGDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:184); (i) The heavy-chain immunoglobulin comprises the amino acid sequence LLQGSGEVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGLIAPRPMGFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO:203), and the light-chain immunoglobulin comprises the amino acid sequence DIQMTQSPSSVSASVGDRVTITCRASQGINSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQADSFPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:205); (j) The heavy-chain immunoglobulin comprises the amino acid sequence LLQGSGQVQLVESGGGVGQPGRSLRLSCAASGFTFSRNAMHWVRQAPGKGLEWVAVISYDGSNKHYADSVKGRFTISRDNSKNTLYLEMNSLRVEDTAVYYCAKGGIPFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO:223), and the light-chain immunoglobulin comprises the amino acid sequence DIVMTQSPLSSPVTLGQPASISCRSSQSLVHFDGNTYLSWLHQRPGQPPRLLIYKISNRFSGVPDRFSGSGAGTDFTLKISRVEPEDVGVYYCMHATQFPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:225); (k) The heavy chain immunoglobulin comprises the amino acid sequence LLQGSGQVQLVESGGGVVQPARSLRLSCAASGFAFSRSAMHWVRQAPGKGLEWVAVISYDGSNKYYTDSVKGRFTISRDNSKNTLYLQMNTLRAEDTALYYCAKMYTTMDSFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO: 243), and the light chain immunoglobulin comprises the amino acid sequence DIQLTQSPSFLSASVGDRVTITCWASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFALYYCQQLNSYPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 245); (l) The heavy-chain immunoglobulin comprises the amino acid sequence LLQGSGEVQLVESGGGLVQPGGSLKLSCAASGFTFSGSAMHWVRQASGKGLEWVGRITSKANSYATAYDASVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCTRQRFLEFLFLDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO:263), and the light-chain immunoglobulin comprises the amino acid sequence DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:265); (m) The heavy-chain immunoglobulin comprises the amino acid sequence LLQGSGQVTLKESGPGILQPSQTLSLTCSFSGFSLSTSGTGVGWIRQPSGKGLEWLSHIWWDDVKRYNPALKSRLTISRDTSYSQVFLRIASVDTADTATYYCARILDGTGPMDYWGQGTSVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO: 267), and the light-chain immunoglobulin comprises the amino acid sequence QIVLTQSPAIMSASPGEKVTMTCSASSRVTYMHWYQQRSGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWGNNPQYTFGGGTRLEIKRRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 269); (n) The heavy chain immunoglobulin comprises the amino acid sequence QVTLKESGPGILQPSQTLSLTCSFSGFSLSTSGTGVGWIRQPSGKGLEWLSHIWWDDVKRYNPALKSRLTISRDTSYSQVFLRIASVDTADTATYYCARILDGTGPMDYWGQGTSVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO: 271), and the light chain immunoglobulin comprises the amino acid sequence LLQGSGQIVLTQSPAIMSASPGEKVTMTCSASSRVTYMHWYQQRSGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWGNNPQYTFGGGTRLEIKRRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 273); (o) The heavy-chain immunoglobulin comprises the amino acid sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMTWVRQAPGKGLEWVANIKQDGSGKNYVDSVMGRYTISRDNAKNSLYLQMNSLRAEDTAVYYCARWIAPDFPGMDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO:291), and the light-chain immunoglobulin comprises the amino acid sequence LLQGSGDIQLTQSPSFLSASVGDRVTITCWASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPADFATYYCQQLNSYPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:293); (p) The heavy-chain immunoglobulin comprises the amino acid sequence EVQLVESGGGLVQPGGSLKLSCAASGFTFSGSAMHWVRQASGKGLEWVGRITSKANSYATAYDASVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCTRQRFLEFLFLDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO: 311), and the light-chain immunoglobulin comprises the amino acid sequence LLQGSGDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 313); (q) The heavy-chain immunoglobulin comprises the amino acid sequence LLQGSGQVQLVESGGGVVQPGRSLRLSCAASGFTFSGYGIHWVRQAPGKGLVWVAVIWYDGSFKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDSSSSGRYYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO: 331), and the light-chain immunoglobulin comprises the amino acid sequence DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGTAPKRLIFAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNYPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 333); (r) The heavy chain immunoglobulin comprises the amino acid sequence LLQGSGQVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHAGSTNYNPSLKSRITISVDTSKNQFSLKLSSVTAADTAVYYCARGWYYGSGSYHRNWFDPWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO:351), and the light chain immunoglobulin comprises the amino acid sequence EIVLTQSPGTLSLSPGERATLSCRASQSVYYSYLAWYQQKPGQAPRLLIYGASNRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGNSPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:353); (s) The heavy chain immunoglobulin comprises the amino acid sequence QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHAGSTNYNPSLKSRITISVDTSKNQFSLKLSSVTAADTAVYYCARGWYYGSGSYHRNWFDPWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO:371), and the light chain immunoglobulin comprises the amino acid sequence LLQGSGEIVLTQSPGTLSLSPGERATLSCRASQSVYYSYLAWYQQKPGQAPRLLIYGASNRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGNSPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:373); (t) The heavy-chain immunoglobulin comprises the amino acid sequence LLQGSGEVQVVESGGGLVQPGRSLRLSCTASGFTFDDYAMFWVRQGPGKGLEWVSGISWNSGSIGYADSVKGRFTTSRDNAKNSLYLQMNSLRTEDTALYYCAKDYRPRSGNHYNNYGMDVWGPGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO:391), and the light-chain immunoglobulin comprises the amino acid sequence EIVLTQSPGTLSLSPGERATLSCRASQSFRGNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFRGSGSGTDFTLTISRLEPEDFAVYYCHQYGRSPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:393); (u) The heavy-chain immunoglobulin comprises the amino acid sequence EVQVVESGGGLVQPGRSLRLSCTASGFTFDDYAMFWVRQGPGKGLEWVSGISWNSGSIGYADSVKGRFTTSRDNAKNSLYLQMNSLRTEDTALYYCAKDYRPRSGNHYNNYGMDVWGPGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO: 411), and the light-chain immunoglobulin comprises the amino acid sequence LLQGSGEIVLTQSPGTLSLSPGERATLSCRASQSFRGNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFRGSGSGTDFTLTISRLEPEDFAVYYCHQYGRSPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 413); (v) the heavy chain immunoglobulin comprises the amino acid sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGLIAPRPMGFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVD KRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSI EKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG(SEQ ID NO:414), and the light chain immunoglobulin comprises the amino acid sequence LLQGSGDIQMTQSPSSVSASVGDRVTITCRASQGINSWLAWYQQKPGKAPKLLIYAASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQADSFPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:84); or (c) the heavy chain immunoglobulin comprises the amino acid sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGLIAPRPMGFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKV DKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSS IEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSL(SEQ ID NO:416), and the light chain immunoglobulin comprises the amino acid sequence LLQGSGDIQMTQSPSSVSASVGDRVTITCRASQGINSWLAWYQQKPGKAPKLLIYAASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQADSFPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:84).

96. An antibody-tethered drug conjugate, the antibody-tethered drug conjugate being represented by the following schematic diagram: in An antibody specifically binding to GLP1R and comprising: (a) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:42, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:44; (b) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:62, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:64; (c) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:82, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:84; (d) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 102, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 104; (e) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 122, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 124; (f) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 162, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 164; (g) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 182, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 184; (h) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 271, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 273; (i) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 291, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 293; (j) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 311, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 313; (k) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 371, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 373; (l) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:411, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:413; (m) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:414, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:84; or (n) a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:416, and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:

84.

97. An antibody-tethered drug conjugate comprising an immunoglobulin heavy chain having the following amino acid sequence (a) EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGLIAPRPMGFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK(SEQ ID NO:82); and A light chain immunoglobulin having the following amino acid sequence: LLQGSGDIQMTQSPSSVSASVGDRVTITCRASQGINSWLAWYQQKPGKAPKLLIYAASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQADSFPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:84); (b) EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGLIAPRPMGFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG(SEQ ID NO:414); and The light chain immunoglobulin having the following amino acid sequence: LLQGSGDIQMTQSPSSVSASVGDRVTITCRASQGINSWLAWYQQKPGKAPKLLIYAASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQADSFPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:84); (c) EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGLIAPRPMGFDYWG QGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGP PCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTI SKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSL(SEQ IDNO:416); and a light chain immunoglobulin comprising the following amino acid sequence: LLQGSGDIQMTQSPSSVSASVGDRVTITCRASQGINSWLAWYQQKPGKAPKLLIYAASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQADSFPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 84); or Comprising a heavy chain immunoglobulin having the amino acid sequence (d) EVQLVESGGGLVKPGGSLRLSCAASGFIFSRYSMNWVRQAPGKGLEWVSSMSSNSKNTYYADSVKGRFTISRDNAKNSLFLQMNTLRAEDTAVYYCARDGYTLRAFDIWGQG TMVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPC PPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISK AKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK(SEQ IDNO:42); and A light chain immunoglobulin having the following amino acid sequence: LLQGSGEIVLTQSPGTLSLSPGERDTLSCRASQSIAGRYVAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEI KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQID NO:44); Where the linker-payload is represented by the following structure: is conjugated to the side chain of Gln3 of the light chain to form an aminated product, wherein] is the point of attachment of the linker-payload to Gln3.

98. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 10 and 90-96, or the antibody-tethered drug conjugate according to any one of claims 1-9 and 11-98, wherein at least about 80% of the antibody-tethered drug conjugates do not contain a C-terminal lysine or a lysine and a glycine in any of the heavy chains.

99. The pharmaceutical composition of claim 99, wherein at least about 90% of the antibodies or antigen-binding fragments or antibody-tethered drug conjugates do not comprise a C-terminal lysine in any of the heavy chains.

100. The pharmaceutical composition of claim 100, wherein about 90% of said antibodies or antigen-binding fragments or antibody-tethered drug conjugates do not comprise a C-terminal lysine in any of said heavy chains.

101. The pharmaceutical composition of claim 101, wherein at least about 95% of the antibodies or antigen-binding fragments or antibody-tethered drug conjugates do not comprise a C-terminal lysine in any of the heavy chains.

102. The pharmaceutical composition of claim 102, wherein at least about 99% of the antibodies or antigen-binding fragments or antibody-tethered drug conjugates do not comprise a C-terminal lysine in any of the heavy chains.

103. A pharmaceutical composition according to any one of claims 99-103, wherein the heavy chain immunoglobulin not comprising a C-terminal lysine comprises an amino acid sequence listed in SEQ ID NO: 414 or 416 or a variant thereof.

104. The pharmaceutical composition of any one of claims 99-104, wherein less than about 20% of the antibodies or antigen-binding fragments or antibody-tethered drug conjugates comprise a C-terminal lysine in at least one heavy chain.

105. The pharmaceutical composition of claim 105, wherein less than about 10% of the antibodies or antigen-binding fragments or antibody-tethered drug conjugates comprise a C-terminal lysine in at least one heavy chain.

106. The pharmaceutical composition of claim 106, wherein about 10% of the antibodies or antigen-binding fragments or antibody-tethered drug conjugates comprise a C-terminal lysine in at least one heavy chain.

107. The pharmaceutical composition of claim 107, wherein less than about 5% of the antibodies or antigen-binding fragments or antibody-tethered drug conjugates comprise a C-terminal lysine in at least one heavy chain.

108. The pharmaceutical composition of claim 108, wherein less than about 1% of the antibodies or antigen-binding fragments or antibody-tethered drug conjugates comprise a C-terminal lysine in at least one heavy chain.

109. A pharmaceutical composition according to any one of claims 105-109, wherein the at least one heavy chain comprising a C-terminal lysine comprises an amino acid sequence listed in SEQ ID NO:42; 62; 82; 102; 122; 142; 162; 182; 203; 223; 243; 263; 267; 271; 291; 311; 331; 351; 371; 391 or 411; or a variant thereof.

110. The pharmaceutical composition of claim 110, wherein the at least one heavy chain comprising a C-terminal lysine comprises the amino acid sequence set forth in SEQ ID NO:

82.

111. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 10 and 90-96 or the antibody-tethered drug conjugate according to any one of claims 1-9 and 11-98 and a pharmaceutically acceptable carrier.

112. A pharmaceutical dosage form comprising the antibody or antigen-binding fragment thereof according to any one of claims 10 and 90-96 or the antibody-tethered drug conjugate according to any one of claims 1-9 and 11-98 or the pharmaceutical composition according to any one of claims 99-112.

113. A vial or injection device comprising the antibody or antigen-binding fragment thereof according to any one of claims 10 and 90-96 or the antibody-tethered drug conjugate according to any one of claims 1-9 and 11-98 or the pharmaceutical composition according to any one of claims 99-112.

114. The vial or injection device according to claim 114, wherein the vial or injection device is an injection device, wherein the injection device is a pre-filled syringe or an auto-injector.

115. A method for administering to a subject an antibody or antigen-binding fragment thereof according to any one of claims 10 and 90-96, or an antibody-tethered drug conjugate according to any one of claims 1-9 and 11-98, or a pharmaceutical composition according to any one of claims 99-112, the method comprising introducing the antibody or fragment or conjugate into the body of the subject.

116. A method for selectively targeting GLP1R on the surface of a cell with a payload in vivo or in vitro in a subject, the method comprising administering to the subject an antibody or antigen-binding fragment thereof according to any one of claims 10 and 90-96, or an antibody-tethered drug conjugate according to any one of claims 1-9 and 11-98, or a pharmaceutical composition according to any one of claims 99-112.

117. The method of claim 117, wherein the cell is a mammalian cell.

118. The method of any one of claims 117-118, wherein the cell is a human cell.

119. The method of any one of claims 117-119, wherein the cell is a pancreatic cell, a brain cell, a heart cell, a vascular tissue cell, a kidney cell, a fat tissue cell, a liver cell, or a muscle cell.

120. A method of enhancing GLP1R activity in a subject in need thereof, comprising administering to the subject an effective amount of an antibody or antigen-binding fragment thereof according to any one of claims 10 and 90-96, or an antibody-tethered drug conjugate according to any one of claims 1-9 and 11-98, or a pharmaceutical composition according to any one of claims 99-112 comprising a pharmaceutically acceptable carrier.

121. A method of lowering blood glucose levels in a subject in need thereof, comprising administering to the subject an effective amount of an antibody or antigen-binding fragment thereof according to any one of claims 10 and 90-96, or an antibody-tethered drug conjugate according to any one of claims 1-9 and 11-98, or a pharmaceutical composition according to any one of claims 99-112 comprising a pharmaceutically acceptable carrier.

122. A method of reducing body weight in a subject in need thereof, comprising administering to the subject an effective amount of an antibody or antigen-binding fragment thereof according to any one of claims 10 and 90-96, or an antibody-tethered drug conjugate according to any one of claims 1-9 and 11-98, or a pharmaceutical composition according to any one of claims 99-112 comprising a pharmaceutically acceptable carrier.

123. A method of treating a GLP1R-related condition in a subject in need thereof, comprising administering to the subject an effective amount of an antibody or antigen-binding fragment thereof according to any one of claims 10 and 90-96, or an antibody-tethered drug conjugate according to any one of claims 1-9 and 11-98, or a pharmaceutical composition according to any one of claims 99-112 comprising a pharmaceutically acceptable carrier.

124. The method of claim 124, wherein the GLP1R-associated condition is type II diabetes, obesity, liver disease, coronary artery disease, or kidney disease.

125. The method of claim 124, wherein the GLP1R-associated condition is type II diabetes and / or obesity.

126. The method of any one of claims 124-126, wherein the antibody or antigen-binding fragment thereof according to any one of claims 10 and 90-96, or the antibody-tethered drug conjugate according to any one of claims 1-9 and 11-98, or the pharmaceutical composition according to any one of claims 99-112 is administered subcutaneously, intravenously, intradermally, intraperitoneally, or intramuscularly.

127. A method for preparing an antibody-tethered drug conjugate of claim 1 having a structure of formula (A): BA-(LP)m(A), The method comprises the following steps: a) contacting a BA comprising at least m glutamine residues (Gln) with at least m equivalents of a compound LP in the presence of a transglutaminase, and b) isolating the produced compound of formula (A); Among them, BA (i) comprising a heavy chain immunoglobulin or a variable region thereof, said heavy chain immunoglobulin or a variable region thereof comprising a CDR-H1, CDR-H2 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO:26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411; or a variant thereof; and / or A light chain immunoglobulin or a variable region thereof, comprising a CDR-L1, CDR-L2 and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373;393 or 413; or a variant thereof; (ii) is an antibody or antigen-binding fragment thereof that competes with the antibody or fragment of (i) for binding to GLP1R; (iii) an antibody or antigen-binding fragment thereof that binds to the same epitope of GLP1R as the antibody or fragment of (i); Optionally, wherein the heavy chain immunoglobulin does not comprise a C-terminal lysine or a lysine and a glycine.

128. A method for preparing an antibody-tethered drug conjugate of claim 2 having a structure of formula (I): BA-LP(I), The method comprises the following steps: a) contacting a BA comprising at least one glutamine residue Gln with a compound LP in the presence of a transglutaminase, and b) isolating the produced compound of formula (I); Among them, BA (i) comprising a heavy chain immunoglobulin or a variable region thereof, said heavy chain immunoglobulin or a variable region thereof comprising a CDR-H1, CDR-H2 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO:26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411; or a variant thereof; and / or A light chain immunoglobulin or a variable region thereof, comprising a CDR-L1, CDR-L2 and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373;393 or 413; or a variant thereof; (ii) is an antibody or antigen-binding fragment thereof that competes with the antibody or fragment of (i) for binding to GLP1R; (iii) an antibody or antigen-binding fragment thereof that binds to the same epitope of GLP1R as the antibody or fragment of (i); Optionally, wherein the heavy chain immunoglobulin does not comprise a C-terminal lysine or a lysine and a glycine.

129. A method for preparing an antibody-tethered drug conjugate of claim 1 having a structure of formula (A): BA-(LP)m(A), Wherein the linker L has a structure of formula (L'): -La-Y-Lp-(L'), wherein La is a first linker covalently attached to said BA; Y is a triazole-containing group, and Lp is a second linker covalently attached to said P, The method comprises the following steps: a) contacting a BA comprising at least m glutamine residues Gln with a first linker La comprising an azide or alkyne moiety in the presence of a transglutaminase; b) contacting the product of step a) with at least m equivalents of a compound Lp-P, wherein the second linker Lp comprises an azide or an alkyne moiety, wherein La and Lp are capable of reacting to produce a triazole, and c) isolating the produced compound of formula (A); Among them, BA (i) comprising a heavy chain immunoglobulin or a variable region thereof, said heavy chain immunoglobulin or a variable region thereof comprising a CDR-H1, CDR-H2 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO:26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411; or a variant thereof; and / or A light chain immunoglobulin or a variable region thereof, comprising a CDR-L1, CDR-L2 and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373;393 or 413; or a variant thereof; (ii) is an antibody or antigen-binding fragment thereof that competes with the antibody or fragment of (i) for binding to GLP1R; (iii) an antibody or antigen-binding fragment thereof that binds to the same epitope of GLP1R as the antibody or fragment of (i); Optionally, wherein the heavy chain immunoglobulin does not comprise a C-terminal lysine or a lysine and a glycine.

130. A method for preparing an antibody-tethered drug conjugate of claim 2 having a structure of formula (I): BA-LP(I), Wherein the linker L has a structure of formula (L'): -La-Y-Lp-(L'), wherein La is a first linker covalently attached to said BA; Y is a triazole-containing group, and Lp is a second linker covalently attached to said P, The method comprises the following steps: a) contacting a BA comprising at least one glutamine residue Gln with a first linker La comprising an azide or alkyne moiety in the presence of a transglutaminase; b) contacting the product of step a) with a compound Lp-P, wherein the second linker Lp comprises an azide or alkyne moiety, wherein La and Lp are capable of reacting to produce a triazole, and c) isolating the produced compound of formula (I); Among them, BA (i) comprising a heavy chain immunoglobulin or a variable region thereof, said heavy chain immunoglobulin or a variable region thereof comprising a CDR-H1, CDR-H2 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO:26;46;66;86;106;126;146;166;187;207;227;247;275;295;315;335;355;375;395;42;62;82;414;416;102;122;142;162;182;203;223;243;263;267;271;291;311;331;351;371;391 or 411; or a variant thereof; and / or A light chain immunoglobulin or a variable region thereof, comprising a CDR-L1, CDR-L2 and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:34;54;74;94;114;134;154;174;195;215;235;255;283;303;323;343;363;383;403;44;64;84;104;124;144;164;184;205;225;245;265;269;273;293;313;333;353;373;393 or 413; or a variant thereof; (ii) is an antibody or antigen-binding fragment thereof that competes with the antibody or fragment of (i) for binding to GLP1R; (iii) an antibody or antigen-binding fragment thereof that binds to the same epitope of GLP1R as the antibody or fragment of (i); Optionally, wherein the heavy chain immunoglobulin does not comprise a C-terminal lysine or a lysine and a glycine.

131. An antibody-tethered drug conjugate which is the product of the method of any one of claims 128-131.